



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

03 November 2022
EMA/CHMP/787052/2022
Human Medicines Division

Committee for medicinal products for human use (CHMP)

Minutes for the meeting on 12-15 September 2022

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

Health and safety information

In accordance with the Agency's health and safety policy, delegates were briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the [CHMP meeting highlights](#) once the procedures are finalised and start of referrals will also be available.

Of note, these minutes are a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



Table of contents

1.	Introduction	8
1.1.	Welcome and declarations of interest of members, alternates and experts.....	8
1.2.	Adoption of agenda	8
1.3.	Adoption of the minutes	8
2.	Oral Explanations	9
2.1.	Pre-authorisation procedure oral explanations.....	9
2.1.1.	spesolimab - EMEA/H/C/005874	9
2.2.	Re-examination procedure oral explanations	9
2.2.1.	Tuznue - trastuzumab - EMEA/H/C/005066 / Hervalous - trastuzumab - EMEA/H/C/005880	9
2.3.	Post-authorisation procedure oral explanations	9
2.4.	Referral procedure oral explanations	9
3.	Initial applications	10
3.1.	Initial applications; Opinions.....	10
3.1.1.	Beyfortus - nirsevimab - PRIME - EMEA/H/C/005304.....	10
3.1.2.	Enjaymo - sutimlimab - Orphan - EMEA/H/C/005776	10
3.1.3.	Livtencity - maribavir - Orphan - EMEA/H/C/005787	11
3.1.4.	Melatonin Neurim - melatonin - EMEA/H/C/005603.....	11
3.1.5.	Mycapssa - octreotide - Orphan - EMEA/H/C/005826	12
3.1.6.	Pyrukynd - mitapivat - Orphan - EMEA/H/C/005540.....	12
3.1.7.	Sorafenib Accord - sorafenib - EMEA/H/C/005921.....	12
3.1.8.	Teriflunomide Accord - teriflunomide - EMEA/H/C/005960	13
3.1.9.	Teriflunomide Mylan - teriflunomide - EMEA/H/C/005962.....	13
3.1.10.	Teriparatide SUN - teriparatide - EMEA/H/C/005793	14
3.1.11.	Ximluci - ranibizumab - EMEA/H/C/005617	14
3.1.12.	Zynlonta - loncastuximab tesirine - Orphan - EMEA/H/C/005685	14
3.2.	Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)	15
3.2.1.	dabigatran etexilate - EMEA/H/C/005639.....	15
3.2.2.	tabelecleucel - PRIME - Orphan - ATMP - EMEA/H/C/004577	15
3.2.3.	abaloparatide - EMEA/H/C/005928.....	16
3.2.4.	maralixibat - Orphan - EMEA/H/C/005857	16
3.2.5.	gozetotide - EMEA/H/C/005488	16
3.2.6.	miglustat - Orphan - EMEA/H/C/005695	16
3.2.7.	pemetrexed - EMEA/H/C/005848.....	17
3.2.8.	pirfenidone - EMEA/H/C/005862.....	17
3.2.9.	cipaglucosidase alfa - Orphan - EMEA/H/C/005703	17

3.2.10.	palovarotene - Orphan - EMEA/H/C/004867	18
3.2.11.	spesolimab - EMEA/H/C/005874	18
3.2.12.	sugammadex - EMEA/H/C/005935	18
3.2.13.	vadadustat - EMEA/H/C/005131	18
3.3.	Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)	19
3.3.1.	aflibercept - EMEA/H/C/006022	19
3.3.2.	polihexanide - Orphan - EMEA/H/C/005858	19
3.3.3.	niraparib / abiraterone acetate - EMEA/H/C/005932.....	19
3.3.4.	ferumoxytol - EMEA/H/C/005974.....	19
3.3.5.	glofitamab - Orphan - EMEA/H/C/005751	20
3.3.6.	adagrasib - EMEA/H/C/006013	20
3.3.7.	lacosamide - EMEA/H/C/006047	20
3.3.8.	futibatinib - Orphan - EMEA/H/C/005627	20
3.3.9.	mirikizumab - EMEA/H/C/005122	21
3.3.10.	sugammadex - EMEA/H/C/006046.....	21
3.3.11.	oteseconazole - EMEA/H/C/005682.....	21
3.4.	Update on on-going initial applications for Centralised procedure.....	21
3.4.1.	germanium (68Ge) chloride / gallium (68Ga) chloride - EMEA/H/C/005165.....	21
3.4.2.	ranibizumab - EMEA/H/C/005610	22
3.4.3.	gefapixant - EMEA/H/C/005884	22
3.4.4.	gefapixant - EMEA/H/C/005476	22
3.4.5.	dabigatran etexilate - EMEA/H/C/006023.....	22
3.5.	Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004	23
3.5.1.	Hervelous - trastuzumab - EMEA/H/C/005880	23
3.5.2.	Tuznue - trastuzumab - EMEA/H/C/005066.....	23
3.6.	Initial applications in the decision-making phase.....	23
3.7.	Withdrawals of initial marketing authorisation application	23

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 24

4.1.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion	24
4.1.1.	Biktarvy - bictegrovir / emtricitabine / tenofovir alafenamide - EMEA/H/C/004449/X/0040/G24	
4.1.2.	Skyrizi - risankizumab - EMEA/H/C/004759/X/0020/G.....	24
4.2.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues	25
4.2.1.	Betmiga - mirabegron - EMEA/H/C/002388/X/0039/G	25
4.2.2.	Xofluza - baloxavir marboxil - EMEA/H/C/004974/X/0008/G	25

4.3.	Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question	26
4.4.	Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008	26
4.4.1.	Calquence - acalabrutinib - EMEA/H/C/005299/X/0009/G	26
4.5.	Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008	26

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1.	Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information.....	26
5.1.1.	Adtralza - tralokinumab - EMEA/H/C/005255/II/0002	26
5.1.2.	Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - ATMP - EMEA/H/C/004731/II/0005.....	27
5.1.3.	Brukinsa - zanubrutinib - EMEA/H/C/004978/II/0002.....	27
5.1.4.	Cosentyx - secukinumab - EMEA/H/C/003729/II/0090	28
5.1.5.	Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/II/0022	28
5.1.6.	Epidyolex - cannabidiol - Orphan - EMEA/H/C/004675/II/0020.....	29
5.1.7.	Evusheld - tixagevimab / cilgavimab - EMEA/H/C/005788/II/0001.....	29
5.1.8.	Exparel liposomal - bupivacaine - EMEA/H/C/004586/II/0005	30
5.1.9.	Gavreto - pralsetinib - EMEA/H/C/005413/II/0002/G	30
5.1.10.	Kerendia - finerenone - EMEA/H/C/005200/II/0001/G.....	31
5.1.11.	Lyumjev - insulin lispro - EMEA/H/C/005037/II/0014.....	31
5.1.12.	Mircera - methoxy polyethylene glycol-epoetin beta - EMEA/H/C/000739/II/0092	32
5.1.13.	Nubeqa - darolutamide - EMEA/H/C/004790/II/0009	32
5.1.14.	Revestive - teduglutide - Orphan - EMEA/H/C/002345/II/0054/G	33
5.1.15.	Revolade - eltrombopag - EMEA/H/C/001110/II/0068	33
5.1.16.	TachoSil - human thrombin / human fibrinogen - EMEA/H/C/000505/II/0117.....	34
5.1.17.	Vaxneuvance - pneumococcal polysaccharide conjugate vaccine (adsorbed) - EMEA/H/C/005477/II/0001.....	34
5.1.18.	Veklury - remdesivir - EMEA/H/C/005622/II/0035/G.....	34
5.1.19.	Vemlidy - tenofovir alafenamide - EMEA/H/C/004169/II/0040.....	35
5.1.20.	Wakix - pitolisant - Orphan - EMEA/H/C/002616/II/0030.....	36
5.1.21.	Xalkori - crizotinib - EMEA/H/C/002489/II/0072	36
5.1.22.	Yescarta - axicabtagene ciloleucel - Orphan - ATMP - EMEA/H/C/004480/II/0046	36
5.2.	Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	37
5.3.	Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	37

6.	Medical devices	37
6.1.	Ancillary medicinal substances - initial consultation	37
6.2.	Ancillary medicinal substances – post-consultation update	37
6.3.	Companion diagnostics - initial consultation	37
6.3.1.	in vitro diagnostic medical device - EMEA/H/D/006107	37
6.4.	Companion diagnostics – follow-up consultation	38
7.	Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)	38
7.1.	Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)	38
8.	Pre-submission issues	38
8.1.	Pre-submission issue	38
8.1.1.	Respiratory Syncytial Virus - H0006054	38
8.2.	Priority Medicines (PRIME)	38
8.2.1.	List of applications received	38
8.2.2.	Recommendation for PRIME eligibility	39
9.	Post-authorisation issues	39
9.1.	Post-authorisation issues	39
9.1.1.	Nulojix – belatacept – EMEA/H/C/002098	39
9.1.2.	Temybric Ellipta - fluticasone furoate/umeclidinium/vilanterol – EMEA/H/C/005254	39
9.1.3.	Qarziba - dinutuximab beta – Orphan - EMEA/H/C/003918/II/0043	39
9.1.4.	Apexxnar - pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) - EMEA/H/C/005451/II/0006	40
9.1.5.	Rubraca - rucaparib - EMEA/H/C/004272/II/0029	40
9.1.6.	Spikevax - elasomeran - EMEA/H/C/005791/II/0075/G	41
9.1.7.	Comirnaty - tozinameran - EMEA/H/C/005735/II/0140	41
9.1.8.	Comirnaty - tozinameran - EMEA/H/C/005735/II/0129	41
9.1.9.	Nuvaxovid - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/II/0014	42
9.1.10.	Comirnaty - tozinameran - EMEA/H/C/005735/II/0143	42
9.1.11.	Comirnaty - tozinameran - EMEA/H/C/005735/R/0137	43
9.1.12.	Spikevax - elasomeran - EMEA/H/C/005791/R/0074	43
9.1.13.	Spikevax - elasomeran - EMEA/H/C/005791/II/0066	43
9.1.14.	Caprelsa - vandetanib - EMEA/H/C/002315/R/0055	44
9.1.15.	Caprelsa - vandetanib - EMEA/H/C/002315/II/0043	44
9.1.16.	Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/II/005645	
9.1.17.	NeoRecormon – epoetin beta – EMEA/H/C/000116	45
9.1.18.	Metalyse – tenecteplase – EMEA/H/C000306	45

10.	Referral procedures	45
10.1.	Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004	46
10.2.	Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004 .	46
10.3.	Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004	46
10.4.	Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC	46
10.4.1.	Rambis - EMEA/H/A-29(4)/1519.....	46
10.5.	Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC....	46
10.6.	Community Interests - Referral under Article 31 of Directive 2001/83/EC	47
10.6.1.	Chlormadinone (NAP); chlormadinone, ethinylestradiol (NAP); nomegestrol (NAP); nomegestrol, estradiol – ZOELY (CAP); NAP - EMEA/H/A-31/1510	47
10.7.	Re-examination Procedure under Article 32(4) of Directive 2001/83/EC.....	47
10.7.1.	Synchron Research Services – various – EMEA/H/A-31/1515	47
10.8.	Procedure under Article 107(2) of Directive 2001/83/EC	48
10.9.	Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003	48
10.10.	Procedure under Article 29 of Regulation (EC) 1901/2006.....	48
10.11.	Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008	48
11.	Pharmacovigilance issue	48
11.1.	Early Notification System	48
12.	Inspections	49
12.1.	GMP inspections	49
12.2.	GCP inspections.....	49
12.3.	Pharmacovigilance inspections.....	49
12.4.	GLP inspections	49
13.	Innovation Task Force	49
13.1.	Minutes of Innovation Task Force.....	49
13.2.	Innovation Task Force briefing meetings.....	49
13.3.	Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004	49
13.4.	Nanomedicines activities	49
14.	Organisational, regulatory and methodological matters	50
14.1.	Mandate and organisation of the CHMP	50
14.1.1.	CHMP membership.....	50

14.1.2.	Vote by proxy	50
14.2.	Coordination with EMA Scientific Committees.....	50
14.2.1.	Pharmacovigilance Risk Assessment Committee (PRAC)	50
14.2.2.	Paediatric Committee (PDCO).....	50
14.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	50
14.3.1.	Biologics Working Party (BWP)	50
14.3.2.	Scientific Advice Working Party (SAWP)	51
14.3.3.	EC Request for a scientific opinion on the classification as medicinal products of certain substances used in blood bags CDP (citrate, dextrose and phosphate) and CDPA (citrate, dextrose, phosphate and adenine)	51
14.3.4.	Call for expression of interest for EMA/EC expert to the ICH E11A (paediatric extrapolation) expert working group	51
14.3.5.	Nomination for new member for CNSWP	52
14.4.	Cooperation within the EU regulatory network.....	52
14.5.	Cooperation with International Regulators.....	52
14.6.	Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee	52
14.7.	CHMP work plan	52
14.8.	Planning and reporting	52
14.8.1.	Update of the Business Pipeline report for the human scientific committees	52
14.9.	Others	52
15.	Any other business	53
15.1.	AOB topic.....	53
15.1.1.	Update on COVID-19	53
Lists of participants		54
Explanatory notes		63

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. Due to the current coronavirus (COVID-19) pandemic, and the associated EMA Business Continuity Plan (BCP), the meeting was held in-person with some members connected remotely (hybrid setting).

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Restrictions applicable to this meeting are captured in the list of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. Adoption of agenda

CHMP agenda for 12-15 September 2022.

The CHMP adopted the agenda.

1.3. Adoption of the minutes

CHMP minutes for 18-21 July 2022 and 16-19 August 2022 written procedure.

Minutes from PReparatory and Organisational Matters (PROM) meeting held on 05 September 2022.

The CHMP adopted the minutes of the July Plenary meeting, the August written procedure as well as the minutes from the September PROM meeting.

2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. spesolimab - EMEA/H/C/005874

treatment of flares in adult patients with generalised pustular psoriasis

Scope: Possible oral explanation

Action: Oral explanation to be held on 14 September 2022 at 14:00

List of Outstanding Issues adopted on 21.07.2022. List of Questions adopted on 24.02.2022.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.2

2.2. Re-examination procedure oral explanations

2.2.1. Tuznue - trastuzumab - EMEA/H/C/005066 / Hovelous - trastuzumab - EMEA/H/C/005880

Prestige Biopharma Belgium, treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: Oral explanation

Action: Oral explanation to be held on 13 September 2022 at 14:00

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

Opinion adopted on 19.05.2022. List of Outstanding Issues adopted on 27.01.2022, 25.03.2021, 10.12.2020. List of Questions adopted on 19.09.2019.

An oral explanation was held on 13 September 2022. The presentation by the applicant focused on the quality data in support of the application.

See 3.5

2.3. Post-authorisation procedure oral explanations

No items

2.4. Referral procedure oral explanations

No items

3. Initial applications

3.1. Initial applications; Opinions

3.1.1. Beyfortus - nirsevimab - PRIME - EMEA/H/C/005304

AstraZeneca AB; prevention of RSV lower respiratory tract infection.

Immunise infants from birth entering their first Respiratory Syncytial Virus (RSV) season for the prevention of RSV lower respiratory tract disease.

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 19.07.2022. List of Questions adopted on 17.05.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that nirsevimab is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to medical prescription.

The CHMP noted the letter of recommendation dated 12 September 2022.

The summary of opinion was circulated for information.

3.1.2. Enjaymo - sutimlimab - Orphan - EMEA/H/C/005776

Genzyme Europe BV; treatment of haemolysis in adult patients with cold agglutinin disease (CAD)

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 23.06.2022. List of Questions adopted on 24.02.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that sutimlimab is a new active substance, as claimed

by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 09 September 2022.

The summary of opinion was circulated for information.

3.1.3. [Livtency - maribavir - Orphan - EMEA/H/C/005787](#)

Takeda Pharmaceuticals International AG Ireland Branch; treatment of cytomegalovirus (CMV) infection

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 23.06.2022, 22.04.2022. List of Questions adopted on 14.10.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that maribavir is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 31 August 2022.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.4. [Melatonin Neurim - melatonin - EMEA/H/C/005603](#)

RAD Neurim Pharmaceuticals EEC SARL; treatment of primary insomnia

Scope: Opinion

Action: For adoption

Informed consent application (Article 10c of Directive No 2001/83/EC), Informed Consent of Circadin

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.5. Mycapssa - octreotide - Orphan - EMEA/H/C/005826

Amryt Pharmaceuticals DAC; treatment of acromegaly

Scope: Opinion

Action: For adoption

Hybrid application (Article 10(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 19.05.2022. List of Questions adopted on 16.12.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.6. Pyrukynd - mitapivat - Orphan - EMEA/H/C/005540

Agios Netherlands B.V.; treatment of pyruvate kinase deficiency

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 21.07.2022, 19.05.2022, 24.03.2022. List of Questions adopted on 11.11.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report.

Furthermore, the CHMP considered that mitapivat is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to medical prescription.

The CHMP noted the letter of recommendation dated 13 September 2022.

The summary of opinion was circulated for information.

3.1.7. Sorafenib Accord - sorafenib - EMEA/H/C/005921

Accord Healthcare S.L.U.; treatment of hepatocellular carcinoma and renal cell carcinoma

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Nexavar

List of Outstanding Issues adopted on 22.04.2022. List of Questions adopted on 11.11.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.8. Teriflunomide Accord - teriflunomide - EMEA/H/C/005960

Accord Healthcare S.L.U.; treatment of multiple sclerosis (MS)

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of AUBAGIO

List of Outstanding Issues adopted on 21.07.2022. List of Questions adopted on 24.02.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.9. Teriflunomide Mylan - teriflunomide - EMEA/H/C/005962

Mylan Pharmaceuticals Limited; treatment of multiple sclerosis (MS)

Scope: Opinion

Action: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of AUBAGIO

List of Outstanding Issues adopted on 23.06.2022. List of Questions adopted on 27.01.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.
The summary of opinion was circulated for information.

3.1.10. Teriparatide SUN - teriparatide - EMEA/H/C/005793

Sun Pharmaceutical Industries Europe B.V.; treatment of osteoporosis

Scope: Opinion

Action: For adoption

Hybrid application (Article 10(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 23.06.2022. List of Questions adopted on 20.05.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The CHMP noted the letter of recommendation dated 12 September 2022.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

3.1.11. Ximluci - ranibizumab - EMEA/H/C/005617

STADA Arzneimittel AG; treatment of neovascular age-related macular degeneration (AMD)

Scope: Opinion

Action: For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 23.06.2022. List of Questions adopted on 27.01.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 12 September 2022.

The summary of opinion was circulated for information.

3.1.12. Zynlonta - loncastuximab tesirine - Orphan - EMEA/H/C/005685

ADC Therapeutics (NL) B.V.; treatment of adult patients with relapsed or refractory large B-

cell lymphoma

Scope: Opinion

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 21.07.2022. List of Questions adopted on 24.02.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a conditional marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that loncastuximab tesirine is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 05 September 2022.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)

3.2.1. dabigatran etexilate - EMEA/H/C/005639

prevention of venous thromboembolic events

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 23.06.2022, 24.02.2022. List of Questions adopted on 12.11.2020.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 3rd list of outstanding issues with a specific timetable.

3.2.2. tabelecleucel - PRIME - Orphan - ATMP - EMEA/H/C/004577

Atara Biotherapeutics Ireland Limited; treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV⁺ PTLD)

Scope: List of outstanding issues

Action: For information

List of Questions adopted on 18.03.2022.

The Committee was reminded of the status of this application and its remaining outstanding

issues.

The Committee endorsed the list of outstanding issues with a specific timetable, as adopted by CAT.

3.2.3. abaloparatide - EMEA/H/C/005928

treatment of osteoporosis

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 24.03.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.4. maralixibat - Orphan - EMEA/H/C/005857

Mirum Pharmaceuticals International B.V.; Treatment of cholestatic liver disease in patients with Alagille syndrome (ALGS) 1 year of age and older

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 23.06.2022. List of Questions adopted on 27.01.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.5. gozetotide - EMEA/H/C/005488

indicated for the identification of prostate-specific membrane antigen (PSMA)-positive lesions after radiolabelling with gallium-68

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 21.07.2022. List of Questions adopted on 24.02.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.6. miglustat - Orphan - EMEA/H/C/005695

Amicus Therapeutics Europe Limited; treatment of adults aged 18 years and older with a

confirmed diagnosis of Pompe disease

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 24.03.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.7. pemetrexed - EMEA/H/C/005848

treatment of malignant pleural mesothelioma and non-small cell lung cancer

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 19.05.2022. List of Questions adopted on 16.12.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.8. pirfenidone - EMEA/H/C/005862

treatment of Idiopathic Pulmonary Fibrosis (IPF)

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 24.03.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.9. cipaglucosidase alfa - Orphan - EMEA/H/C/005703

Amicus Therapeutics Europe Limited; treatment of adults aged 18 years and older with a confirmed diagnosis of Pompe disease

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 24.03.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.10. palovarotene - Orphan - EMEA/H/C/004867

Ipsen Pharma; Treatment of fibrodysplasia ossificans progressiva

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 16.09.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.11. spesolimab - EMEA/H/C/005874

treatment of flares in adult patients with generalised pustular psoriasis

Scope: List of outstanding issues

Action: For adoption

List of Outstanding Issues adopted on 21.07.2022. List of Questions adopted on 24.02.2022.

See 2.1

The CHMP agreed that an oral explanation was not needed at this time.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

3.2.12. sugammadex - EMEA/H/C/005935

reversal of neuromuscular blockade induced by rocuronium or vecuronium

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 24.03.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.13. vadadustat - EMEA/H/C/005131

Treatment of anaemia

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 24.03.2022.

The Committee was reminded of the status of this application and its remaining outstanding

issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. aflibercept - EMEA/H/C/006022

treatment of age-related macular degeneration (AMD) and visual impairment

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.2. polihexanide - Orphan - EMEA/H/C/005858

SIFI SPA; For the treatment of acanthamoeba keratitis

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.3. niraparib / abiraterone acetate - EMEA/H/C/005932

treatment of adult patients with prostate cancer

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.4. ferumoxytol - EMEA/H/C/005974

intravenous treatment of iron deficiency anaemia (IDA)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with

the list of questions.

3.3.5. [glofitamab - Orphan - EMEA/H/C/005751](#)

Roche Registration GmbH; treatment of diffuse large B-cell lymphoma

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.6. [adagrasib - EMEA/H/C/006013](#)

treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.7. [lacosamide - EMEA/H/C/006047](#)

treatment of epilepsy

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.8. [futibatinib - Orphan - EMEA/H/C/005627](#)

Taiho Pharma Netherlands B.V.; treatment of cholangiocarcinoma

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.9. mirikizumab - EMEA/H/C/005122

treatment of moderately to severely active ulcerative colitis

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.10. sugammadex - EMEA/H/C/006046

reversal of neuromuscular blockade induced by rocuronium or vecuronium

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.11. oteseconazole - EMEA/H/C/005682

treatment and prevention of recurrent vulvovaginal candidiasis (RVVC) including the acute episodes of RVVC in adult women

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. germanium (⁶⁸Ge) chloride / gallium (⁶⁸Ga) chloride - EMEA/H/C/005165

indicated for in vitro labelling of kits for radiopharmaceutical preparation

Scope: Letter by the applicant dated 06.09.2022 requesting an extension to the clock stop to respond to the list of questions adopted in December 2021.

Action: For adoption

List of Questions adopted on 16.12.2021.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in December 2021.

3.4.2. ranibizumab - EMEA/H/C/005610

treatment of neovascular age-related macular degeneration in adults

Scope: Letter by the applicant dated 26.08.2022 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in April 2022.

Action: For adoption

List of Outstanding Issues adopted on 22.04.2022, 24.02.2022. List of Questions adopted on 16.09.2021.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in April 2022.

3.4.3. gefapixant - EMEA/H/C/005884

treatment of refractory or unexplained chronic cough

Scope: Update on procedure, MWP's response to the CHMP list of questions (The LoQ to MWP was adopted by the CHMP on 5 September at PROM).

Action: For information

List of Outstanding Issues adopted on 27.01.2022, 16.12.2021, 14.10.2021. List of Questions adopted on 24.06.2021.

The CHMP noted MWP's response to the CHMP list of questions.

3.4.4. gefapixant - EMEA/H/C/005476

treatment of refractory or unexplained chronic cough

Scope: Update on procedure, MWP's response to the CHMP list of questions (The LoQ to MWP was adopted by the CHMP on 5 September at PROM).

Action: For information

List of Outstanding Issues adopted on 27.01.2022, 16.12.2021, 14.10.2021. List of Questions adopted on 24.06.2021.

The CHMP noted MWP's response to the CHMP list of questions.

3.4.5. dabigatran etexilate - EMEA/H/C/006023

Prevention of venous thromboembolic events

Scope: Letter by the applicant dated 06.09.2022 requesting an extension to the clock stop to respond to the list of questions adopted in July 2022.

Action: For adoption

List of Questions adopted on 21.07.2022.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in July 2022.

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

3.5.1. Hervelous - trastuzumab - EMEA/H/C/005880

Prestige Biopharma Belgium; treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: Opinion

Action: For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC), Duplicate of Tuznue

Opinion adopted on 19.05.2022.

See 2.2

An oral explanation was held on 13 September 2022. The presentation by the applicant focused on the quality data in support of the application.

The MAH withdrew the marketing authorisation application.

3.5.2. Tuznue - trastuzumab - EMEA/H/C/005066

Prestige Biopharma Belgium; treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: Opinion

Action: For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

Opinion adopted on 19.05.2022. List of Outstanding Issues adopted on 27.01.2022, 25.03.2021, 10.12.2020. List of Questions adopted on 19.09.2019.

See 2.2

An oral explanation was held on 13 September 2022. The presentation by the applicant focused on the quality data in support of the application.

The MAH withdrew the marketing authorisation application.

3.6. Initial applications in the decision-making phase

No items

3.7. Withdrawals of initial marketing authorisation application

No items

4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

4.1.1. Biktarvy - bictegravir / emtricitabine / tenofovir alafenamide - EMEA/H/C/004449/X/0040/G

Gilead Sciences Ireland UC

Rapporteur: Jean-Michel Race, Co-Rapporteur: Bruno Sepodes, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Extension application to introduce a new strength 30/120/15 mg. The extension application is grouped with a type II variation (C.I.6.a) to include paediatric indication: use in patients 2 years of age and older and weighing at least 14 kg. Sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated to support the extended indication. The RMP (version 3.1) is updated in accordance."

Action: For adoption

List of Outstanding Issues adopted on 21.07.2022, 24.03.2022. List of Questions adopted on 14.10.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

4.1.2. Skyrizi - risankizumab - EMEA/H/C/004759/X/0020/G

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Jayne Crowe, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Extension application to:

- introduce a new pharmaceutical form (concentrate for solution for infusion), a new strength (600 mg) and a new route of administration (intravenous use)

- add a new strength of 360 mg for risankizumab solution for injection (in cartridge) for subcutaneous use

The above new presentations are indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

The RMP (version 4.5) is updated in accordance."

Action: For adoption

List of Outstanding Issues adopted on 21.07.2022. List of Questions adopted on

22.04.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

4.2. **Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues**

4.2.1. **Betmiga - mirabegron - EMEA/H/C/002388/X/0039/G**

Astellas Pharma Europe B.V.

Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Maria del Pilar Rayon

Scope: "Extension application to introduce a new pharmaceutical form associated with new strength (8 mg/ml prolonged-release granules for oral suspension), grouped with a type II variation (C.I.6.a) to include treatment of neurogenic detrusor overactivity (NDO) in paediatric patients aged 3 to less than 18 years. The RMP (version 9.0) is updated in accordance."

Action: For adoption

List of Questions adopted on 22.04.2022.

The Committee discussed the issues identified in this application, concerning quality aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

4.2.2. **Xofluza - baloxavir marboxil - EMEA/H/C/004974/X/0008/G**

Roche Registration GmbH

Rapporteur: Thalia Marie Estrup Blicher, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Sonja Hrabcik

Scope: "Extension application to introduce a new pharmaceutical form associated with a new strength (2 mg/ml granules for oral suspension) grouped with a type II variation (C.I.6.a) to include paediatric use (from 1 year and above). The paediatric indication is applicable to the new presentation (2 mg/ml granules for oral suspension) as well as all approved presentations (EU/1/20/1500/001 and 002). The RMP (version 2.0) is updated in accordance."

Action: For adoption

List of Questions adopted on 22.04.2022.

The Committee discussed the issues identified in this application, concerning quality and clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

No items

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

4.4.1. Calquence - acalabrutinib - EMEA/H/C/005299/X/0009/G

AstraZeneca AB

Rapporteur: Filip Josephson, PRAC Rapporteur: Željana Margan Koletić

Scope: "Extension application to introduce a new pharmaceutical form, film-coated tablet. A.6 - To change the ATC Code of acalabrutinib from L01XE51 to L01EL02."

Action: Update on the status of this application.

List of Outstanding Issues adopted on 21.07.2022, 19.05.2022. List of Questions adopted on 24.02.2022.

The Committee noted the status of this application.

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Adtralza - tralokinumab - EMEA/H/C/005255/II/0002

LEO Pharma A/S

Rapporteur: Jayne Crowe

Scope: "Extension of indication to include treatment of adolescent patients (12-17 years) for Adtralza based on final study LP0162-1334 (ECZTRA 6): a multicentre, randomised,

double-blind, placebo-controlled study in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis to evaluate the efficacy and safety of tralokinumab monotherapy in this population group. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.”

Action: For adoption

Request for Supplementary Information adopted on 24.03.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report.

The summary of opinion was circulated for information.

5.1.2. [Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel - ATMP - EMEA/H/C/004731/II/0005](#)

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli, CHMP Coordinator: Armando Genazzani, PRAC
Rapporteur: Brigitte Keller-Stanislawski

Scope: “Extension of indication to include treatment of adult patients with Second-line (2L) Transplant Intended (TI) Large B-Cell Lymphoma (LBCL) for Breyanzi, based on interim analyses from pivotal study JCAR017-BCM-003; this is a global randomized multicentre Phase III Trial to compare the efficacy and safety of JCAR017 to standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM); As a consequence, sections 4.1, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.0 of the RMP has also been submitted.”

Action: For adoption

The CHMP was updated on discussions at the CAT, concerning clinical aspects.

The Committee endorsed a request for supplementary information with a specific timetable, as adopted by CAT.

5.1.3. [Brukinsa - zanubrutinib - EMEA/H/C/004978/II/0002](#)

BeiGene Ireland Ltd

Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Johanna Lähteenvuo, PRAC Rapporteur:
Menno van der Elst

Scope: “Extension of indication to include treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one-prior anti-CD20-based therapy, based on data from 88 patients with R/R MZL from 2 ongoing pivotal studies; study BGB-3111-214: A Phase 2, open-label, single-arm study designed to evaluate the safety and efficacy of zanubrutinib in patients with R/R MZL, and study BGB-3111-AU-003: A first-in-human, Phase 1/2, dose-escalation and selection, PK/pharmacodynamic, safety, and efficacy study

in adult patients with R/R or treatment-naive B-cell malignancies. As a consequence, sections 4.1, 4.2, 4.5, 4.8 and 5.1 of the SmPC are updated and the Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted. In addition, the MAH is requesting one additional year of market protection." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 22.04.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.4. [Cosentyx - secukinumab - EMEA/H/C/003729/II/0090](#)

Novartis Europharm Limited

Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Eva A. Segovia

Scope: "Extension of indication to include treatment of Hidradenitis Suppurativa (HS) for Cosentyx, based on interim results from two Phase III studies CAIN457M2301 (SUNSHINE) and CAIN457M2302 (SUNRISE); These studies are ongoing, multi-center, randomized, double-blind, placebo-controlled, parallel group Phase 3 studies conducted to assess the short (16 weeks) and long-term (up to 52 weeks) efficacy and safety of two secukinumab dose regimens (Q2W or Q4W) compared to placebo in adult subjects with moderate to severe HS; As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2. of the SmPC are updated. The Package Leaflet is updated in accordance. Version 11 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, concerning the wording of the indication.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.5. [Enhertu - trastuzumab deruxtecan - EMEA/H/C/005124/II/0022](#)

Daiichi Sankyo Europe GmbH

Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication to include treatment of unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. Patients with hormone receptor positive (HR+) breast cancer must additionally have received or be ineligible for endocrine therapy; for Enhertu, based on final results from study DS8201-A-U303 (DESTINY-Breast04). This is a Phase III, multicentre, randomised, open-label, active-controlled trial of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-antibody Drug Conjugate (ADC), versus treatment of physician's choice for

HER2-low, unresectable and/or metastatic breast cancer subjects.

As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.4 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update section 4.4 of the SmPC to update the dosing recommendation for corticosteroid treatment (e.g. prednisolone) with a daily dose.”

Action: For adoption

The Committee discussed the issues identified in this application, concerning the wording of the indication.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.6. Epidyolex - cannabidiol - Orphan - EMEA/H/C/004675/II/0020

GW Pharma (International) B.V.

Rapporteur: Thalia Marie Estrup Blicher, Co-Rapporteur: Ondřej Slanař, PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: “Extension of indication to include treatment with Epidyolex (monotherapy) as adjunctive therapy of seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS) for patients 2 years of age and older (without the restriction for use only in conjunction with clobazam), based on the previously generated data in patients treated without CLB in the LGS and DS pivotal studies re-evaluated in the context of the more recent evidence from study GWEP1521 in tuberous sclerosis complex (TSC). As a consequence, sections 4.1, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement editorial changes in the product information. Version 2.1 of the RMP has also been submitted.”

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.7. Evusheld - tixagevimab / cilgavimab - EMEA/H/C/005788/II/0001

AstraZeneca AB

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Christophe Focke, PRAC Rapporteur: Kimmo Jaakkola

Scope: “Extension of indication to include treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID-19, who do not require supplemental oxygen and are at increased risk of progressing to severe COVID-19. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 4.9, 5.1, 5.2, 6.3 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to make some editorial changes. Version 2.0 of the RMP has also been submitted.”

Action: For adoption

Request for Supplementary Information adopted on 23.06.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.8. [Exparel liposomal - bupivacaine - EMEA/H/C/004586/II/0005](#)

Pacira Ireland Limited

Rapporteur: Elita Poplavska, Co-Rapporteur: Margareta Bego, PRAC Rapporteur: Rhea Fitzgerald

Scope: "Extension of indication to include children over 6 years old."

Action: For adoption

Request for Supplementary Information adopted on 19.05.2022, 16.12.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.9. [Gavreto - pralsetinib - EMEA/H/C/005413/II/0002/G](#)

Roche Registration GmbH

Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication to include monotherapy treatment of adult and paediatric patients 12 years of age and older with locally advanced or metastatic RET-mutant medullary thyroid cancer for Gavreto; based on the efficacy and safety data obtained from the pivotal study BO42863 (ARROW). As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted. Furthermore, some minor changes to the PI have been implemented in line with the latest Anticancer Guidelines Recommendations. Extension of indication to include monotherapy treatment of adult and paediatric patients 12 years of age and older with locally advanced or metastatic RET fusion-positive thyroid cancer for Gavreto; based on the efficacy and safety data obtained from the pivotal study BO42863 (ARROW). As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 23.06.2022, 24.03.2022.

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a 3rd request for supplementary information with a specific

timetable.

5.1.10. [Kerendia - finerenone - EMEA/H/C/005200/II/0001/G](#)

Bayer AG

Rapporteur: Kristina Dunder, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include the treatment of chronic kidney disease (CKD) and for the prevention of cardiovascular (CV) events in adults with CKD (regardless of the stage of albuminuria) associated with type 2 diabetes, based on results from study 17530 (FIGARO-DKD); a randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care. As a consequence, sections 4.1, 4.8, 5.1 and 5.2 of the SmPC is being updated and the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make editorial changes in the SmPC. The updated RMP version 2.1 has also been submitted. Update of the SmPC section 5.2 based on the results of study 21429, a phase 1 drug interaction study of finerenone with rosuvastatin. The CSR PH-42032 was already submitted within the response to Day 180 List of Outstanding Issues of the initial MAA. Submission of the results of study 21325, a phase 1 bioequivalence study assessing BE between finerenone 2 x 10 mg tablets and 20 mg tablet in Japanese healthy male adult participants (required by the Japanese PMDA)."

Action: For adoption

Request for Supplementary Information adopted on 23.06.2022.

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.11. [Lyumjev - insulin lispro - EMEA/H/C/005037/II/0014](#)

Eli Lilly Nederland B.V.

Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Mari Thorn

Scope: "Extension of indication to include the treatment of diabetes mellitus in adolescents and children aged 1 year and above, based on final results from study I8B-MC-ITSB; this is a pivotal Phase 3 study designed to evaluate the safety and efficacy of Lyumjev compared to Humalog in combination with basal insulin in children and adolescent patients with T1D. The study was designed to compare change in HbA1c as the primary endpoint. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial and linguistic changes in the SmPC and Package Leaflet. As part of the application, the MAH is also requesting one additional year of market protection." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 21.07.2022, 22.04.2022.

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a 3rd request for supplementary information with a specific timetable.

5.1.12. Mircera - methoxy polyethylene glycol-epoetin beta - EMEA/H/C/000739/II/0092

Roche Registration GmbH

Rapporteur: Maria Concepcion Prieto Yerro

Scope: "Extension of indication to include treatment of paediatric patients from 3 months to less than 18 years of age requiring dialysis or not yet on dialysis and switching from another ESA to Mircera, based on final results from study NH19708; this is a single-arm, open-label, Phase II study of Mircera in patients aged 3 months to <18 years with CKD on dialysis or not yet on dialysis to generate PK, efficacy, and safety data for subcutaneous (SC) administration of Mircera. In addition, supportive data from studies NH19707, Modelling & Simulation study (study 3) and MH40258 were included. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to update the Instruction for Use in the Package Leaflet."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.13. Nubeqa - darolutamide - EMEA/H/C/004790/II/0009

Bayer AG

Rapporteur: Alexandre Moreau, Co-Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Jan Neuhauser

Scope: "Extension of indication to include treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel, based on final results from study 17777 (ARASENS); this is a randomized, double-blind, placebo-controlled Phase 3 study designed to demonstrate the superiority of darolutamide in combination with docetaxel over placebo in combination with docetaxel in OS in patients with mHSPC. As a consequence, sections 4.1, 4.2, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.1 of the RMP has also been submitted. As part of the application, the MAH is also requesting one additional year of market protection.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 23.06.2022.

The Committee discussed the issues identified in this application, concerning the request for 1 year of market protection.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.14. Revestive - teduglutide - Orphan - EMEA/H/C/002345/II/0054/G

Takeda Pharmaceuticals International AG Ireland Branch

Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: "Extension of indication to include patients from 4 months corrected gestational aged 1 year and above. Consequently sections 4.1, 4.2, 4.8, 5.1 and 5.2 are updated. The Package Leaflet is updated accordingly.

Update of annex II to amend the date of completion of the post authorisation study. The MAH took the opportunity to also amend local representatives."

Action: For adoption

Request for Supplementary Information adopted on 22.04.2022, 11.11.2021.

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a 3rd request for supplementary information with a specific timetable.

5.1.15. Revolade - eltrombopag - EMEA/H/C/001110/II/0068

Novartis Europharm Limited

Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia

Scope: "Extension of indication to include treatment of adult patients with primary immune thrombocytopenia (ITP) who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) irrespective of time since initial diagnosis, based on an ad-hoc analysis of study TAPER (CETB115J2411); an ongoing phase II, open-label, prospective, single-arm study in adult ITP patients who are refractory or relapsed after first-line steroids.

As a consequence, sections 4.1 and 5.1 of the SmPC have been updated.

In addition, the MAH took the opportunity to make some minor amendments in section 4.8 of the SmPC for increased consistency. An updated RMP version 54.1 has been submitted."

Action: For adoption

Request for Supplementary Information adopted on 22.04.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.16. TachoSil - human thrombin / human fibrinogen - EMEA/H/C/000505/II/0117

Corza Medical GmbH

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include treatment of children aged 1 month to 18 years, based on available bibliographical data, results from study TC-2402-040-SP which compared TachoSil with Surgicel Original as adjunct to primary surgical treatment in both adult and paediatric subjects, and results from study TC-019-IN; a prospective, uncontrolled study in paediatric subjects. As a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial changes in the product information. Version 0.1 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.17. Vaxneuvance - pneumococcal polysaccharide conjugate vaccine (adsorbed) - EMEA/H/C/005477/II/0001

Merck Sharp & Dohme B.V.

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Daniela Philadelphia, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include treatment of infants, children and adolescents from 6 weeks to less than 18 years of age for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media for Vaxneuvance. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance.

Version 2.0 of the RMP has also been submitted.

In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to include editorial changes in the product information."

Action: For adoption

Request for Supplementary Information adopted on 21.07.2022, 22.04.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.18. Veklury - remdesivir - EMEA/H/C/005622/II/0035/G

Gilead Sciences Ireland UC

Rapporteur: Janet Koenig, PRAC Rapporteur: Eva Jirsová

Scope: "Grouped application of two extensions of indication to include:

- treatment of paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) or other non-invasive ventilation at start of treatment, based on interim results from study GS-US-540-5823; a phase 2/3 single-arm, open-label study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of Remdesivir in participants from birth to <18 years of age with COVID-19;
- treatment of paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19, based on data from 8 adolescent patients who were included in study GS-US-540-9012, which was initially assessed by the CHMP as part of procedure II/16 (Extension of indication to include treatment of adults).

As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet as well as the instructions for healthcare professionals have been updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Version 5.0 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 19.05.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

5.1.19. [Vemlidy - tenofovir alafenamide - EMEA/H/C/004169/II/0040](#)

Gilead Sciences Ireland UC

Rapporteur: Janet Koenig, Co-Rapporteur: Filip Josephson, PRAC Rapporteur: Valentina Di Giovanni

Scope: "Extension of indication to include treatment of chronic hepatitis B-infected children from 6 years and older and weighing at least 25 kilograms for Vemlidy, based on the interim results from Week 24 clinical study report (CSR) for Cohort 1 and Cohort 2 Group 1 and supporting modular summaries for the category 3 study GS-US-320-1092, 'A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescent Subjects with Chronic Hepatitis B Virus Infection'. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance.

In addition, the MAH took the opportunity to update the wording in section 4.6 of the SmPC related to breastfeeding and pregnancies exposed to TAF, and to update the contact details of the local representative in Romania in the Package Leaflet.

An updated RMP version 8.2 has been provided."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.20. Wakix - pitolisant - Orphan - EMEA/H/C/002616/II/0030

Bioprojet Pharma

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Kirsti Villikka

Scope: "Extension of indication to include treatment of narcolepsy with or without cataplexy in adolescents and children from the age of 6 years, based on results from study P11-06; an ongoing phase III, double-blind, multicentre, randomized, placebo-controlled trial undertaken to evaluate safety and efficacy of pitolisant in children from 6 to less than 18 years with narcolepsy with/without cataplexy. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 7.0 of the RMP has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects and the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.21. Xalkori - crizotinib - EMEA/H/C/002489/II/0072

Pfizer Europe MA EEIG

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant

Scope: "Extension of indication to include treatment of paediatric patients (age \geq 6 to < 18 years) with relapsed or refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) and with unresectable, recurrent, or refractory ALK-positive inflammatory myofibroblastic tumour (IMT) for Xalkori based on the results from studies ADVL0912 and A8081013; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. Information regarding the educational pack in annex II has also been added. The Package Leaflet is updated in accordance. Version 8.2 of the RMP has also been submitted."

Action: For adoption

Request for Supplementary Information adopted on 23.06.2022, 24.02.2022, 16.09.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by majority (30 positive votes out of 31 votes) together with the CHMP assessment report and translation timetable.

The divergent position (Paula Boudewina van Hennik) was appended to the opinion.

The summary of opinion was circulated for information.

5.1.22. Yescarta - axicabtagene ciloleucel - Orphan - ATMP - EMEA/H/C/004480/II/0046

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Claire Beuneu, CHMP Coordinators: Jan

Mueller-Berghaus and Karin Janssen van Doorn, PRAC Rapporteur: Anette Kirstine Stark

Scope: "Extension of indication to include treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) for Yescarta; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 5.3 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the product information with minor editorial changes." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

Request for Supplementary Information adopted on 15.07.2022, 13.05.2022, 18.02.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

Based on the draft opinion prepared by the CAT, the CHMP adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Medical devices

6.1. Ancillary medicinal substances - initial consultation

No items

6.2. Ancillary medicinal substances – post-consultation update

No items

6.3. Companion diagnostics - initial consultation

6.3.1. in vitro diagnostic medical device - EMEA/H/D/006107

In vitro qualitative immunohistochemical detection of programmed death-ligand 1 (PD-L1)

Scope: List of questions

Action: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

6.4. Companion diagnostics – follow-up consultation

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. Respiratory Syncytial Virus - H0006054

indicated for active immunisation for the prevention of respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD) in adults aged 60 years and older.

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP agreed to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information.

8.2.1. List of applications received

Action: For information

The CHMP noted the list of applications received.

8.2.2. Recommendation for PRIME eligibility

Action: For adoption

The CHMP adopted the recommendation for PRIME eligibility. The CHMP reviewed 5 recommendations for eligibility to PRIME: 2 were accepted and 3 were denied.

The individual outcomes are listed in the PRIME Monthly Report on the EMA website.

9. Post-authorisation issues

9.1. Post-authorisation issues

9.1.1. Nulojix – belatacept – EMEA/H/C/002098

Bristol-Myers Squibb Pharma EEIG; prophylaxis of graft rejection in adults receiving a renal transplant

Rapporteur: Filip Josephson, Co-Rapporteur: Romaldas Mačiulaitis

Scope: DHPC and communication plan

Action: For adoption

The CHMP adopted the DHPC and communication plan.

9.1.2. Temybric Ellipta - fluticasone furoate/umeclidinium/vilanterol – EMEA/H/C/005254

GlaxoSmithKline Trading Services, treatment of asthma

Rapporteur: Jayne Crowe, Co-Rapporteur: Janet Koenig

Scope: Withdrawal of marketing authorisation

Action: For information

The CHMP noted the withdrawal of the marketing authorisation.

9.1.3. Qarziba - dinutuximab beta – Orphan - EMEA/H/C/003918/II/0043

EUSA Pharma (Netherlands) B.V.

Rapporteur: Paula Boudewina van Hennik

Scope: "Update of sections 4.1, 4.2 and 5.1 of the SmPC based on final results from study APN311-202V3 listed as a Specific Obligation in the Annex II of the Product Information. This is a Phase I/II dose schedule finding study of Ch14.18/CHO continuous infusion combined with subcutaneous aldesleukin (IL-2) in patients with primary refractory or relapsed neuroblastoma. In addition, the MAH took the opportunity to update Annex II section E. The Package Leaflet is updated accordingly."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.4. [Apexxnar - pneumococcal polysaccharide conjugate vaccine \(20-valent, adsorbed\) - EMEA/H/C/005451/II/0006](#)

Pfizer Europe MA EEIG

Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Jean-Michel Dogné

Scope: "Update of sections 4.5, 4.8 and 5.1 of the SmPC based on final results from study B7471026 listed as a category 3 study in the RMP; this is a Phase III, randomized, double-blind trial to describe the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine when coadministered with a booster dose of BNT162b2 in adults 65 years of age and older; the Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.5. [Rubraca - rucaparib - EMEA/H/C/004272/II/0029](#)

Clovis Oncology Ireland Limited

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Annika Folin

Scope: "Update of sections 4.4 and 4.8 of the SmPC based on safety data from study CO-338-043 (ARIEL 4); this is a phase 3, multicentre, open-label, randomised study evaluating the efficacy and safety of rucaparib versus chemotherapy for treatment of relapsed ovarian cancer listed as a specific obligation in the Annex II; the Package Leaflet is updated accordingly. The RMP version 6.2 is acceptable.

Update of Annex II to remove the specific obligation. The SmPC and Package leaflet are amended accordingly to reflect the conversion from a conditional marketing authorisation to a marketing authorisation no longer subject to specific obligations as recommended by the CHMP as a result of this variation and further to the removal of the indication for monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy (EMEA/H/A-20/1518/C/4272/0033). In addition, the MAH took the opportunity to make minor editorial changes and bring the PI in line with the latest QRD template version 10.2 Rev.1."

Action: For adoption

Request for Supplementary Information adopted on 21.07.2022, 24.03.2022, 11.11.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

9.1.6. Spikevax - elasomeran - EMEA/H/C/005791/II/0075/G

Moderna Biotech Spain, S.L.

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Addition of a new strain (Omicron BA.1) resulting in two new Spikevax bivalent Original/Omicron (25 µg elasomeran / 25 µg imelasomeran per dose) 0.1 mg/mL dispersion for injection presentations. The SmPC, the Package Leaflet and Labelling are updated accordingly. The submission includes a revised RMP version 4.2.

Action: For adoption

At an extraordinary CHMP meeting on 01 September 2022, the CHMP discussed this variation.

On 01 September 2022, the Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

9.1.7. Comirnaty - tozinameran - EMEA/H/C/005735/II/0140

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst

Scope: Addition of a new strain (Omicron BA.1) resulting in a new Comirnaty Original/Omicron BA.1 (15 µg tozinameran/ 15 µg riltozinameran)/dose dispersion for injection presentation. The Annex A, the SmPC, the Labelling and the Package Leaflet are updated accordingly. A revised RMP version 6.1 has been approved.

Action: For adoption

At an extraordinary CHMP meeting on 01 September 2022, the CHMP discussed this variation.

On 01 September 2022, the Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

9.1.8. Comirnaty - tozinameran - EMEA/H/C/005735/II/0129

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson

Scope: Update of sections 4.2, 4.8 and 5.1 of the SmPC of Comirnaty 10 µg Concentrate for dispersion for injection in order to introduce a booster dose for children 5 to 11 years of age based on interim results from study C4591007; this is a Phase 1, Open-Label Dose-Finding Study to Evaluate Safety, Tolerability, and Immunogenicity and Phase 2/3 Placebo-Controlled, Observer-Blinded Safety, Tolerability, and Immunogenicity Study of a SARS-CoV-2 RNA Vaccine Candidate Against COVID-19 in Healthy Children and Young Adults; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make

minor editorial changes throughout the product information.

Action: For adoption

Request for Supplementary Information adopted on 23.06.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report.

9.1.9. [Nuvaxovid - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/II/0014](#)

Novavax CZ, a.s.

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to include a third dose for Nuvaxovid, to boost individuals who have previously completed a primary vaccination series with Nuvaxovid (homologous booster dose) or with an mRNA or adenoviral vector vaccine (heterologous booster dose); based on interim data from study 2019nCoV-101 (Part 2), final data from study 2019nCoV-501, and data from the COV-BOOST study; the Package Leaflet is updated accordingly. The RMP version 2.0 has also been approved. In addition, the Marketing Authorisation Holder (MAH) took the opportunity to make minor editorial corrections in the Annex II and labelling (Annex III B)."

Action: For adoption

Request for Supplementary Information adopted on 21.07.2022.

At an extraordinary CHMP meeting on 01 September 2022, the CHMP discussed this variation.

On 01 September 2022, the Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

9.1.10. [Comirnaty - tozinameran - EMEA/H/C/005735/II/0143](#)

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst

Scope: "Addition of a new strain (Omicron BA.4-5) resulting in a new Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose dispersion for injection presentation. The SmPC, the Package Leaflet and Labelling are updated accordingly. A revised RMP version 7.1 has been approved."

Action: For adoption

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report.

9.1.11. Comirnaty - tozinameran - EMEA/H/C/005735/R/0137

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst

Scope: Renewal of conditional marketing authorisation

Action: For adoption

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation.

Based on the review of the available information, the CHMP was of the opinion that the risk-benefit balance remains favourable and that all specific obligations have been fulfilled. Therefore, the CHMP recommended granting of a Marketing Authorisation not subject to specific obligations.

9.1.12. Spikevax - elasomeran - EMEA/H/C/005791/R/0074

Moderna Biotech Spain, S.L.,

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: Renewal of conditional marketing authorisation

Action: For adoption

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

Based on the review of the available information, the CHMP was of the opinion that the risk-benefit balance remains favourable and that all specific obligations have been fulfilled. Therefore, the CHMP recommended granting of a Marketing Authorisation not subject to specific obligations.

9.1.13. Spikevax - elasomeran - EMEA/H/C/005791/II/0066

Moderna Biotech Spain, S.L.

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: "Update of section 4.5 of the SmPC in order to indicate the possibility of co-administration of Spikevax with a high-dose quadrivalent influenza vaccine, based on the interim results from study QHD00028 (NCT04969276), a Phase II, open-label study aimed to assess the safety and immunogenicity of a high-dose quadrivalent influenza vaccine (2021-2022 formulation) and a third dose of Spikevax administered either concomitantly or singly in adults 65 years of age and older previously primed with Spikevax. The MAH is taking the opportunity to include as editorial updates in sections 5.1 and 6.6 of the SmPC, Annex II and package leaflet, corrections from procedure EMEA/H/C/005791/II/0075."

Action: For adoption

Request for Supplementary Information adopted on 21.07.2022.

The Committee confirmed that all issues previously identified in this application had been

addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

9.1.14. Caprelsa - vandetanib - EMEA/H/C/002315/R/0055

Genzyme Europe BV

Rapporteur: Alexandre Moreau, Co-Rapporteur: Paula Boudewina van Hennik

Scope: Renewal of marketing authorisation

Action: For adoption

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

9.1.15. Caprelsa - vandetanib - EMEA/H/C/002315/II/0043

Genzyme Europe BV

Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Tiphaine Vaillant

Scope: "C.I.4 Update of section 5.1 of the SmPC in order to update pharmacodynamic information based on interim results from study D4200C00104, listed as a specific obligation in the Annex II. This is an observational study (including a retrospective arm to evaluate the Benefit/Risk of vandetanib (Caprelsa) 300 mg in RET mutation negative and RET mutation positive patients with symptomatic, aggressive, sporadic, unresectable, locally advanced/metastatic thyroid cancer (MTC)), to confirm the efficacy and safety of Caprelsa in RET-negative patients with the aim to fulfil SOB001 and convert Caprelsa from conditional to normal Marketing Authorisation.

In addition, the MAH takes to opportunity to rectify the Dutch translation of the Caprelsa Product Information."

Action: For adoption

Request for Supplementary Information adopted on 19.05.2022, 16.12.2021, 24.06.2021, 28.05.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

Based on the review of the available information, the CHMP was of the opinion that all specific obligations have been fulfilled. Therefore, the CHMP recommended granting of a Marketing Authorisation not subject to specific obligations.

The summary of opinion was circulated for information.

The CHMP agreed on the wording of a direct healthcare professional communication (DHPC) together with a communication plan.

9.1.16. Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/II/0056

Orexigen Therapeutics Ireland Limited

Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Martin Huber

Scope: "Submission of updated study design and protocol synopsis for CVOT-2 study, a category 1 study listed in Annex II.D (ANX/001.7) undertaken to assess the effect of naltrexone extended release (ER) / bupropion ER on the occurrence of major adverse cardiovascular events (MACE), as requested in the CHMP AR for ANX/001.6. The Annex II and the RMP version 13 are updated accordingly."

Action: For adoption

Request for Supplementary Information adopted on 24.03.2022.

The Committee discussed the issues identified in this application, concerning clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

9.1.17. NeoRecormon – epoetin beta – EMEA/H/C/000116

Roche Registration GmbH

Rapporteur: Martina Weise, Co-Rapporteur: Alexandre Moreau

Scope: DHPC and communication plan

Action: For adoption

The CHMP agreed on the wording of a direct healthcare professional communication (DHPC) together with a communication plan.

9.1.18. Metalyse – tenecteplase – EMEA/H/C000306

Boehringer Ingelheim International GmbH

Rapporteur: Martina Weise, Co-Rapporteur: Armando Genazzani

Scope: DHPC and communication plan

The CHMP adopted the DHPC and communication plan via written procedure on 26 August 2022.

Action: For information

The CHMP noted the DHPC and communication plan, which were adopted via written procedure.

10. Referral procedures

10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

No items

10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

No items

10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

10.4.1. Rambis - EMEA/H/A-29(4)/1519

Adamed Pharma S.A.

Rapporteur: Ewa Balkowiec Iskra, Co-Rapporteur: Ondrej Slanar

Scope: List of outstanding issues

Action: For adoption

Decentralised procedure number: PL/H/0758/001-006/DC, notification by the Agency of Poland dated 30 May 2022 notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC

The Committee adopted a list of outstanding issues with a specific timetable.

CHMP list of outstanding issues: 15 September 2022 CHMP

Submission of responses: 27 October 2022

Re-start of the procedure: 17 November 2022

Rapporteur/co-rapporteur joint assessment report circulated to CHMP: 25 November 2022

Comments: 02 December 2022

Updated Rapporteur/co-rapporteur joint assessment report circulated to CHMP: 08 December 2022

CHMP opinion: December 2022 CHMP

10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

No items

10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC

10.6.1. Chlormadinone (NAP); chlormadinone, ethinylestradiol (NAP); nomegestrol (NAP); nomegestrol, estradiol – ZOELY (CAP); NAP - EMEA/H/A-31/1510

Applicant(s): Theramex Ireland Limited (Zoely), various

PRAC Rapporteur: Martin Huber; PRAC Co-rapporteur: Zeljana Margan Koletic

Review of the benefit-risk balance following notification by France of a referral under Article 31 of Directive 2001/83/EC, based on pharmacovigilance data.

Scope: Opinion

Action: For adoption

At an extraordinary CHMP meeting on 01 September 2022, the CHMP discussed this referral.

On 01 September 2022, having considered the PRAC recommendation, the CHMP adopted an opinion by majority (26 out of 28 votes), concluding that the benefits of medicines containing nomegestrol or chlormadinone outweigh the risks, provided new measures are taken to minimise the risk of meningioma.

The CHMP has recommended that medicines containing high-dose nomegestrol (3.75 – 5 mg) or high-dose chlormadinone (5 – 10 mg) should be used at the lowest effective dose and for the shortest duration possible, and only when other interventions are not appropriate. In addition, low- and high-dose nomegestrol- or chlormadinone-containing medicines must not be used by patients who have, or have had, meningioma.

As well as restricting the use of the high-dose medicines, the CHMP has recommended that patients should be monitored for symptoms of meningioma. If a patient is diagnosed with meningioma, treatment with these medicines must be permanently stopped.

The divergent position (Jean-Michel Race and Alexandra Branchu) was appended to the opinion.

The CHMP noted the EMA communication.

10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

10.7.1. Synchron Research Services – various – EMEA/H/A-31/1515

Various MAHs

Re-examination Referral Rapporteur: John Joseph Borg, Referral Co-Rapporteur: Paula Boudewina van Hennik

Scope: Opinion

Action: For adoption

Article 31 procedure triggered by the Federal Agency for Medicines and Health Products (FAMHP) in Belgium, the Danish Medicines Agency (DKMA), the Finnish Medicines Agency

(Fimea), the Medicines Evaluation Board (MEB) in the Netherlands and the Medical Products Agency (MPA) in Sweden concerning the contract research organisation (CRO) Synchron Research Services, located in Ahmedabad, Gujarat, India.

The CHMP adopted its initial recommendation in May 2022, after irregularities were found in how the CRO carried out bioequivalence studies, which raised serious concerns about the company's quality management system and the reliability of data from that site. The CHMP concluded that for the majority of the medicines investigated no adequate bioequivalence data were available from other sources and therefore recommended that they be suspended. For a small number of authorised generic medicines, adequate bioequivalence data were available from other sources, and these medicines were allowed to remain on the EU market.

During the re-examination, the CHMP adopted an opinion by consensus concluding that adequate bioequivalence data are available from an alternative study for eight medicines. The marketing authorisations for these medicines can therefore be maintained.

As a result of the CHMP's initial opinion and re-examination, the recommendation to suspend medicines for which adequate bioequivalence data are lacking is confirmed. The suspensions can be lifted once alternative data establishing bioequivalence are provided.

The CHMP noted the EMA communication.

10.8. Procedure under Article 107(2) of Directive 2001/83/EC

No items

10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003

No items

10.10. Procedure under Article 29 of Regulation (EC) 1901/2006

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008

No items

11. Pharmacovigilance issue

11.1. Early Notification System

September 2022 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

The CHMP noted the information.

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

No items

13.2. Innovation Task Force briefing meetings

No items

13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

14.1.1. CHMP membership

New membership:

The Chair welcomed Alexandra Branchu, as the new alternate for Luxembourg and Hjalti Kristinsson as the new alternate for Iceland.

14.1.2. Vote by proxy

At the extraordinary CHMP held on 01 September 2022, Ireland gave a PROXY to Bruno Sepodes (PT) to vote on behalf of Ireland during the entire meeting.

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for September 2022

Action: For adoption

The CHMP adopted the EURD list.

14.2.2. Paediatric Committee (PDCO)

PIPs reaching D30 at September 2022 PDCO

Action: For information

The CHMP noted the information.

Report from the PDCO meeting held on 06-09 September 2022

Action: For information

The CHMP noted the information.

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Biologics Working Party (BWP)

Chair: Sol Ruiz/ Sean Barry

Reports from BWP September 2022 meeting to CHMP for adoption:

- 12 reports on products in scientific advice and protocol assistance
- 11 reports on products in pre-authorisation procedures
- 1 report on products in post-authorisation procedures
- 3 reports on products in plasma master file

Action: For adoption

The CHMP adopted the BWP reports.

14.3.2. Scientific Advice Working Party (SAWP)

Chair: Paolo Foggi

Report from the SAWP meeting held on 29 August - 01 September 2022. Table of conclusions

Action: For information

The CHMP noted the report.

Scientific advice letters:

Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

14.3.3. EC Request for a scientific opinion on the classification as medicinal products of certain substances used in blood bags CDP (citrate, dextrose and phosphate) and CDPA (citrate, dextrose, phosphate and adenine)

Discussion and endorsement of a response letter to the EC.

Action: For adoption

The CHMP adopted the scientific opinion on the classification of substances used in blood bags (EMA/CHMP/BPWP/758757/2022).

The EMA response letter to the EC was also presented.

14.3.4. Call for expression of interest for EMA/EC expert to the ICH E11A (paediatric extrapolation) expert working group

A call for expression of interest for the appointment of a new expert to represent CHMP/EMA/EC in the ICH E11A working group, working on an ongoing guideline on paediatric extrapolation, was launched with the Modelling and Simulation WP with a deadline of 25 August. Following endorsement from MWP chair and vice-chair, an expert nomination is now brought to CHMP for endorsement:

Action: For endorsement

The CHMP endorsed an expert representing CHMP/EMA/EC in the ICH E11A working group.

14.3.5. Nomination for new member for CNSWP

The current CNS WP has only 7 members. It is proposed to add an additional member to bring the Working Party to full capacity. A call for nomination was launched for new member for CNSWP.

Action: For information

The CHMP noted the postponement of the nomination for a new member for the CNSWP.

14.4. Cooperation within the EU regulatory network

No items

14.5. Cooperation with International Regulators

No items

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

14.7. CHMP work plan

No items

14.8. Planning and reporting

14.8.1. Update of the Business Pipeline report for the human scientific committees

Q3-2022 initial marketing authorisation application submissions with eligibility request to central procedure

Action: For information

The CHMP noted the information.

14.9. Others

No items

15. Any other business

15.1. AOB topic

15.1.1. Update on COVID-19

Action: For information

The CHMP noted the information.

Lists of participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the 12-15 September 2022 CHMP meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Harald Enzmann	Chair	Germany	No interests declared	
Andrea Laslop	Member	Austria	No interests declared	
Daniela Philadelphy	Alternate	Austria	No interests declared	
Christophe Focke	Member	Belgium	No restrictions applicable to this meeting	
Karin Janssen van Doorn	Alternate	Belgium	No interests declared	
Velislava Todorova	Alternate	Bulgaria	No interests declared	
Margareta Bego	Member	Croatia	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	
Helena Panayiotopoulou	Member	Cyprus	No interests declared	
Ondřej Slanař	Member	Czechia	No restrictions applicable to this meeting	
Tomas Radimersky	Alternate	Czechia	No interests declared	
Thalia Marie Estrup Blicher	Member	Denmark	No restrictions applicable to this meeting	
Aaron Sosa Mejia	Alternate	Denmark	No restrictions applicable to this meeting	
Alar Irs	Member	Estonia	No restrictions applicable to this meeting	
Edward Laane	Alternate	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Johanna Lähteenvuo	Alternate	Finland	No interests declared	
Alexandre Moreau	Member	France	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Martina Weise	Member	Germany	No restrictions applicable to this meeting	
Janet Koenig	Alternate	Germany	No interests declared	
Konstantina Alexopoulou	Member	Greece	No interests declared	
Anastasia Mountaki	Alternate	Greece	No interests declared	
Robert Porszasz	Member	Hungary	No interests declared	
Agnes Gyurasics	Alternate	Hungary	No interests declared	
Hjalti Kristinsson	Alternate	Iceland	No interests declared	
Jayne Crowe	Member	Ireland	No interests declared	
Armando Genazzani	Member	Italy	No interests declared	
Maria Grazia Evandri	Alternate	Italy	No interests declared	
Elita Poplavska	Member	Latvia	No interests declared	
Romaldas Mačiulaitis	Member	Lithuania	No participation in final deliberations and voting on:	COVID-19 vaccines

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Silvijus Abramavicius	Alternate	Lithuania	No restrictions applicable to this meeting	
Martine Trauffler	Member	Luxembourg	No interests declared	
Alexandra Branchu	Alternate	Luxembourg	No restrictions applicable to this meeting	
John Joseph Borg	Member	Malta	No interests declared	
Johann Lodewijk Hillege	Member	Netherlands	No interests declared	
Paula Boudewina van Hennik	Alternate	Netherlands	No interests declared	
Ingrid Wang	Member	Norway	No interests declared	
Eva Skovlund	Alternate	Norway	No interests declared	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Bruno Sepodes	Member (Vice-Chair)	Portugal	No interests declared	
Fatima Ventura	Alternate	Portugal	No participation in final deliberations and voting on:	COVID-19 vaccines
Simona Badoi	Member	Romania	No interests declared	
Dana Gabriela Marin	Alternate	Romania	No interests declared	
Francisek Drafi	Member	Slovakia	No interests declared	
Dorota Distlerova	Alternate	Slovakia	No interests declared	
Kristina Nadrah	Member	Slovenia	No restrictions applicable to this meeting	
Maria Concepcion Prieto Yerro	Member	Spain	No interests declared	
Blanca Garcia-Ochoa	Alternate	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Christian Gartner	Co-opted member	Austria	No interests declared	
Carla Torre	Co-opted member	Portugal	No interests declared	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Blanka Hirschlerova	Co-opted member	Czechia	No interests declared	
Sol Ruiz	Co-opted member	Spain	No interests declared	
Finbarr Leacy	Expert	Ireland	No interests declared	
Danica Juricic Nahal	Expert	Croatia	No interests declared	
Dijana Derganc	Expert	Croatia	No interests declared	
Petra Sokol	Expert	Croatia	No interests declared	
Melanie Ramberger	Expert	Austria	No interests declared	
Hannah Münch	Expert	Austria	No interests declared	
Linda Trauffler	Expert	Austria	No interests declared	
Bojana Divkovic	Expert	Austria	No restrictions applicable to this meeting	
Barbora Ladinova	Expert	Czechia	No interests declared	
Pavel Simek	Expert	Czechia	No interests declared	
Katerina Pospisilova	Expert	Czechia	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Vincent Gazin	Expert	France	No interests declared	
Celine Jumeau	Expert	France	No interests declared	
Anissa Benlazar	Expert	France	No interests declared	
Fabien Carré	Expert	France	No restrictions applicable to this meeting	
Sargi Caizergues Lama	Expert	France	No interests declared	
Roxane Fornacciari	Expert	France	No interests declared	
Jelena Katic	Expert	Germany	No interests declared	
Stephanie Liane Cini	Expert	Malta	No interests declared	
Ole Henrik Myrdal	Expert	Norway	No interests declared	
Anne-Berit Erdal	Expert	Norway	No restrictions applicable to this meeting	
Greger Abrahamsen	Expert	Norway	No interests declared	
Paula Contreras Alarcón	Expert	Spain	No participation in discussion, final deliberations and voting on:	Skyrizi - risankizumab - EMEA/H/C/004759/X/0020/G
Mas Parra Paloma	Expert	Spain	No restrictions applicable to this meeting	
Maria Victoria Tudanca Pacios	Expert	Spain	No restrictions applicable to this meeting	
Carolina Prieto Fernandez	Expert	Spain	No interests declared	
Lucia Lopez-Anglada Fernandez	Expert	Spain	No interests declared	
Macarena Gajardo	Expert	Spain	No interests declared	
Marcos Timón	Expert	Spain	No interests declared	
Paolo Foggi	Expert	Italy	No interests declared	
Adriana Ammassari	Expert	Italy	No interests declared	
Luca Santi	Expert	Italy	No restrictions applicable to this meeting	
Martina Perini	Expert	Italy	No restrictions applicable to this meeting	
Sara Galluzzo	Expert	Italy	No interests declared	
Antonella Isgrò	Expert	Italy	No interests declared	
Pia Rivetti di Val Cervo	Expert	Italy	No interests declared	
Angelo Molinaro	Expert	Italy	No interests declared	
Cristina Migali	Expert	Italy	No interests declared	
Odoardo Maria Olimpieri	Expert	Italy	No interests declared	
Gabriella Passacuale	Expert	Italy	No interests declared	
Valeria Zoccano	Expert	Italy	No interests declared	
Jorg Engelbergs	Expert	Germany	No interests declared	
Hilke Zander	Expert	Germany	No interests declared	
Susanne Mueller-Egert	Expert	Germany	No interests declared	
Sara Tognarelli	Expert	Germany	No restrictions applicable to this meeting	
Yasmin Molter	Expert	Germany	No interests declared	
Thomas Hinz	Expert	Germany	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Zuzana Jedlickova	Expert	Germany	No interests declared	
Claudia Reichmann	Expert	Germany	No interests declared	
Maren Richter	Expert	Germany	No restrictions applicable to this meeting	
Michal Zwiewka	Expert	Germany	No interests declared	
Katja Findeisen	Expert	Germany	No restrictions applicable to this meeting	
Robert Pollmann	Expert	Germany	No interests declared	
Verena Scheer	Expert	Germany	No interests declared	
Edwige Haelterman Brenneisen	Expert	Belgium	No interests declared	
Olga Kholmanskikh	Expert	Belgium	No interests declared	
Filip Van Nuffel	Expert	Belgium	No interests declared	
Mette Toftegaard Madsen	Expert	Denmark	No interests declared	
Thadeus Bao Quan Nguyen	Expert	Denmark	No interests declared	
Susanne Høpner Rasmussen	Expert	Denmark	No interests declared	
Nanna Borup Johansen	Expert	Denmark	No interests declared	
Anne Hasle Buur	Expert	Denmark	No interests declared	
Kristin Skougaard	Expert	Denmark	No interests declared	
Mette Linnert Jensen	Expert	Denmark	No interests declared	
Deirdre Mannion	Expert	Denmark	No restrictions applicable to this meeting	
Sine Buhl Naess-Schmidt	Expert	Denmark	No restrictions applicable to this meeting	
Bibi Fatima Syed Shah	Expert	Denmark	No interests declared	
Emilie Birch Kristensen	Expert	Denmark	No restrictions applicable to this meeting	
Kristina Bech Jensen	Expert	Denmark	No interests declared	
Mette Tranholm	Expert	Denmark	No interests declared	
Claus Stage	Expert	Denmark	No restrictions applicable to this meeting	
Meera Varma	Expert	Denmark	No restrictions applicable to this meeting	
Line Praest Lauridsen	Expert	Denmark	No restrictions applicable to this meeting	
Jonas Bøje Nielsen	Expert	Denmark	No restrictions applicable to this meeting	
Ebru Karakoc Madsen	Expert	Denmark	No restrictions applicable to this meeting	
Anne-Mette Hoberg	Expert	Denmark	No interests declared	
Mogens Westergaard	Expert	Denmark	No interests declared	
Irene Bachmann	Expert	Germany	No interests declared	
Michael Schramm	Expert	Germany	No interests declared	
Sofia Kapanadze	Expert	Germany	No interests declared	
Lene Weber Vestermark	Expert	Denmark	No interests declared	
Anne-Marie Dalseg	Expert	Denmark	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Jacobus Romme	Expert	Netherlands	No interests declared	
Ineke Havinga	Expert	Netherlands	No interests declared	
Susanne Breedijk-van den Ende	Expert	Netherlands	No interests declared	
Charlotte Hejl	Expert	Denmark	No restrictions applicable to this meeting	
Petra Arndt	Expert	Germany	No interests declared	
Alvar Per Olof Jansson	Expert	Denmark	No interests declared	
Jacqueline Bräutigam	Expert	Germany	No restrictions applicable to this meeting	
Michal Gryz	Expert	Poland	No interests declared	
Daiana Vasilcanu	Expert	Sweden	No interests declared	
Carlo Pini	Expert	Italy	No restrictions applicable to this meeting	
Elmer Schabel	Expert	Germany	No interests declared	
Ingrid Schellens	Expert	Netherlands	No interests declared	
Joerg Zinserling	Expert	Germany	No interests declared	
Clemens Mittmann	Expert	Germany	No interests declared	
Rosalinde Bot	Expert	Netherlands	No participation in discussion, final deliberations and voting on:	Evusheld - tixagevimab / cilgavimab - EMEA/H/C/005788/II/0001 Beyfortus - nirsevimab - EMEA/H/C/005304
Sean Barry	Expert	Ireland	No restrictions applicable to this meeting	
Roeland Martinj Van der Plas	Expert	Netherlands	No interests declared	
Niklas Ekman	Expert	Finland	No interests declared	
Silvia Perez Lopez	Expert	Spain	No interests declared	
Janis Kurlovics	Expert	Latvia	No interests declared	
Stine Husa	Expert	Norway	No interests declared	
Kairi Rooma	Expert	Estonia	No interests declared	
Jan Klimasová	Expert	Slovakia	No restrictions applicable to this meeting	
Elina Rönnemaa	Expert	Sweden	No interests declared	
Charlotta Bergquist	Expert	Sweden	No interests declared	
Helena Back	Expert	Sweden	No interests declared	
Charlotte Anderberg	Expert	Sweden	No restrictions applicable to this meeting	
Therese Solstad Saunders	Expert	Norway	No interests declared	
Francesca Luciani	Expert	Italy	No interests declared	
Wilmar Igl	Expert	Sweden	No interests declared	
Maria Grünwald	Expert	Sweden	No interests declared	
Hinke Johanna Van der Woude	Expert	Netherlands	No interests declared	
Jeroen Koomen	Expert	Netherlands	No interests declared	
Martina Schuessler-Lenz	Expert	Germany	No interests declared	
Sabine Mayrhofer	Expert	Germany	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Nora Cascante Estepa	Expert	Germany	No interests declared	
Filip Kukulski	Expert	Health Canada	No interests declared	
Charlotte Geluk	Expert	Swissmedic	No interests declared	
Meeting run with the help of EMA staff				

Experts were evaluated against the agenda topics or activities they participated in.

Experts from international organisations or regulatory authorities in third countries cannot participate in the adoption of any procedural decision, scientific opinion or recommendation by the Committee at any step of the procedure.

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the extraordinary CHMP meeting held on 1 September 2022.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Harald Enzmann	Chair	Germany	No interests declared	
Andrea Laslop	Member	Austria	No interests declared	
Daniela Philadelphly	Alternate	Austria	No interests declared	
Christophe Focke	Member	Belgium	No restrictions applicable to this meeting	
Ilko Getov	Member	Bulgaria	No interests declared	
Margareta Bego	Member	Croatia	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	
Helena Panayiotopoulou	Member	Cyprus	No interests declared	
Ondřej Slanař	Member	Czechia	No restrictions applicable to this meeting	
Tomas Radimersky	Alternate	Czechia	No interests declared	
Thalia Marie Estrup Blicher	Member	Denmark	No restrictions applicable to this meeting	
Alar Irs	Member	Estonia	No restrictions applicable to this meeting	
Edward Laane	Alternate	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Johanna Lähteenvuo	Alternate	Finland	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Martina Weise	Member	Germany	No restrictions applicable to this meeting	
Konstantina Alexopoulou	Member	Greece	No interests declared	
Anastasia Mountaki	Alternate	Greece	No interests declared	
Robert Porszasz	Member	Hungary	No interests declared	
Agnes Gyurasics	Alternate	Hungary	No interests declared	
Hrefna Gudmundsdottir	Member	Iceland	No interests declared	
Armando Genazzani	Member	Italy	No interests declared	
Maria Grazia Evandri	Alternate	Italy	No interests declared	
Elita Poplavska	Member	Latvia	No interests declared	
Alexandra Branchu	Alternate	Luxembourg	No restrictions applicable to this meeting	
John Joseph Borg	Member	Malta	No interests declared	
Johann Lodewijk Hillege	Member	Netherlands	No interests declared	
Paula Boudewina van Hennik	Alternate	Netherlands	No interests declared	
Ingrid Wang	Member	Norway	No interests declared	
Eva Skovlund	Alternate	Norway	No interests declared	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Grzegorz Cessak	Alternate	Poland	No participation in final deliberations and voting on:	COVID-19 vaccines
Bruno Sepodes	Member (Vice-Chair)	Portugal	No interests declared	
Fatima Ventura	Alternate	Portugal	No participation in final deliberations and voting on:	COVID-19 vaccines
Dana Gabriela Marin	Alternate	Romania	No interests declared	
Francisek Drafi	Member	Slovakia	No interests declared	
Kristina Nadrah	Member	Slovenia	No restrictions applicable to this meeting	
Blanca Garcia-Ochoa	Alternate	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Christian Gartner	Co-opted member	Austria	No interests declared	
Carla Torre	Co-opted member	Portugal	No interests declared	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Blanka Hirschlerova	Co-opted member	Czechia	No interests declared	
Sol Ruiz	Co-opted member	Spain	No interests declared	
Charlotta Bergquist	Expert	Sweden	No interests declared	
Helena Faust	Expert	Sweden	No interests declared	
Helena Back	Expert	Sweden	No interests declared	
Bernice Aronsson	Expert	Sweden	No interests declared	
Kim Sherwood	Expert	Sweden	No interests declared	
Martin Huber	Expert	Germany	No interests declared	
Zeljana Margan Koletić	Expert	Croatia	No interests declared	
Finbarr Leacy	Expert	Ireland	No interests declared	
Meera Varma	Expert	Denmark	No restrictions applicable to this meeting	
Theis Moeslund Jensen	Expert	Denmark	No restrictions applicable to this meeting	
Sabine Mayrhofer	Expert	Germany	No interests declared	
Nora Cascante Estepa	Expert	Germany	No interests declared	
Maja Sommerfelt Grønvold	Expert	Norway	No interests declared	
Maria Victoria Tudanca Pacios	Expert	Spain	No restrictions applicable to this meeting	
Mas Parra Paloma	Expert	Spain	No restrictions applicable to this meeting	
Alicia Pérez González	Expert	Spain	No interests declared	
Edwige Haelterman Brenneisen	Expert	Belgium	No interests declared	
Violette Dirix	Expert	Belgium	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Inne Crèvecoeur	Expert	Belgium	No restrictions applicable to this meeting	
Valerie Lescrainier	Expert	Belgium	No interests declared	
Poleta Luga	Expert	Germany	No interests declared	
Lars Krueger	Expert	Germany	No restrictions applicable to this meeting	
Adriana Ammassari	Expert	Italy	No interests declared	
Sara Galluzzo	Expert	Italy	No interests declared	
Martina Perini	Expert	Italy	No restrictions applicable to this meeting	
Marie Louise Schougaard Christiansen	Expert	Denmark	No interests declared	
Anette Kirstine Stark	Expert	Denmark	No interests declared	
Kairi Rooma	Expert	Estonia	No interests declared	
Mikael Andersson	Expert	Sweden	No interests declared	
Jean-Michel Dogné	Expert	France	No interests declared	
Yasuhiro Araki	Expert	PMDA	No interests declared	
Ting Lu	Expert	TGA Australia	No interests declared	
Deepak Rai	Expert	TGA Australia	No interests declared	
Mohit Khera	Expert	TGA Australia	No interests declared	
Meeting run with the help of EMA staff				

Experts were evaluated against the agenda topics or activities they participated in.

Experts from international organisations or regulatory authorities in third countries cannot participate in the adoption of any procedural decision, scientific opinion or recommendation by the Committee at any step of the procedure.

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations (section 2)

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

Initial applications (section 3)

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 (section 4)

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures (section 5)

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices (section 6)

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 3.5)

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures (section 5.3)

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application (section 3.7)

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) (section 7)

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues (section 8)

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues (section 9)

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures (section 10)

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found [here](#).

Pharmacovigilance issues (section 11)

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues (section 12)

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force (section 13)

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found [here](#).

Scientific advice working party (SAWP) (section 14.3.1)

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found [here](#).

Satellite groups / other committees (section 14.2)

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmacovigilance Risk Assessment Committee (PRAC).

Invented name issues (section 14.3)

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found [here](#).

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/



03 November 2022
EMA/CHMP/770516/2022

Annex to 12-15 September 2022 CHMP Minutes

Pre-submission and post-authorisations issues

A. PRE-SUBMISSION ISSUES	3
A.1. ELIGIBILITY REQUESTS.....	3
A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications	3
A.3. PRE-SUBMISSION ISSUES FOR INFORMATION	3
B. POST-AUTHORISATION PROCEDURES OUTCOMES	3
B.1. Annual re-assessment outcomes	3
B.1.1. Annual reassessment for products authorised under exceptional circumstances	3
B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES.....	4
B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal	4
B.2.2. Renewals of Marketing Authorisations for unlimited validity.....	4
B.2.3. Renewals of Conditional Marketing Authorisations.....	6
B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES.....	7
B.4. EPARs / WPARs	11
B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES	11
B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects	11
B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects.....	20
B.5.3. CHMP-PRAC assessed procedures	36
B.5.4. PRAC assessed procedures.....	51
B.5.5. CHMP-CAT assessed procedures	55
B.5.6. CHMP-PRAC-CAT assessed procedures	57
B.5.7. PRAC assessed ATMP procedures	58
B.5.8. Unclassified procedures and worksharing procedures of type I variations.....	58
B.5.9. Information on withdrawn type II variation / WS procedure	60
B.5.10. Information on type II variation / WS procedure with revised timetable.....	61
B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION	61
B.6.1. Start of procedure for New Applications: timetables for information	61
B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information	61



B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information.....	61
B.6.4. Annual Re-assessments: timetables for adoption	63
B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed	63
B.6.6. VARIATIONS – START OF THE PROCEDURE.....	63
B.6.7. Type II Variations scope of the Variations: Extension of indication	63
B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects	63
B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects.....	66
B.6.10. CHMP-PRAC assessed procedures.....	68
B.6.11. PRAC assessed procedures	70
B.6.12. CHMP-CAT assessed procedures	72
B.6.13. CHMP-PRAC-CAT assessed procedures.....	72
B.6.14. PRAC assessed ATMP procedures	73
B.6.15. Unclassified procedures and worksharing procedures of type I variations	73
B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY.....	74
B.7.1. Yearly Line listing for Type I and II variations.....	74
B.7.2. Monthly Line listing for Type I variations.....	74
B.7.3. Opinion on Marketing Authorisation transfer (MMD only)	74
B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)	74
B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)	74
B.7.6. Notifications of Type I Variations (MMD only)	74
C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)	74
D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)	74
E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES	74
E.1. PMF Certification Dossiers:.....	74
E.1.1. Annual Update.....	74
E.1.2. Variations:	74
E.1.3. Initial PMF Certification:.....	74
E.2. Time Tables – starting & ongoing procedures: For information	74
F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver	75
G. ANNEX G.....	75
G.1. Final Scientific Advice (Reports and Scientific Advice letters):	75
G.2. PRIME.....	75
G.2.1. List of procedures concluding at 12-15 September 2022 CHMP plenary:	75
G.2.2. List of procedures starting in September 2022 for October 2022 CHMP adoption of outcomes	75

H. ANNEX H - Product Shared Mailboxes – e-mail address..... 75

A. PRE-SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for September 2022: For adoption	Adopted
---	---------

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Outcome of Rapporteurship allocation for September 2022: For adoption	Adopted
---	---------

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

Elaprase - idursulfase - EMA/H/C/000700/S/0099 Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross- Martirosyan Request for Supplementary Information adopted on 21.07.2022.	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The Marketing Authorisation remains under exceptional circumstances.
EVKEEZA - evinacumab - EMA/H/C/005449/S/0005 Ultragenyx Germany GmbH, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Mari Thorn	Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. The Marketing Authorisation remains under exceptional circumstances.

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

B.2.2. Renewals of Marketing Authorisations for unlimited validity

<p>ADYNOVI - ruriococog alfa pegol - EMEA/H/C/004195/R/0033 Baxalta Innovations GmbH, Rapporteur: Andrea Laslop, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Menno van der Elst Request for Supplementary Information adopted on 21.07.2022.</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p>Alkindi - hydrocortisone - EMEA/H/C/004416/R/0014 Diurnal Europe BV, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Mari Thorn Request for Supplementary Information adopted on 21.07.2022.</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p>Alofisel - darvadstrocel - EMEA/H/C/004258/R/0036, Orphan, ATMP Takeda Pharma A/S, Rapporteur: Lisbeth Barkholt, Co-Rapporteur: Margarida Menezes-Ferreira, CHMP Coordinators: Kristina Dunder and Fátima Ventura, PRAC Rapporteur: Brigitte Keller-Stanislawski Request for Supplementary Information adopted on 09.09.2022.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>Anagrelide Mylan - anagrelide - EMEA/H/C/004585/R/0010 Mylan Pharmaceuticals Limited, Generic, Generic of Xagrid, Rapporteur: Alar Irs, PRAC Rapporteur: Tiphaine Vaillant</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p>Darunavir Krka - darunavir - EMEA/H/C/004273/R/0013 KRKA, d.d., Novo mesto, Generic, Generic of Prezista, Rapporteur: John Joseph Borg, PRAC Rapporteur: Liana Gross-Martirosyan</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p>Efavirenz/Emtricitabine/Tenofovir</p>	<p>Positive Opinion adopted by consensus together</p>

<p>disoproxil Krka - efavirenz / emtricitabine / tenofovir disoproxil - EMEA/H/C/004274/R/0015 KRKA, d.d., Novo mesto, Generic, Generic of Atripla (SRD), Rapporteur: John Joseph Borg, PRAC Rapporteur: Martin Huber</p>	<p>with the CHMP assessment report. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p>Fulvestrant Mylan - fulvestrant - EMEA/H/C/004649/R/0016 Mylan Pharmaceuticals Limited, Generic, Generic of Faslodex, Rapporteur: Elita Poplavska, PRAC Rapporteur: Ulla Wändel Liminga Request for Supplementary Information adopted on 13.09.2022.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>Herzuma - trastuzumab - EMEA/H/C/002575/R/0050 Celltrion Healthcare Hungary Kft., Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Brigitte Keller-Stanislawski</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p>Mylotarg - gemtuzumab ozogamicin - EMEA/H/C/004204/R/0025, Orphan Pfizer Europe MA EEIG, Rapporteur: Aaron Sosa Mejia, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p>Segluromet - ertugliflozin / metformin hydrochloride - EMEA/H/C/004314/R/0015 Merck Sharp & Dohme B.V., Rapporteur: Kristina Dunder, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Menno van der Elst</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p>Steglatro - ertugliflozin - EMEA/H/C/004315/R/0015 Merck Sharp & Dohme B.V., Rapporteur: Kristina Dunder, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Menno van der Elst</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p>
<p>Steglujan - ertugliflozin / sitagliptin - EMEA/H/C/004313/R/0018 Merck Sharp & Dohme B.V., Rapporteur:</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and</p>

Kristina Dunder, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Menno van der Elst

translation timetable.

Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.

B.2.3. Renewals of Conditional Marketing Authorisations

**Caprelsa - vandetanib -
EMA/H/C/002315/R/0055**

Genzyme Europe BV, Rapporteur: Alexandre Moreau, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Tiphaine Vaillant

Positive Opinion adopted by consensus together with the CHMP assessment report.

The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted.

The Marketing Authorisation remains conditional.

See 9.1

**COMIRNATY - tozinameran -
EMA/H/C/005735/R/0137**

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst

Positive Opinion adopted by consensus together with the CHMP assessment report.

Based on the review of the available information, the CHMP was of the opinion that the risk-benefit balance remains favourable and that all specific obligations have been fulfilled, therefore the CHMP recommended granting of a Marketing Authorisation not subject to specific obligations.

See 9.1

**Enhertu - trastuzumab deruxtecan -
EMA/H/C/005124/R/0023**

Daiichi Sankyo Europe GmbH, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Positive Opinion adopted by consensus together with the CHMP assessment report.

The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted.

The Marketing Authorisation remains conditional.

**Lumykras - sotorasib -
EMA/H/C/005522/R/0002**

Amgen Europe B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Positive Opinion adopted by consensus together with the CHMP assessment report.

The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted.

The Marketing Authorisation remains conditional.

**NUVAXOVID - SARS-CoV-2, spike protein,
recombinant, expressed in Sf9 cells derived**

Positive Opinion adopted by consensus together

**from Spodoptera frugiperda -
EMA/H/C/005808/R/0020**

Novavax CZ, a.s., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Brigitte Keller-Stanislawski

with the CHMP assessment report.

The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted.

The Marketing Authorisation remains conditional.

**Ocaliva - obeticholic acid -
EMA/H/C/004093/R/0034, Orphan**

Intercept Pharma International Limited, Rapporteur: Blanca Garcia-Ochoa, Co-Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan

Positive Opinion adopted by consensus together with the CHMP assessment report.

The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted.

The Marketing Authorisation remains conditional.

**Spikevax - elasmomeran -
EMA/H/C/005791/R/0074**

Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Positive Opinion adopted by consensus together with the CHMP assessment report.

Based on the review of the available information, the CHMP was of the opinion that the risk-benefit balance remains favourable and that all specific obligations have been fulfilled, therefore the CHMP recommended granting of a Marketing Authorisation not subject to specific obligations.

See 9.1

**Tecartus - brexucabtagene autoleucel -
EMA/H/C/005102/R/0025, Orphan,
ATMP**

Kite Pharma EU B.V., Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Rune Kjekken, PRAC Rapporteur: Menno van der Elst

Positive Opinion adopted by consensus together with the CHMP assessment report.

The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted.

The Marketing Authorisation remains conditional.

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

Post-authorisation safety studies

PRAC recommendations on PASS results adopted at the PRAC meeting held on 29 August – 01 September 2022

**XARELTO (CAP) -
EMA/H/C/PSR/S/0027**

(rivaroxaban)

CHMP Rapporteur: Kristina Dunder, PRAC

Rapporteur: Ulla Wändel Liminga

Scope: Assessment of final study report comprising the pharmacoepidemiological imposed study program of rivaroxaban use and potential adverse outcomes in routine clinical practice in the UK, Germany, the Netherlands and Sweden.

PRAC recommendation to CHMP

Action: For adoption

The CHMP adopted the PRAC recommendation.

PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its September 2022 meeting:

EMA/H/C/PSUSA/00002645/202112

(riluzole)

CAPS:

Rilutek (EMA/H/C/000109) (riluzole), Sanofi Mature IP, Rapporteur: Thalia Marie Estrup Blicher

Riluzole Zentiva (EMA/H/C/002622) (riluzole), Zentiva, k.s., Rapporteur: Thalia Marie Estrup Blicher

NAPS:

EU - NAPs

PRAC Rapporteur: Anette Kirstine Stark, "12/12/2019 To: 12/12/2021"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following change(s):

Update of section 4.8 of the SmPC to add the adverse reaction rash with a frequency 'Not known'. The package leaflet is updated accordingly.

EMA/H/C/PSUSA/0003085/202112

(ustekinumab)

CAPS:

Stelara (EMA/H/C/000958) (ustekinumab),
Janssen-Cilag International N.V., Rapporteur:
Jayne Crowe, PRAC Rapporteur: Rhea
Fitzgerald, "01/01/2021 To: 31/12/2021"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of sections 4.4 and 4.8 of the SmPC to add a warning regarding lupus-related conditions and to add the adverse reactions cutaneous lupus and lupus-like syndrome with a frequency very rare. The package leaflet is updated accordingly.

Update of section 4.4 of the SmPC to amend a warning regarding opportunistic infections. The package leaflet is updated accordingly.

Update of section 2 of the package leaflet to amend a warning regarding breast-feeding.

Additionally, minor editorial changes have been included throughout the PI.

EMA/H/C/PSUSA/00010263/202112

(umeclidinium)

CAPS:

Incruse Ellipta (EMA/H/C/002809)
(umeclidinium bromide), GlaxoSmithKline
(Ireland) Limited, Rapporteur: Maria
Concepcion Prieto Yerro
Rolufta Ellipta (EMA/H/C/004654)
(umeclidinium), GlaxoSmithKline Trading
Services Limited, Rapporteur: Maria
Concepcion Prieto Yerro, PRAC Rapporteur:
Amelia Cupelli, "18/12/2018 To: 17/12/2021"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of section 4.8 of the SmPC to add the adverse reaction Anaphylaxis, in the existing wording for hypersensitivity reactions. The package leaflet is updated accordingly.

EMA/H/C/PSUSA/00010264/202112

(umeclidinium bromide / vilanterol)

CAPS:

Anoro Ellipta (EMA/H/C/002751)
(umeclidinium / vilanterol), GlaxoSmithKline
(Ireland) Limited, Rapporteur: Jayne Crowe
Laventair Ellipta (EMA/H/C/003754)
(umeclidinium / vilanterol), GlaxoSmithKline
(Ireland) Limited, Rapporteur: Jayne Crowe,
PRAC Rapporteur: Amelia Cupelli,
"18/12/2018 To: 17/12/2021"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of section 4.8 of the SmPC to add the adverse reaction Muscle spasms with a frequency uncommon. The package leaflet is updated accordingly.

Update of section 4.8 of the SmPC to add the adverse reaction Eye pain. The package leaflet is updated accordingly.

EMA/H/C/PSUSA/00010695/202202

(bictegravir / emtricitabine / tenofovir alafenamide)

CAPS:

Biktarvy (EMA/H/C/004449) (bictegravir / emtricitabine / tenofovir alafenamide), Gilead Sciences Ireland UC, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Liana Gross-Martirosyan, "07/08/2021 To: 06/02/2022"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above-mentioned medicinal product(s), concerning the following change(s):

Update of section 4.4 of the SmPC to amend the existing warning on nephrotoxicity. The package leaflet is updated accordingly.

EMA/H/C/PSUSA/00010820/202201

(osilodrostat)

CAPS:

Isturisa (EMA/H/C/004821) (osilodrostat), Recordati Rare Diseases, Rapporteur: Kristina Dunder, PRAC Rapporteur: Eva A. Segovia, "08/01/2021 To: 08/01/2022"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of section 4.8 of the SmPC to add the adverse reaction 'myalgia' with a frequency very common and to add the adverse reaction 'arthralgia' with a frequency very common under the SOC Musculoskeletal and connective tissue disorders. The package leaflet is updated accordingly.

EMA/H/C/PSUSA/00010924/202201

(remimazolam)

CAPS:

Byfavo (EMA/H/C/005246) (remimazolam),
PAION Netherlands B.V., Rapporteur: Bruno
Sepodes, PRAC Rapporteur: Rhea Fitzgerald,
"22/07/2021 To: 22/01/2022"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):
Update of section 6.2 of the SmPC to add information regarding incompatibilities between remimazolam and co-administered solutions which may result in precipitation/turbidity, which may cause occlusion of vascular access site. The package leaflet is updated accordingly.

B.4. EPARs / WPARs

B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

**ADCETRIS - brentuximab vedotin -
EMA/H/C/002455/II/0102/G, Orphan**

Takeda Pharma A/S, Rapporteur: Paula
Boudewina van Hennik
Opinion adopted on 01.09.2022.
Request for Supplementary Information adopted
on 23.06.2022.

Positive Opinion adopted by consensus on
01.09.2022.

**Adtralza - tralokinumab -
EMA/H/C/005255/II/0005**

LEO Pharma A/S, Rapporteur: Jayne Crowe
Request for Supplementary Information adopted
on 01.09.2022.

Request for supplementary information adopted
with a specific timetable.

**Alecensa - alectinib -
EMA/H/C/004164/II/0041**

Roche Registration GmbH, Rapporteur: Filip
Josephson
Request for Supplementary Information adopted
on 01.09.2022.

Request for supplementary information adopted
with a specific timetable.

**Apexxnar - pneumococcal polysaccharide
conjugate vaccine (20-valent, adsorbed) -
EMA/H/C/005451/II/0007/G**

Request for supplementary information adopted
with a specific timetable.

Pfizer Europe MA EEIG, Rapporteur: Daniela
Philadelphia
Request for Supplementary Information adopted
on 08.09.2022.

**Aranesp - darbepoetin alfa -
EMA/H/C/000332/II/0161**

Amgen Europe B.V., Rapporteur: Martina Weise
Request for Supplementary Information adopted
on 15.09.2022.

Request for supplementary information adopted
with a specific timetable.

**ARIKAYCE liposomal - amikacin -
EMA/H/C/005264/II/0008/G, Orphan**

Insmed Netherlands B.V., Rapporteur: Jayne
Crowe
Request for Supplementary Information adopted
on 15.09.2022.

Request for supplementary information adopted
with a specific timetable.

**BLINCYTO - blinatumomab -
EMA/H/C/003731/II/0047/G, Orphan**

Amgen Europe B.V., Rapporteur: Alexandre
Moreau
Opinion adopted on 01.09.2022.
Request for Supplementary Information adopted
on 16.06.2022.

Positive Opinion adopted by consensus on
01.09.2022.

**Elaprase - idursulfase -
EMA/H/C/000700/II/0101**

Takeda Pharmaceuticals International AG
Ireland Branch, Rapporteur: Johann Lodewijk
Hillege
Opinion adopted on 01.09.2022.

Positive Opinion adopted by consensus on
01.09.2022.

**Erbitux - cetuximab -
EMA/H/C/000558/II/0094/G**

Merck Europe B.V., Rapporteur: Filip Josephson
Opinion adopted on 01.09.2022.

Positive Opinion adopted by consensus on
01.09.2022.

**EVUSHELD - tixagevimab / cilgavimab -
EMA/H/C/005788/II/0002/G**

AstraZeneca AB, Rapporteur: Jan Mueller-
Berghaus
Opinion adopted on 15.09.2022.
Request for Supplementary Information adopted
on 21.07.2022.

Positive Opinion adopted by consensus on
15.09.2022.

**Fortacin - lidocaine / prilocaine -
EMA/H/C/002693/II/0035/G**

Recordati Ireland Ltd, Rapporteur: Maria
Concepcion Prieto Yerro
Opinion adopted on 15.09.2022.

Positive Opinion adopted by consensus on
15.09.2022.

**Gazyvaro - obinutuzumab -
EMA/H/C/002799/II/0050, Orphan**

Positive Opinion adopted by consensus on
01.09.2022.

Roche Registration GmbH, Rapporteur: Aaron
Sosa Mejia
Opinion adopted on 01.09.2022.

**Grepid - clopidogrel -
EMA/H/C/001059/II/0054**

Pharmathen S.A., Generic, Generic of Plavix,
Rapporteur: Nevenka Trsinar Brodt
Request for Supplementary Information adopted
on 15.09.2022.

Request for supplementary information adopted
with a specific timetable.

**Hepcludex - bulevirtide -
EMA/H/C/004854/II/0014/G, Orphan**

Gilead Sciences Ireland Unlimited Company,
Rapporteur: Filip Josephson
Opinion adopted on 15.09.2022.
Request for Supplementary Information adopted
on 23.06.2022.

Positive Opinion adopted by consensus on
15.09.2022.

**Hizentra - human normal immunoglobulin -
EMA/H/C/002127/II/0135**

CSL Behring GmbH, Rapporteur: Jan Mueller-
Berghaus
Opinion adopted on 08.09.2022.
Request for Supplementary Information adopted
on 02.06.2022.

Positive Opinion adopted by consensus on
08.09.2022.

**Hizentra - human normal immunoglobulin -
EMA/H/C/002127/II/0136/G**

CSL Behring GmbH, Rapporteur: Jan Mueller-
Berghaus
Opinion adopted on 01.09.2022.
Request for Supplementary Information adopted
on 16.06.2022.

Positive Opinion adopted by consensus on
01.09.2022.

**Hizentra - human normal immunoglobulin -
EMA/H/C/002127/II/0139**

CSL Behring GmbH, Rapporteur: Jan Mueller-
Berghaus
Request for Supplementary Information adopted
on 01.09.2022.

Request for supplementary information adopted
with a specific timetable.

**Increlex - mecasermin -
EMA/H/C/000704/II/0077/G**

Ipsen Pharma, Rapporteur: Outi Mäki-Ikola
Opinion adopted on 15.09.2022.
Request for Supplementary Information adopted
on 21.07.2022.

Positive Opinion adopted by consensus on
15.09.2022.

**JCOVDEN - adenovirus type 26 encoding
the SARS-CoV-2 spike glycoprotein -
EMA/H/C/005737/II/0057**

Janssen-Cilag International N.V., Rapporteur:
Christophe Focke

Positive Opinion adopted by consensus on
01.09.2022.

Opinion adopted on 01.09.2022.	
<p>JCOVDEN - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0058/G</p> <p>Janssen-Cilag International N.V., Rapporteur: Christophe Focke</p> <p>Opinion adopted on 01.09.2022.</p>	Positive Opinion adopted by consensus on 01.09.2022.
<p>Jivi - damoctocog alfa pegol - EMEA/H/C/004054/II/0024/G</p> <p>Bayer AG, Rapporteur: Thalia Marie Estrup Blicher</p> <p>Request for Supplementary Information adopted on 08.09.2022.</p>	Request for supplementary information adopted with a specific timetable.
<p>Kadcyla - trastuzumab emtansine - EMEA/H/C/002389/II/0066/G</p> <p>Roche Registration GmbH, Rapporteur: Thalia Marie Estrup Blicher</p> <p>Opinion adopted on 08.09.2022.</p> <p>Request for Supplementary Information adopted on 21.07.2022.</p>	Positive Opinion adopted by consensus on 08.09.2022.
<p>Kovaltry - octocog alfa - EMEA/H/C/003825/II/0039</p> <p>Bayer AG, Rapporteur: Kristina Dunder</p> <p>Opinion adopted on 01.09.2022.</p>	Positive Opinion adopted by consensus on 01.09.2022.
<p>LIVOGIVA - teriparatide - EMEA/H/C/005087/II/0010</p> <p>Theramex Ireland Limited, Rapporteur: Daniela Philadelphly</p> <p>Request for Supplementary Information adopted on 15.09.2022, 23.06.2022.</p>	Request for supplementary information adopted with a specific timetable.
<p>Lyumjev - insulin lispro - EMEA/H/C/005037/II/0016</p> <p>Eli Lilly Nederland B.V., Rapporteur: Outi Mäki-Ikola</p> <p>Request for Supplementary Information adopted on 08.09.2022.</p>	Request for supplementary information adopted with a specific timetable.
<p>NovoSeven - eptacog alfa (activated) - EMEA/H/C/000074/II/0117</p> <p>Novo Nordisk A/S, Rapporteur: Paula Boudewina van Hennik</p> <p>Opinion adopted on 01.09.2022.</p> <p>Request for Supplementary Information adopted on 16.06.2022.</p>	Positive Opinion adopted by consensus on 01.09.2022.
<p>Nuceiva - botulinum toxin type A - EMEA/H/C/004587/II/0027</p> <p>Evolus Pharma B.V., Rapporteur: Jayne Crowe</p>	Request for supplementary information adopted with a specific timetable.

Request for Supplementary Information adopted on 01.09.2022.	
Obizur - susoctocog alfa - EMEA/H/C/002792/II/0047/G Baxalta Innovations GmbH, Rapporteur: Andrea Laslop Request for Supplementary Information adopted on 01.09.2022.	Request for supplementary information adopted with a specific timetable.
Ocaliva - obeticholic acid - EMEA/H/C/004093/II/0035, Orphan Intercept Pharma International Limited, Rapporteur: Blanca Garcia-Ochoa Opinion adopted on 15.09.2022.	Positive Opinion adopted by consensus on 15.09.2022.
Ogluo - glucagon - EMEA/H/C/005391/II/0005/G Tetris Pharma B.V., Rapporteur: Karin Janssen van Doorn Opinion adopted on 15.09.2022.	Positive Opinion adopted by consensus on 15.09.2022.
Onpattro - patisiran - EMEA/H/C/004699/II/0027/G, Orphan Alnylam Netherlands B.V., Rapporteur: Kristina Dunder Opinion adopted on 01.09.2022.	Positive Opinion adopted by consensus on 01.09.2022.
Phesgo - pertuzumab / trastuzumab - EMEA/H/C/005386/II/0012/G Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia Request for Supplementary Information adopted on 01.09.2022.	Request for supplementary information adopted with a specific timetable.
Polivy - polatuzumab vedotin - EMEA/H/C/004870/II/0017/G, Orphan Roche Registration GmbH, Rapporteur: Alexandre Moreau Opinion adopted on 15.09.2022. Request for Supplementary Information adopted on 21.07.2022, 23.06.2022.	Positive Opinion adopted by consensus on 15.09.2022.
Prasugrel Mylan - prasugrel - EMEA/H/C/004644/II/0013 Mylan Pharmaceuticals Limited, Generic, Generic of Efient, Rapporteur: Alar Irs Opinion adopted on 15.09.2022.	Positive Opinion adopted by consensus on 15.09.2022.
Prevenar 13 - pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) - EMEA/H/C/001104/II/0206/G Pfizer Europe MA EEIG, Rapporteur: Kristina	Positive Opinion adopted by consensus on 01.09.2022.

Dunder Opinion adopted on 01.09.2022.	
PREVYMIS - letermovir - EMA/H/C/004536/II/0028/G, Orphan Merck Sharp & Dohme B.V., Rapporteur: Filip Josephson Request for Supplementary Information adopted on 01.09.2022.	Request for supplementary information adopted with a specific timetable.
Privigen - human normal immunoglobulin - EMA/H/C/000831/II/0188 CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus Opinion adopted on 15.09.2022. Request for Supplementary Information adopted on 14.07.2022.	Positive Opinion adopted by consensus on 15.09.2022.
Puregon - follitropin beta - EMA/H/C/000086/II/0124 Organon N.V., Rapporteur: Jayne Crowe Opinion adopted on 01.09.2022. Request for Supplementary Information adopted on 07.07.2022.	Positive Opinion adopted by consensus on 01.09.2022.
Qarziba - dinutuximab beta - EMA/H/C/003918/II/0045, Orphan EUSA Pharma (Netherlands) B.V., Rapporteur: Paula Boudewina van Hennik Opinion adopted on 01.09.2022.	Positive Opinion adopted by consensus on 01.09.2022.
Rekovelte - follitropin delta - EMA/H/C/003994/II/0034 Ferring Pharmaceuticals A/S, Rapporteur: Jean-Michel Race Request for Supplementary Information adopted on 01.09.2022, 21.07.2022.	Request for supplementary information adopted with a specific timetable.
Respreeza - human alpha1-proteinase inhibitor - EMA/H/C/002739/II/0060 CSL Behring GmbH, Rapporteur: Kristina Dunder Opinion adopted on 01.09.2022.	Positive Opinion adopted by consensus on 01.09.2022.
RINVOQ - upadacitinib - EMA/H/C/004760/II/0025/G AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 15.09.2022.	Request for supplementary information adopted with a specific timetable.
Ruxience - rituximab - EMA/H/C/004696/II/0011 Pfizer Europe MA EEIG, Rapporteur: Paula	Positive Opinion adopted by consensus on 01.09.2022.

Boudewina van Hennik
Opinion adopted on 01.09.2022.
Request for Supplementary Information adopted
on 16.06.2022.

Sialanar - glycopyrronium -
EMA/H/C/003883/II/0025/G Positive Opinion adopted by consensus on
01.09.2022.
Proveca Pharma Limited, Rapporteur: Thalia
Marie Estrup Blicher
Opinion adopted on 01.09.2022.

Simulect - basiliximab -
EMA/H/C/000207/II/0114/G Positive Opinion adopted by consensus on
08.09.2022.
Novartis Europharm Limited, Rapporteur: Jan
Mueller-Berghaus
Opinion adopted on 08.09.2022.
Request for Supplementary Information adopted
on 23.06.2022.

Spectrila - asparaginase -
EMA/H/C/002661/II/0029 Request for supplementary information adopted
with a specific timetable.
medac Gesellschaft fur klinische
Spezialpräparate mbH, Rapporteur: Andrea
Laslop
Request for Supplementary Information adopted
on 01.09.2022, 02.06.2022.

Spectrila - asparaginase -
EMA/H/C/002661/II/0031 Positive Opinion adopted by consensus on
01.09.2022.
medac Gesellschaft fur klinische
Spezialpräparate mbH, Rapporteur: Andrea
Laslop
Opinion adopted on 01.09.2022.
Request for Supplementary Information adopted
on 07.07.2022.

Stelara - ustekinumab -
EMA/H/C/000958/II/0094/G Positive Opinion adopted by consensus on
01.09.2022.
Janssen-Cilag International N.V., Rapporteur:
Jayne Crowe
Opinion adopted on 01.09.2022.
Request for Supplementary Information adopted
on 14.07.2022.

Tecentriq - atezolizumab -
EMA/H/C/004143/II/0070/G Positive Opinion adopted by consensus on
01.09.2022.
Roche Registration GmbH, Rapporteur: Aaron
Sosa Mejia
Opinion adopted on 01.09.2022.

Tysabri - natalizumab -
EMA/H/C/000603/II/0133 Request for supplementary information adopted
with a specific timetable.
Biogen Netherlands B.V., Rapporteur: Jan
Mueller-Berghaus

Request for Supplementary Information adopted on 08.09.2022.

Ultomiris - ravulizumab - EMEA/H/C/004954/II/0029 Positive Opinion adopted by consensus on 01.09.2022.
Alexion Europe SAS, Rapporteur: Blanca Garcia-Ochoa
Opinion adopted on 01.09.2022.

Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis b (rdna), poliomyelitis (inact.) and haemophilus type b conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0104/G Positive Opinion adopted by consensus on 08.09.2022.
MCM Vaccine B.V., Rapporteur: Christophe Focke
Opinion adopted on 08.09.2022.

Vaxneuvance - pneumococcal polysaccharide conjugate vaccine (adsorbed) - EMEA/H/C/005477/II/0007/G Positive Opinion adopted by consensus on 01.09.2022.
Merck Sharp & Dohme B.V., Rapporteur: Johann Lodewijk Hillege
Opinion adopted on 01.09.2022.

Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0076/G Positive Opinion adopted by consensus on 01.09.2022.
AstraZeneca AB, Rapporteur: Sol Ruiz
Opinion adopted on 01.09.2022.

Vazkepa - icosapent ethyl - EMEA/H/C/005398/II/0009/G Request for supplementary information adopted with a specific timetable.
Amarin Pharmaceuticals Ireland Limited, Rapporteur: Martina Weise
Request for Supplementary Information adopted on 01.09.2022.

Vectibix - panitumumab - EMEA/H/C/000741/II/0099 Positive Opinion adopted by consensus on 01.09.2022.
Amgen Europe B.V., Rapporteur: Eva Skovlund
Opinion adopted on 01.09.2022.

Votrient - pazopanib - EMEA/H/C/001141/II/0071/G Positive Opinion adopted by consensus on 01.09.2022.
Novartis Europharm Limited, Rapporteur: Aaron Sosa Mejia
Opinion adopted on 01.09.2022.
Request for Supplementary Information adopted on 02.06.2022, 17.02.2022.

VPRIV - velaglucerase alfa - EMEA/H/C/001249/II/0055, Orphan Positive Opinion adopted by consensus on 01.09.2022.

Takeda Pharmaceuticals International AG,
Rapporteur: Martina Weise
Opinion adopted on 01.09.2022.
Request for Supplementary Information adopted
on 21.07.2022.

Xenical - orlistat -
EMA/H/C/000154/II/0086
CHEPLAPHARM Arzneimittel GmbH, Rapporteur:
Jean-Michel Race
Request for Supplementary Information adopted
on 01.09.2022.

Request for supplementary information adopted
with a specific timetable.

WS2138/G
Hexacima-
EMA/H/C/002702/WS2138/0120/G
Hexyon-
EMA/H/C/002796/WS2138/0124/G
Sanofi Pasteur Europe, Duplicate, Duplicate of
Hexacima, Lead Rapporteur: Jan Mueller-
Berghaus
Opinion adopted on 01.09.2022.
Request for Supplementary Information adopted
on 23.06.2022, 22.04.2022, 02.12.2021.

Positive Opinion adopted by consensus on
01.09.2022.

WS2283/G
Eucreas-
EMA/H/C/000807/WS2283/0098/G
Galvus-
EMA/H/C/000771/WS2283/0077/G
Icandra-
EMA/H/C/001050/WS2283/0103/G
Jalra-
EMA/H/C/001048/WS2283/0080/G
Xiliarx-
EMA/H/C/001051/WS2283/0078/G
Zomarist-
EMA/H/C/001049/WS2283/0100/G
Novartis Europharm Limited, Lead Rapporteur:
Kristina Dunder
Request for Supplementary Information adopted
on 01.09.2022.

Request for supplementary information adopted
with a specific timetable.

WS2288
Humalog-
EMA/H/C/000088/WS2288/0196
Liprolog-
EMA/H/C/000393/WS2288/0156
Eli Lilly Nederland B.V., Lead Rapporteur:
Kristina Dunder
Request for Supplementary Information adopted
on 01.09.2022.

Request for supplementary information adopted
with a specific timetable.

<p>WS2296/G Infanrix hexa- EMA/H/C/000296/WS2296/0316/G GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke Opinion adopted on 08.09.2022.</p>	<p>Positive Opinion adopted by consensus on 08.09.2022.</p>
<p>WS2300/G Infanrix hexa- EMA/H/C/000296/WS2300/0317/G GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke Opinion adopted on 08.09.2022.</p>	<p>Positive Opinion adopted by consensus on 08.09.2022.</p>
<p>WS2313 Hexacima- EMA/H/C/002702/WS2313/0133 Hexyon- EMA/H/C/002796/WS2313/0137 Sanofi Pasteur Europe, Duplicate, Duplicate of Hexacima, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 15.09.2022.</p>	<p>Positive Opinion adopted by consensus on 15.09.2022.</p>
<p>WS2319 Nuwiq-EMA/H/C/002813/WS2319/0049 Vihuma- EMA/H/C/004459/WS2319/0031 Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 01.09.2022.</p>	<p>Positive Opinion adopted by consensus on 01.09.2022.</p>
<p>WS2327 Incesync- EMA/H/C/002178/WS2327/0042 Vipdomet- EMA/H/C/002654/WS2327/0039 Vipidia-EMA/H/C/002182/WS2327/0031 Takeda Pharma A/S, Lead Rapporteur: Johann Lodewijk Hillege Opinion adopted on 15.09.2022.</p>	<p>Positive Opinion adopted by consensus on 15.09.2022.</p>
<p>B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects</p>	
<p>Adakveo - crizanlizumab - EMA/H/C/004874/II/0007, Orphan Novartis Europharm Limited, Rapporteur: Daniela Philadelphia, "Update of section 5.2 of the SmPC in order to update pharmacokinetic information based on the results from PK reanalysis. In addition, the MAH took the opportunity to introduce minor editorial changes</p>	<p>Positive Opinion adopted by consensus on 08.09.2022.</p>

to the SmPC.”

Opinion adopted on 08.09.2022.

Request for Supplementary Information adopted on 12.05.2022.

**Avonex - interferon beta-1A -
EMA/H/C/000102/II/0192**

Positive Opinion adopted by consensus on 01.09.2022.

Biogen Netherlands B.V., Rapporteur: Maria Concepcion Prieto Yerro, “Update of section 4.4 of the SmPC in order to add a new warning regarding the risk of injection site necrosis based on post-marketing experience. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.”

Opinion adopted on 01.09.2022.

Request for Supplementary Information adopted on 12.05.2022.

**Bavencio - avelumab -
EMA/H/C/004338/II/0035**

Positive Opinion adopted by consensus on 15.09.2022.

Merck Europe B.V., Rapporteur: Filip Josephson, “Update of sections 4.2, 5.1 and 5.2 of the SmPC based on final results from study MS100070-0306 following a P46 procedure (EMA/H/C/004338/P46/009). This is a Phase I, multi-centre, open-label, international study to evaluate the dose, safety and tolerability, antitumor activity, pharmacokinetic and pharmacodynamics of avelumab in paediatric subjects 0 to less than 18 years of age with refractory or relapsed malignant solid tumours (including central nervous system tumours) and lymphoma for which no standard therapy is available or for which the subject is not eligible for the existing therapy. In addition, the MAH took the opportunity to update Annex II section D to be aligned with the EU Educational materials (EM) and the EU Risk Management Plan (RMP).

Furthermore, the MAH took the opportunity to implement editorial changes.”

Opinion adopted on 15.09.2022.

**Besremi - ropeginterferon alfa-2b -
EMA/H/C/004128/II/0021**

Request for supplementary information adopted with a specific timetable.

AOP Orphan Pharmaceuticals GmbH, Rapporteur: Janet Koenig, “Update of sections 4.8, 5.1 and 5.2 of the SmPC based on results from CONTINUATION-PV study. An open-label, multicentre, phase IIIb study assessing the

long-term efficacy and safety of AOP2014 and standard first line treatment (BAT) in patients with polycythaemia vera who previously participated in the PROUDPV study. The Package Leaflet is updated accordingly.”

Request for Supplementary Information adopted on 01.09.2022, 23.06.2022.

Bexsero - meningococcal group B vaccine (recombinant, component, adsorbed) - EMEA/H/C/002333/II/0112

GSK Vaccines S.r.l, Rapporteur: Filip Josephson, “Update of section 5.1 of the SmPC in order to add information based on Real World Evidence (RWE) on vaccination impact and effectiveness from literature references available up to July 2021. The MAH also proposes to remove the existing statement related to paediatric studies in section 5.1 of the SmPC. In addition, the MAH took the opportunity to introduce minor editorial changes to the SmPC.”

Opinion adopted on 15.09.2022.

Request for Supplementary Information adopted on 02.06.2022.

Positive Opinion adopted by consensus on 15.09.2022.

CABOMETYX - cabozantinib - EMEA/H/C/004163/II/0029

Ipsen Pharma, Rapporteur: Ingrid Wang, “Update of sections 4.4 and 4.8 of the SmPC in order to update special warnings data and information of adverse drug reactions (ADRs) based on results from study XL184-311 (COSMIC-311); study XL184-311 was a Phase 3 international, multicenter, randomized, double-blind, placebo-controlled study of cabozantinib in subjects with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) who had progressed during or after prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy.

In addition, the MAH is taking this opportunity to propose minor updates to the Package Leaflet.”

Opinion adopted on 15.09.2022.

Positive Opinion adopted by consensus on 15.09.2022.

Calquence - acalabrutinib - EMEA/H/C/005299/II/0013

AstraZeneca AB, Rapporteur: Filip Josephson, “Update of section 5.1 of the SmPC in order to update efficacy and safety information based on final results from study ACE-CL-309 (A Phase 3 randomized open-label active-control study

Positive Opinion adopted by consensus on 15.09.2022.

investigating Calquence for the Treatment of Subjects With Relapsed or Refractory Chronic Lymphocytic Leukaemia) listed as a category 3 study in the RMP.”

Opinion adopted on 15.09.2022.

Cervarix - human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed) - EMEA/H/C/000721/II/0115

GlaxoSmithkline Biologicals SA, Rapporteur: Christophe Focke, “Submission of the final report from study HPV-027 listed as a category 3 study in the RMP to fulfil MEA 024.2; this is a long-term follow-up registry-based cohort study of HPV vaccine effectiveness against cervical pre-cancerous lesions and cervical cancer in a cohort of females previously enrolled from Finland in study HPV-008, as compared to an unvaccinated population-based reference cohort of females from Finland.”

Request for Supplementary Information adopted on 15.09.2022.

Request for supplementary information adopted with a specific timetable.

Cibinqo - abrocitinib - EMEA/H/C/005452/II/0005

Pfizer Europe MA EEIG, Rapporteur: Kristina Dunder, “Update of section 4.5 of the SmPC based on final results from Drug-Drug Interaction (DDI) study B7451092. This is a Phase I, open-label, fixed-sequence, 2-period study to estimate the effect of multiple dose abrocitinib on the pharmacokinetics of single doses of caffeine, efavirenz and omeprazole in healthy participants.”

Opinion adopted on 08.09.2022.

Positive Opinion adopted by consensus on 08.09.2022.

COMIRNATY - tozinameran - EMEA/H/C/005735/II/0129

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, “Update of sections 4.2, 4.8 and 5.1 of the SmPC of COMIRNATY 10 µg Concentrate for dispersion for injection in order to introduce a booster dose for children 5 to 11 years of age based on interim results from study C4591007; this is a Phase 1, Open-Label Dose-Finding Study to Evaluate Safety, Tolerability, and Immunogenicity and Phase 2/3 Placebo-Controlled, Observer-Blinded Safety, Tolerability, and Immunogenicity Study of a SARS-CoV-2 RNA Vaccine Candidate Against COVID-19 in Healthy Children and Young Adults; the Package Leaflet is updated

Positive Opinion adopted by consensus on 15.09.2022.

See 9.1

accordingly.

In addition, the MAH took the opportunity to make minor editorial changes throughout the product information.”

Opinion adopted on 15.09.2022.

Request for Supplementary Information adopted on 23.06.2022.

**Darzalex - daratumumab -
EMA/H/C/004077/II/0062, Orphan**

Janssen-Cilag International N.V., Rapporteur: Aaron Sosa Mejia, “Update of section 4.8 of the SmPC in order to add COVID-19 to the list of adverse drug reactions (ADRs) with frequency uncommon, based on a pooled dataset from the following interventional studies 4767414MMY2004, 54767414MMY3003, 54767414MMY3006, 54767414MMY3008, and 54767414MMY3013. The Package Leaflet is updated accordingly.”

Request for Supplementary Information adopted on 15.09.2022.

Request for supplementary information adopted with a specific timetable.

**Evoltra - clofarabine -
EMA/H/C/000613/II/0077**

Genzyme Europe BV, Rapporteur: Alexandre Moreau, “Update of the Package Leaflet in order to update information regarding breast-feeding based on a comprehensive safety review. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.”

Request for Supplementary Information adopted on 08.09.2022.

Request for supplementary information adopted with a specific timetable.

**JCOVDEN - adenovirus type 26 encoding
the SARS-CoV-2 spike glycoprotein -
EMA/H/C/005737/II/0060**

Janssen-Cilag International N.V., Rapporteur: Christophe Focke, “Update of section 4.8 of the SmPC in order to update the list of adverse drug reactions (ADRs) based on pooled analyses of clinical safety data from the following Phase III interventional studies: VAC31518COV3001 and VAC31518COV3009; and from the Phase I/II interventional studies: VAC31518COV1001, VAC31518COV1002, VAC31518COV1003 and VAC31518COV2001. The Package Leaflet is updated accordingly.”

Opinion adopted on 15.09.2022.

Positive Opinion adopted by consensus on 15.09.2022.

Keytruda - pembrolizumab -

Positive Opinion adopted by consensus on

EMA/H/C/003820/II/0126

15.09.2022.

Merck Sharp & Dohme B.V., Rapporteur:
Armando Genazzani, "To update sections 4.2 and 5.2 of the SmPC to include data for patients with moderate hepatic impairment based on KEYNOTE-240 (a double-blind, randomized, Phase 3 study of pembrolizumab in participants with previously systemically treated advanced HCC) and KEYNOTE-224 (a Phase 2 study of pembrolizumab as monotherapy in participants with advanced HCC).

The MAH took the opportunity to make some editorial changes."

Opinion adopted on 15.09.2022.

**Leqvio - inclisiran -
EMA/H/C/005333/II/0011**

Request for supplementary information adopted with a specific timetable.

Novartis Europharm Limited, Rapporteur:
Martina Weise, "Submission of the final report from non-clinical study no. 2120284 in order to address a recommendation (REC). This is an in-silico assessment of the cross-tissue mRNA expression of the genes encoding for SULF1, INSYN2B (also referred to as FAM196B), ASGR1 and ASGR2 in tissues in man, monkey, rat and mouse."

Request for Supplementary Information adopted on 01.09.2022.

**Lucentis - ranibizumab -
EMA/H/C/000715/II/0098**

Positive Opinion adopted by consensus on 15.09.2022.

Novartis Europharm Limited, Rapporteur:
Kristina Dunder, "Update of section 4.6 of the SmPC in order to update information on breastfeeding following the PRAC Recommendation (EMA/H/C/PSUSA/00002609/202010) based on a cumulative assessment of pre-clinical studies, pharmacokinetic data, published literature and post-marketing spontaneous reports.

The Package Leaflet is updated accordingly."

Opinion adopted on 15.09.2022.

Request for Supplementary Information adopted on 02.06.2022.

**Lumebblue - methylthioninium chloride -
EMA/H/C/002776/II/0004**

Request for supplementary information adopted with a specific timetable.

Alfasigma S.p.A., Rapporteur: Thalia Marie Estrup Blicher, "Update of sections 4.2 and 5.2 of the SmPC in order to introduce a new posology regimen based on scientific literature."

Request for Supplementary Information adopted on 15.09.2022.

**Lumykras - sotorasib -
EMA/H/C/005522/II/0003**

Amgen Europe B.V., Rapporteur: Alexandre Moreau, "Update of section 4.2 of the SmPC based on results from the enteral feeding tube in vitro study (RPT-574024), undertaken to assess the feasibility of administration of sotorasib 120 mg film-coated tablets through an enteral feeding tube. The Package Leaflet was updated accordingly."

Opinion adopted on 15.09.2022.

Positive Opinion adopted by consensus on 15.09.2022.

**Lumykras - sotorasib -
EMA/H/C/005522/II/0004**

Amgen Europe B.V., Rapporteur: Alexandre Moreau, "Update of section 4.5 of the SmPC based on the results of study 2020042, a phase 1 clinical drug interaction study undertaken to assess the effect of concomitant sotorasib administration on the systemic exposure of breast cancer resistance protein (BCRP) transporter substrates. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement minor editorial changes in the SmPC and Package Leaflet."

Opinion adopted on 15.09.2022.

Positive Opinion adopted by consensus on 15.09.2022.

**Lysodren - mitotane -
EMA/H/C/000521/II/0026**

HRA Pharma Rare Diseases, Rapporteur: Blanca Garcia-Ochoa, "Update of sections 4.4 and 4.8 of the SmPC new safety information regarding skin reactions (including rash, pruritus, urticaria...) and estrogenic effects in children based on post-marketing safety report and literature. The Package Leaflet is updated accordingly."

Request for Supplementary Information adopted on 01.09.2022.

Request for supplementary information adopted with a specific timetable.

**Neuraceq - florbetaben (18F) -
EMA/H/C/002553/II/0038**

Life Radiopharma Berlin GmbH, Rapporteur: Maria Concepcion Prieto Yerro, "Update of sections 4.4 and 5.1 of the SmPC in order to include information on the possibility of quantitative assessment as an adjunct to visual read of Neuraceq scans based on final results from study titled "Evaluation of quantitative

Positive Opinion adopted by consensus on 01.09.2022.

assessment of florbetaben (18F) PET scans as an adjunct to visual assessment". This is a retrospective data analysis to evaluate florbetaben PET quantification as an adjunct to the approved visual assessment method."

Opinion adopted on 01.09.2022.

Request for Supplementary Information adopted on 16.06.2022.

**Orladeyo - berotralstat -
EMA/H/C/005138/II/0006**

BioCryst Ireland Limited, Rapporteur: Jayne Crowe, "Update of sections 4.4 and 4.5 of the SmPC in order to remove the warning for women of childbearing potential and amend drug-drug interaction information with desogestrel based on final results from study BCX7353-111; this is a phase 1 drug interaction study to evaluate the effects of berotralstat on the pharmacokinetics of a combination oral contraceptive, desogestrel with ethinyl estradiol; the Package Leaflet is updated accordingly."

Opinion adopted on 01.09.2022.

Request for Supplementary Information adopted on 23.06.2022, 12.05.2022.

Positive Opinion adopted by consensus on 01.09.2022.

Paxlovid - (1r,2s,5s)-n-((1s)-1-cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2s)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMA/H/C/005973/II/0008

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Submission of the final report from study PMAR-EQDD-C467a-DP4-1323, listed as a legally binding measure. This is the updated population pharmacokinetics module results including PK data from the patients enrolled in the EPIC-HR study of Paxlovid."

Opinion adopted on 15.09.2022.

Request for Supplementary Information adopted on 16.06.2022.

Positive Opinion adopted by consensus on 15.09.2022.

Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMA/H/C/005973/II/0015

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Submission of an exploratory lipid

Positive Opinion adopted by consensus on 01.09.2022.

analysis conducted retrospectively using the left-over safety and PK samples from the multiple ascending dose (PART-2) of study C4671001 (phase I randomised controlled trial) submitted as part of the initial marketing authorisation.”

Opinion adopted on 01.09.2022.

Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl)-6,6-dimethyl-3-

azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0016/G

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, “Update of section 4.8 of the SmPC in order to include the adverse reactions nausea, abdominal pain and malaise based on global safety database of the MAH and Literature Review.

The Package Leaflet is updated accordingly.”

Request for Supplementary Information adopted on 01.09.2022.

Request for supplementary information adopted with a specific timetable.

Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl)-6,6-dimethyl-3-

azabicyclo[3.1.0]hexane-2-carboxamide / ritonavir - EMEA/H/C/005973/II/0017

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, “Submission of the final report from study In Vivo Efficacy Of Pf-07321332 As A Single Agent Or In Combination With Ritonavir In Balb/C Mouse-Adapted Sars-Cov-2 Model (PAM 023).

The objective of this study was to evaluate whether Ritonavir has in vivo antiviral activity against SARS-CoV-2 and whether combination of Ritonavir with PF-07321332 increased the exposure of PF-07321332 in the mouse model and further decreased viral lung replication.”

Request for Supplementary Information adopted on 01.09.2022.

Request for supplementary information adopted with a specific timetable.

Qarziba - dinutuximab beta - EMEA/H/C/003918/II/0043, Orphan

EUSA Pharma (Netherlands) B.V., Rapporteur: Paula Boudewina van Hennik, “Update of sections 4.1, 4.2 and 5.1 of the SmPC based on final results from study APN311-202V3 listed as a Specific Obligation in the Annex II of the

Request for supplementary information adopted with a specific timetable.

See 9.1

Product Information. This is a Phase I/II dose schedule finding study of Ch14.18/CHO continuous infusion combined with subcutaneous aldesleukin (IL-2) in patients with primary refractory or relapsed neuroblastoma. In addition, the MAH took the opportunity to update Annex II section E. The Package Leaflet is updated accordingly. "

Request for Supplementary Information adopted on 15.09.2022.

Qarziba - dinutuximab beta - EMEA/H/C/003918/II/0044, Orphan
EUSA Pharma (Netherlands) B.V., Rapporteur: Paula Boudewina van Hennik, "Update of sections 4.2 and 4.8 of the SmPC with new safety information regarding central nervous system toxicity based on post-marketing safety report and literature."
Request for Supplementary Information adopted on 15.09.2022.

Request for supplementary information adopted with a specific timetable.

QUVIVIQ - daridorexant - EMEA/H/C/005634/II/0004/G
Idorsia Pharmaceuticals Deutschland GmbH, Rapporteur: Alexandre Moreau, "Submission of the final report from studies BA-17.030 (Validation of an analytical method for the determination of ACT-541468 and its metabolites ACT-776063, ACT-776537 and ACT-1016-3307 in rat plasma samples by LC-MS/MS) and study BA-18.023 (Validation of an analytical method for the determination of ACT-541468 and its metabolites ACT-776063, ACT-776537 and ACT-1016-3307 in rabbit plasma samples by LC-MS/MS). Both studies are part of the same post-authorisation measure evaluating the long-term stability of daridorexant and its metabolites (ACT-776063, ACT776537 and ACT-1016-3307) in rat and rabbit."
Opinion adopted on 08.09.2022.

Positive Opinion adopted by consensus on 08.09.2022.

Reblozyl - luspatercept - EMEA/H/C/004444/II/0011, Orphan
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Daniela Philadelphia, "Update of sections 4.2, 4.4 and 4.8 of the SmPC in order to include new safety information about Extramedullary Hematopoietic Masses in transfusion-dependent beta-thalassemia patients based on the open-label phase of the ACE-536-B-THAL-001 Phase III study, the long-term follow-up study and

Request for supplementary information adopted with a specific timetable.

post-marketing data. The Package Leaflet is updated accordingly.”

Request for Supplementary Information adopted on 15.09.2022.

**REKAMBYS - rilpivirine -
EMA/H/C/005060/II/0008**

Positive Opinion adopted by consensus on 01.09.2022.

Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, “Update of sections 4.4 and 5.1 of the SmPC in order to update efficacy and safety information based on week 96 results from the clinical study 207966 (ATLAS-2M). This is an open-label, randomized, Phase IIIb trial to demonstrate non-inferior antiviral activity and safety of CAB + RPV Q8W compared with CAB + RPV Q4W. Supporting Cabotegravir (CAB) Long-acting Injectable (LA) + Rilpivirine (RPV) LA every 2 months (Q8W) dosing regimen for the treatment of HIV-1 infection.”

Opinion adopted on 01.09.2022.

Request for Supplementary Information adopted on 23.06.2022, 16.12.2021.

**REKAMBYS - rilpivirine -
EMA/H/C/005060/II/0012**

Positive Opinion adopted by consensus on 15.09.2022.

Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, “Update of sections 4.2 and 5.1 of the SmPC in order to describe data regarding oral bridging using other suppressive regimens than oral bridging with cabotegravir and rilpivirine based on studies 201584 (FLAIR), 207966 (ATLAS-2M), 200056 (LATTE 2) and 201585 (ATLAS).

In addition, the MAH is also taking this opportunity to introduce editorial changes in the SmPC and Package Leaflet.”

Opinion adopted on 15.09.2022.

Request for Supplementary Information adopted on 21.07.2022.

**Revlimid - lenalidomide -
EMA/H/C/000717/II/0122**

Positive Opinion adopted by consensus on 15.09.2022.

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Alexandre Moreau, “Update of section 4.2 of the SmPC to update the dosage for patients with impaired renal function (severe renal impairment and end stage renal disease) for the follicular lymphoma (FL) indication based on additional PK analysis. In addition, the MAH proposed to update the existing warning in section 4.4 of the SmPC to highlight that male patients should not donate semen or sperm

during treatment and for at least seven days after the end of treatment in order to align with the Revlimid Annex IID requirements for the patient educational brochures and to align with similar wording in the Imnovid (pomaldiomide) and Thalidomide BMS (thalidomide) SmPCs. The Package Leaflet is updated accordingly.”
Opinion adopted on 15.09.2022.
Request for Supplementary Information adopted on 22.04.2022.

**Rozlytrek - entrectinib -
EMA/H/C/004936/II/0012**

Roche Registration GmbH, Rapporteur: Armando Genazzani, “Submission of the final integrated analysis report for cardiac risks, listed as a category 3 study in the RMP, in order to fulfil MEA/003. This is an integrated safety analysis report to assess cardiac risks based on GO40782 [STARTRK-2], CO40778 [STARTRK-NG], and BO41932 [TAPISTRY] studies (PAESs).”
Opinion adopted on 08.09.2022.

Positive Opinion adopted by consensus on 08.09.2022.

**Simponi - golimumab -
EMA/H/C/000992/II/0107**

Janssen Biologics B.V., Rapporteur: Kristina Dunder, “Submission of the final report from study MK-8259-038 (Go-BACK) in order to fulfil MEA/30.2. This is a phase 4, randomized, double-blind, parallel-group, withdrawal, post-authorisation efficacy study (PAES) of golimumab in adult participants, aged 18 to 45 years, with active non-radiographic axial spondyloarthritis.”
Request for Supplementary Information adopted on 01.09.2022.

Request for supplementary information adopted with a specific timetable.

**Soliris - eculizumab -
EMA/H/C/000791/II/0122, Orphan**

Alexion Europe SAS, Rapporteur: Blanca Garcia-Ochoa, “Submission of the final report from study ECU-NMO-302, a phase III, open-label, extension trial of ECU-NMO-301 to evaluate the safety and efficacy of eculizumab in subjects with neuromyelitis optica spectrum disorder (NMOSD) following procedure II/0105.”
Opinion adopted on 01.09.2022.

Positive Opinion adopted by consensus on 01.09.2022.

**Spikevax - elasmomeran -
EMA/H/C/005791/II/0066**

Moderna Biotech Spain, S.L., Rapporteur: Jan

Positive Opinion adopted by consensus on 15.09.2022.

<p>Mueller-Berghaus, "Update of section 4.5 of the SmPC in order to indicate the possibility of co-administration of Spikevax with a high-dose quadrivalent influenza vaccine, based on the interim results from study QHD00028 (NCT04969276), a Phase II, open-label study aimed to assess the safety and immunogenicity of a high-dose quadrivalent influenza vaccine (2021-2022 formulation) and a third dose of Spikevax administered either concomitantly or singly in adults 65 years of age and older previously primed with Spikevax.</p> <p>The MAH is taking the opportunity to include as editorial updates in sections 5.1 and 6.6 of the SmPC, Annex II and package leaflet, corrections from procedure EMEA/H/C/005791/II/0075." Opinion adopted on 15.09.2022.</p> <p>Request for Supplementary Information adopted on 21.07.2022.</p>	<p>See 9.1</p>
<p>Trecondi - treosulfan - EMEA/H/C/004751/II/0016, Orphan medac Gesellschaft fur klinische Spezialpreparate mbH, Rapporteur: Fátima Ventura, "Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on final results from study MC-FludT.14/L Trial II; a phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens. The Package Leaflet is updated accordingly." Request for Supplementary Information adopted on 01.09.2022, 23.06.2022.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>Tygacil - tigecycline - EMEA/H/C/000644/II/0121 Pfizer Europe MA EEIG, Rapporteur: Blanca Garcia-Ochoa, "Update of section 5.1 of the SmPC in order to reflect updated breakpoint tables regarding antimicrobial susceptibility testing (EUCAST). In addition, the MAH is taking the opportunity to update section 4.6 of the SmPC to remove reference to "pharmacodynamic/toxicological" data and update the contact details of the local representatives in the Package Leaflet." Opinion adopted on 15.09.2022.</p>	<p>Positive Opinion adopted by consensus on 15.09.2022.</p>

Request for Supplementary Information adopted on 19.05.2022.

**Veltassa - patiomer -
EMA/H/C/004180/II/0029**

Vifor Fresenius Medical Care Renal Pharma France, Rapporteur: Jayne Crowe, "Update of sections 4.2 and 4.5 of the SmPC in order to introduce new drug-drug interaction information based on results from four in vitro studies: RLY-TR-0174, titled "In Vitro Evaluation of Potential RLY5016S and Immunosuppressant Drug-Drug Interactions"; RLY-TR-0184 (titled "In Vitro Evaluation of Potential Drug-Drug Interactions Between Patiomer and Sevelamer Hydrochloride"); "In Vitro Evaluation of Drug-Drug Interactions of commonly prescribed renal and cardiovascular Drugs with Patiomer DS" and "Drug-drug interactions of commonly prescribed renal and cardiovascular Drugs with Patiomer DS in a simulated GI tract passage study". The Package Leaflet is updated accordingly."

Request for Supplementary Information adopted on 01.09.2022, 19.05.2022.

Request for supplementary information adopted with a specific timetable.

**Venclyxto - venetoclax -
EMA/H/C/004106/II/0042**

AbbVie Deutschland GmbH & Co. KG, Rapporteur: Filip Josephson, "Update of section 5.1 of the SmPC in order to update data supporting the efficacy of the combined regimen of obinutuzumab and venetoclax (VEN+G; also known as GDC-0199 or ABT-199) versus obinutuzumab plus chlorambucil (GClb) in previously untreated CLL patients based on final results from study BO25323/CLL14; this is a prospective, open-label, multicenter randomized phase 3 trial to compare the efficacy and safety of a combined regimen of obinutuzumab and venetoclax (GDC-0199/ABT-199) versus obinutuzumab and chlorambucil in previously untreated patients with CLL and coexisting medical conditions. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI."

Request for Supplementary Information adopted on 15.09.2022.

Request for supplementary information adopted with a specific timetable.

**Vocabria - cabotegravir -
EMA/H/C/004976/II/0008**

ViiV Healthcare B.V., Rapporteur: Jean-Michel

Positive Opinion adopted by consensus on 01.09.2022.

Race, "Update of sections 4.4 and 5.1 of the SmPC in order to update efficacy and safety information based on week 96 results from the clinical study 207966 (ATLAS-2M). This is an open-label, randomized, Phase IIIb trial to demonstrate non-inferior antiviral activity and safety of CAB + RPV Q8W compared with CAB + RPV Q4W. Supporting Cabotegravir (CAB) Long-acting Injectable (LA) + Rilpivirine (RPV) LA every 2 months (Q8W) dosing regimen for the treatment of HIV-1 infection."

Opinion adopted on 01.09.2022.

Request for Supplementary Information adopted on 23.06.2022, 16.12.2021.

**Vocabria - cabotegravir -
EMA/H/C/004976/II/0012**

ViiV Healthcare B.V., Rapporteur: Jean-Michel Race, "Update of sections 4.2 and 5.1 of the SmPC in order to describe data regarding oral bridging using other suppressive regimens than oral bridging with cabotegravir and rilpivirine based on studies 201584 (FLAIR), 207966 (ATLAS-2M), 200056 (LATTE 2) and 201585 (ATLAS).

In addition, the MAH is also taking this opportunity to introduce editorial changes in the SmPC and Package Leaflet."

Opinion adopted on 15.09.2022.

Request for Supplementary Information adopted on 21.07.2022.

Positive Opinion adopted by consensus on 15.09.2022.

**Xevudy - sotrovimab -
EMA/H/C/005676/II/0004**

Glaxosmithkline Trading Services Limited, Rapporteur: Thalia Marie Estrup Blicher, "Submission of the final report from study PC-7831-0126 in order to fulfil the recommendation by the CHMP to submit an in vivo study in hamsters challenged with the alpha (B.1.1.7) SARS-CoV-2 variant."

Opinion adopted on 01.09.2022.

Positive Opinion adopted by consensus on 01.09.2022.

**Xevudy - sotrovimab -
EMA/H/C/005676/II/0007**

Glaxosmithkline Trading Services Limited, Rapporteur: Thalia Marie Estrup Blicher, "Update of sections 5.1 and 5.2 of the SmPC based on final results from study COMET-ICE (214367; VIR-7831-5001); this is a Phase II/III randomised, multi-centre, double-blind, placebo-controlled study to assess the safety

Request for supplementary information adopted with a specific timetable.

and efficacy of monoclonal antibody VIR-7831 for the early treatment of coronavirus disease 2019 (COVID-19) in non-hospitalised patients.” Request for Supplementary Information adopted on 15.09.2022.

**Zercepac - trastuzumab -
EMA/H/C/005209/II/0020**

Accord Healthcare S.L.U., Rapporteur: Sol Ruiz, “Submission of the final report from study HLX02-BC01 in order to fulfil REC/006. This is a double-blind, randomised, parallel-controlled, multicentre, international, phase 3 study to compare the efficacy, safety, and immunogenicity of HLX02 versus EU-sourced Herceptin in combination with docetaxel.” Request for Supplementary Information adopted on 01.09.2022.

Request for supplementary information adopted with a specific timetable.

**WS2244
Nuwiq-EMA/H/C/002813/WS2244/0048
Vihuma-
EMA/H/C/004459/WS2244/0030**

Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus, “Update of sections 4.8 and 5.1 of the SmPC in order to add safety and efficacy data based on the final CSR from the category 3 study GENA-21b; a prospective, open-label, multicentre phase 3b study to assess the efficacy and safety of personalized prophylaxis with Human-cl rhFVIII in previously treated adult patients with severe haemophilia A. Further, upon request by the CHMP following the assessment of study GENA-05 (P46 013 and P46 014), the MAH is updating the numbers of evaluated subjects in SmPC section 4.8 and is removing the sentence “A prospective open-label clinical study in PUPs with severe haemophilia A (<1% FVIII:C) is ongoing” in section 5.1 of the SmPC. The Package Leaflet is updated accordingly.” Request for Supplementary Information adopted on 01.09.2022, 16.06.2022, 05.05.2022.

Request for supplementary information adopted with a specific timetable.

**WS2289
OPDIVO-
EMA/H/C/003985/WS2289/0122
Yervoy-EMA/H/C/002213/WS2289/0099**

Bristol-Myers Squibb Pharma EEIG, Lead Rapporteur: Blanca Garcia-Ochoa, “To update sections 4.8 and 5.1 of the SmPC to include 7.5 years of minimum follow-up for all subjects

Positive Opinion adopted by consensus on 01.09.2022.

based on addendum 04 Clinical Study Report for study CA209067; this is a phase 3 randomized, double-blind study of nivolumab monotherapy or nivolumab in combination with ipilimumab versus ipilimumab monotherapy in subjects with previously untreated, unresectable melanoma. The MAH has taken the opportunity to introduce minor editorial revisions in the SmPC.”
Opinion adopted on 01.09.2022.

WS2304/G

Exviera-

EMA/H/C/003837/WS2304/0054/G

Viekirax-

EMA/H/C/003839/WS2304/0066/G

AbbVie Deutschland GmbH & Co. KG, Lead Rapporteur: Filip Josephson, “Submission of the final reports from studies M14-423 (TOPAZ-1) and M14-222 (TOPAZ-II) listed as category 3 studies in the RMP for Viekirax and Exviera in order to fulfil MEA/018 for Viekirax and MEA/016 for Exviera. These are phase 3, open-label, multicentre, post-authorisation safety studies (PASS) to evaluate long-term outcomes with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin (RBV) in adults with GT1 chronic HCV infection.”
Opinion adopted on 01.09.2022.

Positive Opinion adopted by consensus on 01.09.2022.

WS2312

Kispilix-EMA/H/C/004224/WS2312/0053

Lenvima-

EMA/H/C/003727/WS2312/0048

Eisai GmbH, Lead Rapporteur: Karin Janssen van Doorn, “To update of SmPC sections 4.2 and 6.6 to include the option of administering the capsules as a suspension, including instructions for the administration and preparation of the suspension. The MAH also took the opportunity to include some editorial changes to the SmPC.”
Request for Supplementary Information adopted on 15.09.2022.

Request for supplementary information adopted with a specific timetable.

B.5.3. CHMP-PRAC assessed procedures

Apexxnar - pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) -

EMA/H/C/005451/II/0006

Pfizer Europe MA EEIG, Rapporteur: Daniela Philadelphia, PRAC Rapporteur: Jean-Michel

Request for supplementary information adopted with a specific timetable.

Dogné, "Update of sections 4.5, 4.8 and 5.1 of the SmPC based on final results from study B7471026 listed as a category 3 study in the RMP; this is a Phase III, randomized, double-blind trial to describe the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine when coadministered with a booster dose of BNT162b2 in adults 65 years of age and older; the Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted."

Request for Supplementary Information adopted on 01.09.2022.

**Caprelsa - vandetanib -
EMA/H/C/002315/II/0043**

Genzyme Europe BV, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Tiphaine Vaillant, "C.I.4 Update of section 5.1 of the SmPC in order to update pharmacodynamic information based on interim results from study D4200C00104, listed as a specific obligation in the Annex II. This is an observational study (including a retrospective arm to evaluate the Benefit/Risk of vandetanib (Caprelsa) 300 mg in RET mutation negative and RET mutation positive patients with symptomatic, aggressive, sporadic, unresectable, locally advanced/metastatic thyroid cancer (MTC)), to confirm the efficacy and safety of Caprelsa in RET-negative patients with the aim to fulfil SOB001 and convert Caprelsa from conditional to normal Marketing Authorisation.

In addition, the MAH takes to opportunity to rectify the Dutch translation of the Caprelsa Product Information."

Opinion adopted on 15.09.2022.

Request for Supplementary Information adopted on 19.05.2022, 16.12.2021, 24.06.2021, 28.05.2020.

Positive Opinion adopted by consensus on 15.09.2022.

See 9.1

**Cibinco - abrocitinib -
EMA/H/C/005452/II/0001**

Pfizer Europe MA EEIG, Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, "Update of sections 4.4 and 4.8 of the SmPC based on updated safety data from the Full Cumulative Pool (April 2021 data cut) from the ongoing long-term extension study B7451015. The RMP version v1.0 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes in

Positive Opinion adopted by consensus on 01.09.2022.

the SmPC and to update the contact details of the local representatives in the Package Leaflet.”

Opinion adopted on 01.09.2022.

Request for Supplementary Information adopted on 07.07.2022, 07.04.2022.

**COMIRNATY - tozinameran -
EMA/H/C/005735/II/0140**

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst “Addition of a new strain (Omicron BA.1) resulting in a new Comirnaty Original/Omicron BA.1 (15 µg tozinameran/ 15 µg riltozinameran)/dose dispersion for injection presentation. The Annex A, the SmPC, the Labelling and the Package Leaflet are updated accordingly. A revised RMP version 6.1 has been approved.”

Opinion adopted on 01.09.2022.

Positive Opinion adopted by consensus on 01.09.2022.

See 9.1

**COMIRNATY - tozinameran -
EMA/H/C/005735/II/0141**

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst, “Update of sections 4.4 and 4.8 of the SmPC in order to update the existing information on myocarditis and pericarditis after a third dose and in the age group 5-11 years based on real-world evidence as requested in the outcome of the post Authorization Measure PAM MEA/002.13 (EMA/H/C/005735/MEA/002.13, dated 08 June 2022). The package leaflet is updated accordingly.

In addition, the MAH took the opportunity to implement editorial changes in section 4.4 of the SmPC.”

Opinion adopted on 15.09.2022.

Positive Opinion adopted by consensus on 15.09.2022.

**COMIRNATY - tozinameran -
EMA/H/C/005735/II/0143**

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst “Addition of a new strain (Omicron BA.4-5) resulting in a new Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose dispersion for injection presentation. The SmPC, the Package Leaflet and Labelling are updated accordingly. A revised RMP version 7.1 has been approved.”

Positive Opinion adopted by consensus on 12.09.2022.

See 9.1

Opinion adopted on 12.09.2022.

**Dapivirine Vaginal Ring 25 mg - dapivirine
- EMEA/H/W/002168/II/0015/G**

Positive Opinion adopted by consensus on
01.09.2022.

International Partnership for Microbicides
Belgium AISBL, Rapporteur: Paula Boudewina
van Hennik, PRAC Rapporteur: Jan Neuhauser,
"Submission of the four addenda from studies
IPM 032, MTN-025, IPM 007 and MTN-015 listed
as category 3 studies in the RMP. The data
presented in the addenda are the results of
retrospective next generation sequencing (NGS)
and phenotype susceptibility testing on blood
samples to further assess the potential
development of nonnucleoside reverse
transcriptase inhibitor (NNRTI) resistance in
women with unrecognized or acute HIV-1
infection. The tested samples are all from
women who were initially enrolled in the Phase
III clinical trials IPM 027 and MTN-020 and then
had the option to participate in the open-label
extension (OLE) studies IPM 032 and MTN-025.
If the women became infected with HIV during
any of the trials, they could enrol in the
observational studies IPM 007 and MTN-015.
The RMP version 0.9 has also been submitted.
Additionally, the MAH would like to take the
opportunity to update the EMA on other
commitments outlined in the RMP as additional
risk minimisation measures. These include the
development of a Healthcare Professional Guide
(HCP Guide) and a User Guide with agreed
objectives and key messages."

Opinion adopted on 01.09.2022.

Request for Supplementary Information adopted
on 07.04.2022.

**Deltyba - delamanid -
EMEA/H/C/002552/II/0053, Orphan**

Positive Opinion adopted by consensus on
01.09.2022.

Otsuka Novel Products GmbH, Rapporteur:
Christophe Focke, PRAC Rapporteur: Jo Robays,
"Update of section 4.8 of the SmPC in order to
update the list of adverse drug reactions (ADRs
table) following the development of an improved
methodology to identify relevant ADRs likely
attributable to delamanid. The section 4 of the
Package Leaflet is updated accordingly. The RMP
version 4.1 has also been submitted."

Opinion adopted on 01.09.2022.

Request for Supplementary Information adopted
on 05.05.2022, 13.01.2022.

**JEMPERLI - dostarlimab -
EMA/H/C/005204/II/0013**

GlaxoSmithKline (Ireland) Limited, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "Update of section 5.1 of the SmPC in order to update efficacy and safety information based on interim results from study 4010-01-001 (GARNET) listed as a specific obligation in the Annex II; This is a single-arm, open-label, phase I trial of intravenous dostarlimab in advanced solid tumours. In addition, the MAH took the opportunity to update section E of Annex II. The RMP version 1.2 has also been submitted." Request for Supplementary Information adopted on 01.09.2022.

Request for supplementary information adopted with a specific timetable.

**Jorveza - budesonide -
EMA/H/C/004655/II/0015, Orphan**

Dr. Falk Pharma GmbH, Rapporteur: Martina Weise, PRAC Rapporteur: Zane Neikena, "Update of section 4.8 of the SmPC in order to update the list of adverse reactions based on final results from the long-term maintenance study BUL-2/EER; this is a double-blind, randomized, placebo-controlled, phase III study on the efficacy and tolerability of a 48-week treatment with two different doses of budesonide effervescent tablets vs. placebo for maintenance of clinico-pathological remission in adult patients with eosinophilic esophagitis. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet. The RMP version 3.0 has also been submitted. The MAH also submitted the final report of study BUL-6/BIO, which was previously assessed within the scope of extension EMA/H/C/004655/X/0007/G as applicant's response to CHMP Day 120 List of Questions." Request for Supplementary Information adopted on 15.09.2022, 19.05.2022.

Request for supplementary information adopted with a specific timetable.

**Jyseleca - filgotinib -
EMA/H/C/005113/II/0018**

Galapagos N.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, "Update of sections 4.4, 4.6 and 5.1 of the SmPC in order to update information on fertility based on interim results from studies

Request for supplementary information adopted with a specific timetable.

GLPG0634-CL-227 (MANTA Ray) and GS-US-418-4279 (MANTA) listed as a category 3 study in the RMP.

The Package Leaflet and Annex II are updated accordingly. The RMP version 4.1 has also been submitted.”

Request for Supplementary Information adopted on 01.09.2022.

Kaftrio - ivacaftor / tezacaftor / elexacaftor - EMEA/H/C/005269/II/0024, Orphan

Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber, “Update of sections 4.8 and 5.1 of the SmPC in order to update efficacy and safety information based on interim results from clinical study VX17-445-105 (study 105) listed as a category 3 study in the RMP; this is a Phase III, open label extension study to evaluate the long-term safety and efficacy of ELX/TEZ/IVA in CF subjects homozygous for F508del (F/F genotype) or heterozygous for F508del and a minimal function (MF) mutation (F/MF genotypes).

The RMP version 6.1 has also been submitted.

In addition, the MAH took the opportunity to implement minor corrections (sections 5.3 and 6.5); as well as editorial changes to the SmPC. The requested variation proposed amendments to the Summary of Product Characteristics and to the Risk Management Plan (RMP).”

Request for Supplementary Information adopted on 01.09.2022, 10.06.2022.

Request for supplementary information adopted with a specific timetable.

Leqvio - inclisiran - EMEA/H/C/005333/II/0013

Novartis Europharm Limited, Rapporteur: Martina Weise, PRAC Rapporteur: Kimmo Jaakkola, “Submission of the final report from ORION-3 study (CKJX839A12201E1 or MDCO-PCS-16-01) listed as a category 3 study in the RMP. This is an open label, active comparator extension trial to assess the effect of long-term dosing of inclisiran and evolocumab given as subcutaneous injections in subjects with high cardiovascular risk and elevated LDL-C. The RMP version 2.0 has also been submitted.”

Opinion adopted on 01.09.2022.

Positive Opinion adopted by consensus on 01.09.2022.

Lorviqua - lorlatinib - EMEA/H/C/004646/II/0022

Positive Opinion adopted by consensus on

Pfizer Europe MA EEIG, Rapporteur: Aaron Sosa 15.09.2022.
Mejia, PRAC Rapporteur: Nikica Mirošević
Skvrce, "Submission of an updated RMP version
5.0 to revise plans for conduct of hepatic
impairment studies.

The RMP is updated to reflect the hepatic
impairment study B7461009 "A Phase 1 Study
to Evaluate the Effect of Hepatic Impairment on
the Pharmacokinetics and Safety of Lorlatinib in
Advanced Cancer Patients" termination and to
include new hepatic impairment study
B7461040 "A Phase 1, Open-label, Single-dose,
Parallel-group Study to Evaluate The Plasma
Pharmacokinetics and Safety of Lorlatinib in
Participants with Moderate and Severe Hepatic
Impairment Relative to Participants with Normal
Hepatic Function".

Opinion adopted on 15.09.2022.

Request for Supplementary Information adopted
on 21.07.2022.

**MenQuadfi - meningococcal group A, C,
W135 and Y conjugate vaccine -
EMA/H/C/005084/II/0018/G**

Request for supplementary information adopted
with a specific timetable.

Sanofi Pasteur, Rapporteur: Andrea Laslop,
PRAC Rapporteur: Jean-Michel Dogné, "Update
of sections 4.2, 4.5, 4.8 and 5.1 of the SmPC in
order to add long term antibody persistence at
least 3 years after primary vaccination,
immunogenicity and safety of a booster dose of
MenQuadfi in adolescents, adults and older
adults, as well as co-administration data with
meningococcal serogroup B vaccine in
adolescents and adults, in order to fulfil
ANX/002 and ANX/003 based on final results
from studies MET59 and MEQ00066,
respectively, listed as specific obligations in the
Annex II. MET59 is a phase 3b, open-label,
partially randomized, parallel-group, active-
controlled, multi-center study evaluating the
immunogenicity and safety of a booster dose of
an investigational quadrivalent MenACYW
conjugate vaccine in adolescents and adults,
while MEQ00066 is a phase 3, two-stage,
randomized, open-label, multi-center trial
evaluating the safety and immunogenicity of a
single dose of MenACYW conjugate vaccine at
least 3 years following initial vaccination with
either Menomune vaccine or MenACYW
conjugate vaccine in older adults. The Annex II
and Package Leaflet are updated accordingly.

The RMP version 1.1 has also been submitted.
In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”
Request for Supplementary Information adopted on 15.09.2022.

Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/II/0056

Orexigen Therapeutics Ireland Limited,
Rapporteur: Thalia Marie Estrup Blicher, PRAC
Rapporteur: Martin Huber, “Submission of updated study design and protocol synopsis for CVOT-2 study, a category 1 study listed in Annex II.D (ANX/001.7) undertaken to assess the effect of naltrexone extended release (ER) / bupropion ER on the occurrence of major adverse cardiovascular events (MACE), as requested in the CHMP AR for ANX/001.6. The Annex II and the RMP version 13 are updated accordingly.”

Request for Supplementary Information adopted on 15.09.2022, 24.03.2022.

Request for supplementary information adopted with a specific timetable.

See 9.1

NUBEQA - darolutamide - EMEA/H/C/004790/II/0012

Bayer AG, Rapporteur: Alexandre Moreau, PRAC
Rapporteur: Jan Neuhauser, “Submission of the final report of carcinogenicity study T104877-7 listed as a category 3 study in the RMP. This is a non-clinical study to assess the carcinogenic potential in mice. The study evaluates the effects of daily oral administration of darolutamide for a period of 6 months in tg-rasH2 transgenic mouse model.
The updated RMP version 3.1 has also been submitted.”

Request for Supplementary Information adopted on 01.09.2022.

Request for supplementary information adopted with a specific timetable.

NUVAXOVID - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/II/0014

Novavax CZ, a.s., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Brigitte Keller-Stanislawski, “Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to include a third dose for Nuvaxovid, to boost individuals who have previously completed a primary vaccination series with Nuvaxovid (homologous booster dose) or with an mRNA or adenoviral vector

Positive Opinion adopted by consensus on 01.09.2022.

See 9.1

vaccine (heterologous booster dose); based on interim data from study 2019nCoV-101 (Part 2), final data from study 2019nCoV-501, and data from the COV-BOOST study; the Package Leaflet is updated accordingly. The RMP version 2.0 has also been approved.

In addition, the Marketing Authorisation Holder (MAH) took the opportunity to make minor editorial corrections in the Annex II and labelling (Annex IIIB)."

Opinion adopted on 01.09.2022.

Request for Supplementary Information adopted on 21.07.2022.

**Oxlumo - lumasiran -
EMA/H/C/005040/II/0008, Orphan**

Alnylam Netherlands B.V., Rapporteur: Martina Weise, PRAC Rapporteur: Mari Thorn, "Update of sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to clarify administration instructions, remove an existing warning on metabolic acidosis in patients with severe or end stage renal impairment, update the description of adverse reactions injection site reactions, abdominal pain and immunogenicity, update efficacy, pharmacokinetic information based on interim results from a category 3 study in the RMP ILLUMINATE-C (ALN-GO1-005): A single arm study to evaluate efficacy, safety, pharmacokinetics, and pharmacodynamics of lumasiran in patients with advanced primary hyperoxaluria type 1 (PH1) and, in addition, based on available long-term efficacy and safety data from ongoing phase 3 studies ALN-GO1-003 in PH1 patients >6 years old and ALN-GO1-004 in PH1 patients <6 years old, and open-label extension study ALN-GO1-002. The Package Leaflet is updated accordingly. The RMP version 1.1 has also been submitted."

Opinion adopted on 15.09.2022.

Request for Supplementary Information adopted on 23.06.2022, 24.02.2022.

Positive Opinion adopted by consensus on 15.09.2022.

**Paxlovid - (1R,2S,5S)-N-((1S)-1-Cyano-2-((3s)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide /
ritonavir - EMA/H/C/005973/II/0007**

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Martin Huber,

Request for supplementary information adopted with a specific timetable.

"Submission of the final report from study C4671010 listed as a category 3 study in the RMP. This is a phase I, non-randomized, open label study to assess the pharmacokinetics, safety and tolerability of PF-07321332 boosted with ritonavir in adults with moderate hepatic impairment and individuals with normal hepatic function. The RMP version 2.0 has also been submitted."

Request for Supplementary Information adopted on 01.09.2022, 10.06.2022.

**QINLOCK - ripretinib -
EMA/H/C/005614/II/0004, Orphan**

Deciphera Pharmaceuticals (Netherlands) B.V.,
Rapporteur: Filip Josephson, PRAC Rapporteur:
Željana Margan Koletić, "Update of sections 4.2
and 5.2 of the SmPC in order to change
posology recommendations in patients with
hepatic impairment and update the description
of pharmacokinetics based on final results from
study DCC-2618-01-004; a Phase 1 study of the
Pharmacokinetics, Safety, and Tolerability of
Ripretinib in Subjects With Hepatic Impairment
Compared to Healthy Control Subjects. The
Package Leaflet is updated accordingly. The RMP
version 2.0 has also been submitted."

Request for Supplementary Information adopted
on 15.09.2022.

Request for supplementary information adopted
with a specific timetable.

**RINVOQ - upadacitinib -
EMA/H/C/004760/II/0020/G**

AbbVie Deutschland GmbH & Co. KG,
Rapporteur: Kristina Dunder, PRAC Rapporteur:
Nikica Mirošević Skvrce, "Update of sections 4.4
and 4.8 of the SmPC in order to add a new
warning on 'Hypersensitivity' and add it to the
list of adverse drug reactions (ADRs) with
frequency not known. The MAH also proposed to
update section 4.8 of the SmPC in order to add
'Non-Melanoma Skin Cancer (NMSC)' to the list
of adverse drug reactions (ADRs) with frequency
uncommon. The Package Leaflet has been
updated accordingly. The RMP version 9.0 has
also been submitted."

Request for Supplementary Information adopted
on 15.09.2022, 10.06.2022.

Request for supplementary information adopted
with a specific timetable.

**Rubraca - rucaparib -
EMA/H/C/004272/II/0029**

Clovis Oncology Ireland Limited, Rapporteur:
Blanca Garcia-Ochoa, PRAC Rapporteur: Ulla

Positive Opinion adopted by consensus on
15.09.2022.

See 9.1

Wändel Liminga, "Update of sections 4.4 and 4.8 of the SmPC based on safety data from study CO-338-043 (ARIEL 4); this is a phase 3, multicentre, open-label, randomised study evaluating the efficacy and safety of rucaparib versus chemotherapy for treatment of relapsed ovarian cancer listed as a specific obligation in the Annex II; the Package Leaflet is updated accordingly. The RMP version 6.2 is acceptable. Update of Annex II to remove the specific obligation. The SmPC and Package leaflet are amended accordingly to reflect the conversion from a conditional marketing authorisation to a marketing authorisation no longer subject to specific obligations as recommended by the CHMP as a result of this variation and further to the removal of the indication for monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy (EMA/H/A-20/1518/C/4272/0033). In addition, the MAH took the opportunity to make minor editorial changes and bring the PI in line with the latest QRD template version 10.2 Rev.1." Opinion adopted on 15.09.2022.
Request for Supplementary Information adopted on 21.07.2022, 24.03.2022, 11.11.2021.

Rydapt - midostaurin - EMEA/H/C/004095/II/0024, Orphan
Novartis Europharm Limited, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "C.I.11.b Submission of the final report from study CPKC412E2301 listed as an obligation in the Annex II of the Product Information. This is a Phase III study to investigate the efficacy in elderly patients. A final pharmacogenomic report is also provided to fulfil MEA004. The Annex II and the RMP (submitted version 7.0) are updated accordingly."
Opinion adopted on 15.09.2022.
Request for Supplementary Information adopted on 07.07.2022, 10.03.2022.

Positive Opinion adopted by consensus on 15.09.2022.

Spikevax - elasmomeran -

Positive Opinion adopted by consensus on

<p>EMA/H/C/005791/II/0075/G Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen, "B.I.a.6.a (Type II): Addition of a new strain (Omicron BA.1) resulting in two new Spikevax bivalent Original/Omicron (25 µg elasomeron / 25 µg imelasomeron per dose) 0.1 mg/mL dispersion for injection presentations. The SmPC, the Package Leaflet and Labelling are updated accordingly. The submission includes a revised RMP version 4.2. Opinion adopted on 01.09.2022.</p>	<p>01.09.2022. See 9.1</p>
<p>Symtuza - darunavir / cobicistat / emtricitabine / tenofovir alafenamide - EMA/H/C/004391/II/0045 Janssen-Cilag International N.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ana Sofia Diniz Martins, "Submission of the interim report from study GS-US-292-0106 listed as a category 3 study in the RMP. This is a Phase II/III, open-label study to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) single tablet regimen in HIV-1 infected antiretroviral treatment-naive adolescents and virologically suppressed HIV-infected children. The RMP version 8.1 has also been submitted." Opinion adopted on 01.09.2022.</p>	<p>Positive Opinion adopted by consensus on 01.09.2022.</p>
<p>Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMA/H/C/005675/II/0075 AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, "Update of section 5.1 of the SmPC in order to include updated efficacy information based on the 6 months follow-up analysis from study D8110C00001 listed as a specific obligation in the Annex II; this is a phase III randomised, double-blind, placebo-controlled, multicenter study in adults to determine the safety, efficacy and immunogenicity of Vaxzevria. In addition, the MAH took the opportunity to implement other administrative updates in the product information. The RMP version 5.2 has also been submitted. The MAH removed the important identified risk of anaphylaxis from the list of</p>	<p>Positive Opinion adopted by consensus on 15.09.2022.</p>

safety concerns, updated the routine and additional pharmacovigilance activities section and took the opportunity to implement other administrative updates.”

Opinion adopted on 15.09.2022.

Request for Supplementary Information adopted on 23.06.2022.

**Vemlidy - tenofovir alafenamide -
EMA/H/C/004169/II/0038**

Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, PRAC Rapporteur: Valentina Di Giovanni, “Submission of the final week 192 report from study GS-US-320-3912; ‘A Phase 2, Randomized, Open Label Study to Evaluate the Efficacy and Safety of Tenofovir Alafenamide (TAF) versus Tenofovir Disoproxil Fumarate (TDF)-containing Regimens in Subjects with Chronic HBV Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant’, listed as a category 3 study in the RMP.

The RMP version 9.0 has also been submitted.”

Opinion adopted on 01.09.2022.

Request for Supplementary Information adopted on 10.06.2022.

Positive Opinion adopted by consensus on 01.09.2022.

**Vumerity - diroximel fumarate -
EMA/H/C/005437/II/0005**

Biogen Netherlands B.V., Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, “Submission of the final report from study ALK8700-A301, A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults with Relapsing Remitting Multiple Sclerosis listed as a category 3 study in the RMP. This is a multicentre, open-label study to evaluate the long-term safety, tolerability, and treatment effect over time of DRF administered for up to 96 weeks in adult participants with RRMS.

The RMP version 1.1 has also been submitted.”

Request for Supplementary Information adopted on 01.09.2022.

Request for supplementary information adopted with a specific timetable.

**Vyndaqel - tafamidis -
EMA/H/C/002294/II/0081, Orphan**

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, PRAC Rapporteur: Tiphaine Vaillant, “Update of section 5.1 of the SmPC in order to update information based on final results from study B3461029 listed as a Specific Obligation

Request for supplementary information adopted with a specific timetable.

in the Annex II of the Product Information. This is a non-interventional PASS sub-study evaluating effects of tafamidis on disease progression in patients with non-Val30Met mutations and symptomatic neuropathy. Consequently, the MAH proposes a switch from marketing authorisation under exceptional circumstances to full marketing authorisation given the fulfilment of the SOB. The Annex II and Package Leaflet are updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.”

Request for Supplementary Information adopted on 15.09.2022, 21.07.2022.

WS2187
OPDIVO-
EMA/H/C/003985/WS2187/0121
Yervoy-EMA/H/C/002213/WS2187/0098

Bristol-Myers Squibb Pharma EEIG, Lead Rapporteur: Blanca Garcia-Ochoa, Lead PRAC Rapporteur: Brigitte Keller-Stanislawski, “Update of section 4.8 of the SmPC in alignment with the recommendations made by the CHMP to revise the pooling approach used to describe irARs and tabulated summaries of ADRs following II/0096. Individual study data included within this application has been previously reviewed by the CHMP.

The updated Opdivo RMP version 29.0 and Yervoy RMP version 37.0 have also been submitted.

The MAH took the opportunity to introduce editorial changes.

The Package Leaflet was updated accordingly.”

Request for Supplementary Information adopted on 01.09.2022.

Request for supplementary information adopted with a specific timetable.

WS2274
Relvar Ellipta-
EMA/H/C/002673/WS2274/0054
Revinty Ellipta-
EMA/H/C/002745/WS2274/0052

GlaxoSmithKline (Ireland) Limited, Lead Rapporteur: Maria Concepcion Prieto Yerro, Lead PRAC Rapporteur: Maria del Pilar Rayon, “Submission of the final report from study HZA114971 listed as a category 3 study in the RMP. This is a multicentre randomised, double-blind, placebo-controlled, parallel-group study

Positive Opinion adopted by consensus on 15.09.2022.

to evaluate the effects of a one-year regimen of orally inhaled fluticasone furoate 50 mcg once daily on growth velocity in prepubertal, paediatric subjects with asthma. The RMP version 11.1 has also been submitted.”

Opinion adopted on 15.09.2022.

Request for Supplementary Information adopted on 07.07.2022.

WS2307

Rixathon-

EMA/H/C/003903/WS2307/0062

Riximyo-

EMA/H/C/004729/WS2307/0063

Sandoz GmbH, Lead Rapporteur: Jan Mueller-Berghaus, Lead PRAC Rapporteur: Anette Kirstine Stark, “Update of section 4.1 of the SmPC in order to include the rapid infusion regimen (90 minutes) for second and subsequent infusions in the label for patients with non-Hodgkin’s lymphoma (NHL) or chronic lymphocytic leukaemia (CLL) based on non-interventional PASS CGP2013ES01R and scientific literature.

The RMP version 7.0 has also been submitted.”

Request for Supplementary Information adopted on 15.09.2022.

Request for supplementary information adopted with a specific timetable.

WS2323

Juluca-EMA/H/C/004427/WS2323/0045

Tivicay-EMA/H/C/002753/WS2323/0081

Triumeq-

EMA/H/C/002754/WS2323/0106

ViiV Healthcare B.V., Lead Rapporteur: Janet Koenig, Lead PRAC Rapporteur: Nathalie Gault, “Submission of the final report from study 200336 listed as a category 3 study in the RMP. This is a prospective, interventional pharmacokinetic and safety study of DTG/ABC/3TC in pregnant women. The summary of objective of this PASS study is to investigate the use of DTG during pregnancy and address the safety concerns of pregnant/breastfeeding women. The RMP versions 18.0, 20.0 and 4.0 for Tivicay, Triumeq and Juluca, respectively, have also been submitted.”

Opinion adopted on 01.09.2022.

Positive Opinion adopted by consensus on 01.09.2022.

B.5.4. PRAC assessed procedures

<p>PRAC Led</p> <p>Adasuve - loxapine - EMA/H/C/002400/II/0033</p> <p>Ferrer Internacional s.a., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, "Revision of sections 4.2, 4.4 and 4.8 of the SmPC in order to update safety information on bronchospasm, based on the final results from study AMDC-204-401 EU PASS: a post-authorisation observational study to evaluate the safety of ADASUVE (Staccato loxapine for inhalation) in agitated persons in routine clinical care (category 3 study in the RMP); Annex IID of the PI, the Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.</p> <p>Version 10.1 of the RMP has also been agreed." Opinion adopted on 01.09.2022. Request for Supplementary Information adopted on 05.05.2022, 02.12.2021.</p>	<p>Positive Opinion adopted by consensus on 01.09.2022.</p>
<p>PRAC Led</p> <p>Besremi - ropeginterferon alfa-2b - EMA/H/C/004128/II/0025</p> <p>AOP Orphan Pharmaceuticals GmbH, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, PRAC-CHMP liaison: Bruno Sepodes, "Submission of an updated RMP version 1.1 for Besremi to revise safety concerns according to GVP Module V Rev.2." Request for Supplementary Information adopted on 01.09.2022.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>PRAC Led</p> <p>Candidas - caspofungin - EMA/H/C/000379/II/0078</p> <p>Merck Sharp & Dohme B.V., PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Karin Janssen van Doorn, "Submission of an updated RMP version 4.1 in order to remove safety concerns and align it with the EU GVP Module V (Revision 2)." Request for Supplementary Information adopted on 01.09.2022.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>PRAC Led</p> <p>Cotellic - cobimetinib -</p>	<p>Request for supplementary information adopted with a specific timetable.</p>

EMA/H/C/003960/II/0027

Roche Registration GmbH, PRAC Rapporteur:
Menno van der Elst, PRAC-CHMP liaison: Johann
Lodewijk Hillege, "Update of sections 4.4 and
5.1 of the SmPC in order to update information
based on final results from study ML39302 listed
as a category 3 study in the RMP in order to
fulfil MEA/003.5; this is a non-interventional
PASS study to investigate the effectiveness,
safety and utilisation of cobimetinib and
vemurafenib in patients with and without brain
metastasis with BRAF V600 mutant melanoma
under real world conditions. The RMP version
5.0 has also been submitted."
Request for Supplementary Information adopted
on 01.09.2022.

PRAC Led

**Gazyvaro - obinutuzumab -
EMA/H/C/002799/II/0051, Orphan**

Roche Registration GmbH, PRAC Rapporteur:
Ulla Wändel Liminga, PRAC-CHMP liaison:
Kristina Dunder, "Update of section 4.8 of the
SmPC in line with the SmPC Guideline following
the recommendation by PRAC in the outcome
for the signal assessment of non-overt
disseminated intravascular coagulation (DIC)
(EPITT no: 19711). The Package Leaflet is
updated accordingly."
Opinion adopted on 01.09.2022.

Positive Opinion adopted by consensus on
01.09.2022.

PRAC Led

**Jinarc - tolvaptan -
EMA/H/C/002788/II/0036**

Otsuka Pharmaceutical Netherlands B.V., PRAC
Rapporteur: Amelia Cupelli, PRAC-CHMP liaison:
Armando Genazzani, "Submission of an updated
RMP version 15.0 in order to reflect the outcome
of the substantial amendment to the protocol of
the category 1 PASS study (156-12-299) as
concluded in (PSA/S/0078.1). The Annex II is
updated accordingly. In addition, the MAH took
the opportunity to correct an oversight/editorial
error in the Package Leaflet relevant to
(II/0033/G)."
Opinion adopted on 01.09.2022.
Request for Supplementary Information adopted
on 10.06.2022.

Positive Opinion adopted by consensus on
01.09.2022.

PRAC Led

**Mycamine - micafungin -
EMA/H/C/000734/II/0047**

Request for supplementary information adopted
with a specific timetable.

Astellas Pharma Europe B.V., PRAC Rapporteur:
Martin Huber, PRAC-CHMP liaison: Janet Koenig,
"To update Annex II and the RMP to version
23.0 to include the results of the non-
interventional PASS as an Effectiveness Check
of the Prescriber Checklist for Mycamine
(micafungin) - 9463-PV-0002."
Request for Supplementary Information adopted
on 01.09.2022.

PRAC Led

**Nplate - romiplostim -
EMA/H/C/000942/II/0083**

Amgen Europe B.V., Rapporteur: Maria
Concepcion Prieto Yerro, PRAC Rapporteur: Eva
A. Segovia, PRAC-CHMP liaison: Maria
Concepcion Prieto Yerro, "Submission of the
final report from study 20070797 listed as a
category 3 study in the RMP. This is an
observational study assessing the long-term
safety of romiplostim treatment in real-life
clinical practice in three Nordic countries. The
RMP version 21.0 has also been submitted."
Opinion adopted on 01.09.2022.
Request for Supplementary Information adopted
on 10.02.2022.

Positive Opinion adopted by consensus on
01.09.2022.

PRAC Led

**SCENESSE - afamelanotide -
EMA/H/C/002548/II/0042, Orphan**

Clinuvel Europe Limited, PRAC Rapporteur:
Martin Huber, PRAC-CHMP liaison: Janet Koenig,
"Submission of an updated RMP version 9.1 in
order to update the allergy and hypersensitivity
risk from potential to identified, following
reported cases of positive allergy test results,
confirming the causal association between the
allergies to afamelanotide. Consequently, the
RMP has been revised to reclassify the
important potential risk Allergy and
hypersensitivity to important identified risk."
Request for Supplementary Information adopted
on 01.09.2022.

Request for supplementary information adopted
with a specific timetable.

PRAC Led

**Stelara - ustekinumab -
EMA/H/C/000958/II/0095**

Janssen-Cilag International N.V., PRAC
Rapporteur: Rhea Fitzgerald, PRAC-CHMP
liaison: Jayne Crowe, "Submission of the final
report from study PSOLAR (C0168Z03) listed as
a category 3 study in the RMP. This is a

Request for supplementary information adopted
with a specific timetable.

Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy Including Biologics: PSOLAR. The RMP version 22.2 has also been submitted.”
Request for Supplementary Information adopted on 01.09.2022.

PRAC Led
Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0038

Positive Opinion adopted by consensus on 01.09.2022.

AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC Rapporteur: Jean-Michel Dogné, PRAC-CHMP liaison: Christophe Focke, “Submission of the final report from study MS1222-0003
"Assessment of anti-PF4 antibodies prior to, and following, vaccination with AZD1222" listed as a category 3 study in the RMP. This is a study where sera of vaccinated individuals in study D8110C00001 are tested to elucidate whether vaccination with Vaxzevria leads to increased levels of circulating anti-PF4 antibodies, a key component of the hypothesised mechanism underlying thrombosis with thrombocytopenia syndrome (TTS).”
Opinion adopted on 01.09.2022.
Request for Supplementary Information adopted on 10.02.2022, 28.10.2021.

PRAC Led
VIZAMYL - flutemetamol (18F) - EMEA/H/C/002557/II/0029
GE Healthcare AS, PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, “Submission of the final report from study (GE067-027) listed as a category 3 study in the RMP in addition to a comprehensive root-cause analysis on the contributing factors having an impact on reader performance as requested by PRAC. This is a non-interventional post-authorisation safety study (PASS) to evaluate the effectiveness of VIZAMYL reader training in Europe. The RMP version 3.1 has also been submitted and updated to reflect the completion of study GE067-028, previously assessed in MEA 003.3.”
Request for Supplementary Information adopted on 01.09.2022, 10.06.2022.

Request for supplementary information adopted with a specific timetable.

PRAC Led
WS2268
Dovato-EMEA/H/C/004909/WS2268/0031

Positive Opinion adopted by consensus on 01.09.2022.

Juluca-EMA/H/C/004427/WS2268/0044

Tivicay-EMA/H/C/002753/WS2268/0079

Triumeq-

EMA/H/C/002754/WS2268/0104

ViiV Healthcare B.V., Lead Rapporteur: Filip Josephson, Lead PRAC Rapporteur: Martin Huber, PRAC-CHMP liaison: Martina Weise, "To update section 4.8 of the SmPC and section 4 of the PL to include the ADR "weight increased" with a frequency "common".

In addition, the marketing authorisation holder has taken the opportunity to implement a minor editorial change in the German SmPC for Juluca."

Opinion adopted on 01.09.2022.

Request for Supplementary Information adopted on 10.06.2022.

PRAC Led

WS2270

Vfend-EMA/H/C/000387/WS2270/0147

Pfizer Europe MA EEIG, Lead Rapporteur:

Johann Lodewijk Hillege, Lead PRAC

Rapporteur: Liana Gross-Martirosyan, PRAC-

CHMP liaison: Johann Lodewijk Hillege, "To

update the Annex II and RMP to version 6.0 to include the results from final clinical study

report (CSR) following the completion of a non-interventional (NI) post-authorisation safety study (PASS), A1501103 "An Active Safety

Surveillance Program to Monitor Selected Events in Patients with Long-term Voriconazole Use" - MEA091.

In addition, the MAH is taking this opportunity to introduce editorial changes."

Request for Supplementary Information adopted on 01.09.2022.

Request for supplementary information adopted with a specific timetable.

B.5.5. CHMP-CAT assessed procedures

Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel -

EMA/H/C/004731/II/0004, ATMP

Bristol-Myers Squibb Pharma EEIG, Rapporteur:

Concetta Quintarelli, CHMP Coordinator:

Armando Genazzani

Request for Supplementary Information adopted on 09.09.2022.

Request for supplementary information adopted with a specific timetable.

Imlygic - talimogene laherparepvec - EMA/H/C/002771/II/0054, ATMP

Positive Opinion adopted by consensus on 15.09.2022.

Amgen Europe B.V., Rapporteur: Maija Tarkkanen, CHMP Coordinator: Johanna Lähteenvuo, " - To update the SmPC (section 6.6) and PIL (Thawing Imlygic vials) to revise the time for complete vial thaw from "approximately 30 minutes" to "the time to achieve complete vial thaw is expected to be 30 to 70 minutes, depending on the ambient temperature."

The MAH took the opportunity to introduce minor editorial changes in section 4.8 of the SmPC."

Opinion adopted on 15.09.2022, 09.09.2022.

**Kymriah - tisagenlecleucel -
EMA/H/C/004090/II/0055, Orphan,
ATMP**

Positive Opinion adopted by consensus on 15.09.2022.

Novartis Europharm Limited, Rapporteur: Rune Kjekken, CHMP Coordinator: Ingrid Wang
Opinion adopted on 15.09.2022, 09.09.2022.

Request for Supplementary Information adopted on 17.06.2022.

**Kymriah - tisagenlecleucel -
EMA/H/C/004090/II/0056, Orphan,
ATMP**

Positive Opinion adopted by consensus on 15.09.2022.

Novartis Europharm Limited, Rapporteur: Rune Kjekken, CHMP Coordinator: Ingrid Wang,

"Update of sections 4.2 and 5.1 of the SmPC in order to update efficacy and safety information in paediatric population based on study CCTL019C2202, a phase II, single arm, multicenter open label trial to determine the safety and efficacy of tisagenlecleucel in paediatric patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma (NHL) (BIANCA).

The Package Leaflet is updated accordingly."

Opinion adopted on 15.09.2022, 09.09.2022.
Request for Supplementary Information adopted on 17.06.2022.

**Kymriah - tisagenlecleucel -
EMA/H/C/004090/II/0061/G, Orphan,
ATMP**

Positive Opinion adopted by consensus on 15.09.2022.

Novartis Europharm Limited, Rapporteur: Rune Kjekken, CHMP Coordinator: Ingrid Wang
Opinion adopted on 15.09.2022, 09.09.2022.

Request for Supplementary Information adopted on 15.07.2022.

Kymriah - tisagenlecleucel -

Positive Opinion adopted by consensus on

EMA/H/C/004090/II/0062, Orphan, ATMP 15.09.2022.

Novartis Europharm Limited, Rapporteur: Rune Kjekken, CHMP Coordinator: Ingrid Wang, "Submission of the final report from study CCTL019B2401 listed as a category 1 study in the Annex II of the Product Information in order to fulfil ANX/007.3. This is a sub-analysis (PAES) to assess efficacy in patients with relapsed or refractory diffuse large B-cell lymphoma based on data from the registry study to assess the long-term safety of patients with B lymphocyte malignancies treated with tisagenlecleucel. The Annex II is updated accordingly."

Opinion adopted on 15.09.2022, 09.09.2022.

Zolgensma - onasemnogene abeparvovec - EMA/H/C/004750/II/0031, Orphan, ATMP Request for supplementary information adopted with a specific timetable.

Novartis Europharm Limited, Rapporteur: Carla Herberts, CHMP Coordinator: Johann Lodewijk Hillege

Request for Supplementary Information adopted on 09.09.2022.

WS2247 Tecartus- EMA/H/C/005102/WS2247/0020 Yescarta- EMA/H/C/004480/WS2247/0050 Positive Opinion adopted by consensus on 09.09.2022.

Kite Pharma EU B.V., Lead Rapporteur: Jan Mueller-Berghaus

Opinion adopted on 09.09.2022.

Request for Supplementary Information adopted on 15.07.2022, 13.05.2022.

B.5.6. CHMP-PRAC-CAT assessed procedures

Kymriah - tisagenlecleucel - EMA/H/C/004090/II/0060, Orphan, ATMP Positive Opinion adopted by consensus on 15.09.2022.

Novartis Europharm Limited, Rapporteur: Rune Kjekken, CHMP Coordinator: Ingrid Wang, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of section 4.2 of the SmPC in order to update the paediatric statement for the B-cell ALL indication and section 4.4 to update the warning on 'prior treatment with anti-CD19 therapy' as well as sections 4.4 and 4.8 in order to update safety data to reflect the pool of the 3

studies B2202, B2205J and B2001X. The proposed changes are in line with the request of the CHMP following the assessment of P46/012. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to correct the Complete Response Rate (CRR) 95% Confidence Interval (CI) on Enrolled set for E2202 study presented in Table 8 in section 5.1 of the SmPC. The RMP version 5.1 has also been submitted.”

Opinion adopted on 15.09.2022, 09.09.2022.

Request for Supplementary Information adopted on 15.07.2022.

B.5.7. PRAC assessed ATMP procedures

PRAC Led

**Imlygic - talimogene laherparepvec -
EMA/H/C/002771/II/0056, ATMP**

Amgen Europe B.V., CHMP Coordinator:

Johanna Lähteenvuo, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, “Submission of the final report from study 20120139 listed as a category 3 study in the RMP in order to fulfil MEA/004.

This is a multicenter, observational registry study to evaluate the survival and long-term safety of subjects who previously received talimogene laherparepvec in Amgen or BioVEX sponsored clinical trials.”

Request for Supplementary Information adopted on 09.09.2022.

Request for supplementary information adopted with a specific timetable.

B.5.8. Unclassified procedures and worksharing procedures of type I variations

WS2277

Herceptin-

EMA/H/C/000278/WS2277/0182

MabThera-

EMA/H/C/000165/WS2277/0192

Roche Registration GmbH, Lead Rapporteur: Jan Mueller-Berghaus

Opinion adopted on 01.09.2022.

Positive Opinion adopted by consensus on 01.09.2022.

WS2291/G

Ambirix-

EMA/H/C/000426/WS2291/0122/G

Twinrix Adult-

EMA/H/C/000112/WS2291/0157/G

Twinrix Paediatric-

EMA/H/C/000129/WS2291/0158/G

Positive Opinion adopted by consensus on 08.09.2022.

GlaxoSmithkline Biologicals SA, Lead
Rapporteur: Christophe Focke
Opinion adopted on 08.09.2022.

WS2292
Abseamed-
EMA/H/C/000727/WS2292/0099
Binocrit-
EMA/H/C/000725/WS2292/0098

Positive Opinion adopted by consensus on
15.09.2022.

Epoetin alfa Hexal-
EMA/H/C/000726/WS2292/0098
Sandoz GmbH, Lead Rapporteur: Alexandre
Moreau

Opinion adopted on 15.09.2022.
Request for Supplementary Information adopted
on 21.07.2022.

WS2301/G
M-M-RvaxPro-
EMA/H/C/000604/WS2301/0117/G
ProQuad-
EMA/H/C/000622/WS2301/0158/G

Positive Opinion adopted by consensus on
01.09.2022.

Merck Sharp & Dohme B.V., Lead Rapporteur:
Jan Mueller-Berghaus,
Opinion adopted on 01.09.2022.

WS2308/G
AZILECT-
EMA/H/C/000574/WS2308/0090/G
Rasagiline ratiopharm-
EMA/H/C/003957/WS2308/0022/G

Request for supplementary information adopted
with a specific timetable.

Teva B.V., Lead Rapporteur: Bruno Sepodes
Request for Supplementary Information adopted
on 08.09.2022.

WS2310
Dovato-EMA/H/C/004909/WS2310/0033
Triumeq-
EMA/H/C/002754/WS2310/0107

Positive Opinion adopted by consensus on
01.09.2022.

ViiV Healthcare B.V., Lead Rapporteur: Filip
Josephson
Opinion adopted on 01.09.2022.

WS2324/G
Suboxone-
EMA/H/C/000697/WS2324/0053/G

Request for supplementary information adopted
with a specific timetable.

Indivior Europe Limited, Lead Rapporteur: Janet
Koenig
Request for Supplementary Information adopted
on 15.09.2022.

WS2337/G
Copalia-

Request for supplementary information adopted
with a specific timetable.

EMA/H/C/000774/WS2337/0126/G

Dafiro-

EMA/H/C/000776/WS2337/0130/G

Exforge-

EMA/H/C/000716/WS2337/0125/G

Novartis Europharm Limited, Lead Rapporteur:
Thalia Marie Estrup Blicher, "C.I.z - To update section 4.9 of the SmPC, to implement the wording related to the risk of non-cardiogenic pulmonary oedema in amlodipine overdose, following finalisation of procedure PSUSA/00010434/202107.

C.I.11.a - To update Annex II to reflect the fulfilment of Condition B, as set out by the Commission Decision as an outcome of the assessment for the impact of the Article 5(3) scientific opinion on nitrosamines in human medicinal products on the opinion adopted pursuant to Article 31 of Directive 2001/83/EC for angiotensin-II-receptor antagonists (sartans) containing a tetrazole group."

Request for Supplementary Information adopted on 08.09.2022.

WS2338

Copalia HCT-

EMA/H/C/001159/WS2338/0102

Dafiro HCT-

EMA/H/C/001160/WS2338/0104

Exforge HCT-

EMA/H/C/001068/WS2338/0101

Novartis Europharm Limited, Lead Rapporteur:
Thalia Marie Estrup Blicher, "C.I.z - To update section 4.9 of the SmPC, to implement the wording related to the risk of non-cardiogenic pulmonary oedema in amlodipine overdose, following finalisation of procedure PSUSA/00010434/202107."

Request for Supplementary Information adopted on 08.09.2022.

Request for supplementary information adopted with a specific timetable.

B.5.9. Information on withdrawn type II variation / WS procedure

Abevmy - bevacizumab -

EMA/H/C/005327/II/0009

Mylan IRE Healthcare Limited, Rapporteur: Jan Mueller-Berghaus

Request for Supplementary Information adopted on 16.06.2022.

The MAH withdrew the procedure on 07.09.2022.

B.5.10. Information on type II variation / WS procedure with revised timetable

PRAC Led

**Duavive - estrogens conjugated /
bazedoxifene -**

EMA/H/C/002314/II/0032

Pfizer Europe MA EEIG, PRAC Rapporteur:
Martin Huber, PRAC-CHMP liaison: Martina
Weise, "Submission of an updated RMP version
3.2 in order to reflect the updated study
milestones and completion of the post-
authorisation safety study of CE/BZA in the
United States (US PASS, study B2311060)
previously assessed as part of II/0030
(MEA002.15), as well as to update the post-
marketing data with the data lock point of 31
October 2021."
Request for Supplementary Information adopted
on 07.07.2022.

Request by the applicant for an extension to the
clock stop to respond to the RSI adopted in July
2022.

The CHMP agreed to the request by the
applicant.

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

**sodium phenylbutyrate /
ursodoxicoltaurine - EMA/H/C/005901,
Orphan**

Amylyx Pharmaceuticals EMEA B.V., treatment
of amyotrophic lateral sclerosis (ALS)
List of Questions adopted on 23.06.2022.

**Byfavo - remimazolam -
EMA/H/C/005246/X/0002**

PAION Netherlands B.V., Rapporteur: Bruno
Sepodes, Co-Rapporteur: Selma Arapovic
Dzakula, PRAC Rapporteur: Rhea Fitzgerald,
"Extension application to introduce a new
pharmaceutical form associated with new
strength (50 mg powder for concentrate for
solution for injection/infusion). The new
presentation is indicated to include the
intravenous induction and maintenance of
general anesthesia (GA) in adults for Byfavo 50
mg, based on final results from two pivotal

trials: Study ONO-2745-05, a phase IIb/III, single-blind, randomised, parallel-group study assessing safety and efficacy in induction and maintenance of anaesthesia in ASA I/II patients (general surgery), and study CNS-7056-022, a phase III, randomized, propofol controlled, parallel group, confirmatory single-blind efficacy and safety trial during induction and maintenance of anaesthesia in ASA III/IV patients.

A new combined version of the SmPC, labelling and Package Leaflet solely for the 50 mg strength and the GA indication is provided accordingly.

Version 1.1 of the RMP has also been submitted. As part of the application, the MAH also requests an extension of the market protection by one additional year.”

List of Questions adopted on 19.05.2022.

dapagliflozin - EMEA/H/C/006006

treatment of type 2 diabetes mellitus, heart failure and chronic kidney disease

List of Questions adopted on 23.06.2022.

pegunigalsidase alfa - EMEA/H/C/005618, Orphan

Chiesi Farmaceutici S.p.A., treatment of Fabry disease

List of Questions adopted on 23.06.2022.

gadopiclenol - EMEA/H/C/005626

for diagnostic: contrast-enhanced magnetic resonance imaging (MRI) to improve detection, visualisation and assist in characterisation of lesions in the central nervous system and in other body regions (including breast, liver and prostate).

List of Questions adopted on 23.06.2022.

sirolimus - EMEA/H/C/005896, Orphan

Plusultra pharma GmbH, Treatment of angiofibroma associated with tuberous sclerosis complex

List of Questions adopted on 22.04.2022.

bardoxolone methyl - EMEA/H/C/005869, Orphan

Reata Ireland Limited, treatment of chronic kidney disease

List of Questions adopted on 24.02.2022.

daprodustat - EMEA/H/C/005746

treatment of anaemia associated with chronic kidney disease (CKD) in adults
List of Questions adopted on 23.06.2022.

spironolactone - EMEA/H/C/005535
Management of refractory oedema
List of Questions adopted on 24.03.2022.

sitagliptin / metformin hydrochloride - EMEA/H/C/005778
treatment of type 2 diabetes mellitus
List of Questions adopted on 23.06.2022.

tremelimumab - EMEA/H/C/006016, Orphan
AstraZeneca AB, For use in combination with durvalumab for the treatment of adults with unresectable hepatocellular carcinoma.
List of Questions adopted on 21.07.2022.

filgrastim - EMEA/H/C/005888
Reduction in the duration of neutropenia and the incidence of febrile neutropenia, indicated for the mobilisation of peripheral blood progenitor cells and persistent neutropenia in patients with advanced HIV infection
List of Questions adopted on 23.06.2022.

B.6.4. Annual Re-assessments: timetables for adoption

B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

SIRTURO - bedaquiline - EMEA/H/C/002614/R/0050, Orphan
Janssen-Cilag International N.V., Rapporteur:
Filip Josephson, PRAC Rapporteur: Ulla Wändel
Liminga

B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

Adjupanrix - pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) - EMEA/H/C/001206/II/0079/G

GlaxoSmithkline Biologicals SA, Informed
Consent of Pandemrix (EXP), Rapporteur:
Johann Lodewijk Hillege

**AMGEVITA - adalimumab -
EMA/H/C/004212/II/0031**

Amgen Europe B.V., Rapporteur: Kristina
Dunder

**Caelyx pegylated liposomal - doxorubicin -
EMA/H/C/000089/II/0103**

Baxter Holding B.V., Rapporteur: Ondřej Slanař

**Cosentyx - secukinumab -
EMA/H/C/003729/II/0092/G**

Novartis Europharm Limited, Rapporteur: Outi
Mäki-Ikola

**Doptelet - avatrombopag -
EMA/H/C/004722/II/0015/G**

Swedish Orphan Biovitrum AB (publ),
Rapporteur: Aaron Sosa Mejia

**Foclivia - prepandemic influenza vaccine
(H5N1) (surface antigen, inactivated,
adjuvanted) - EMA/H/C/001208/II/0079**

Seqirus S.r.l, Rapporteur: Armando Genazzani

**Imfinzi - durvalumab -
EMA/H/C/004771/II/0051**

AstraZeneca AB, Rapporteur: Aaron Sosa Mejia

**IMVANEX - smallpox vaccine (live modified
vaccinia virus Ankara) -
EMA/H/C/002596/II/0079**

Bavarian Nordic A/S, Rapporteur: Jan Mueller-
Berghaus

**Inflectra - infliximab -
EMA/H/C/002778/II/0108/G**

Pfizer Europe MA EEIG, Duplicate, Duplicate of
Remsima, Rapporteur: Outi Mäki-Ikola

**Nulojix - belatacept -
EMA/H/C/002098/II/0082/G**

Bristol-Myers Squibb Pharma EEIG, Rapporteur:
Filip Josephson

**Reblozyl - luspatercept -
EMA/H/C/004444/II/0013, Orphan**

Bristol-Myers Squibb Pharma EEIG, Rapporteur:
Daniela Philadelphia

**Shingrix - herpes zoster vaccine
(recombinant, adjuvanted) -
EMA/H/C/004336/II/0059/G**

GlaxoSmithkline Biologicals SA, Rapporteur:
Christophe Focke

**Somavert - pegvisomant -
EMA/H/C/000409/II/0104**

Pfizer Europe MA EEIG, Rapporteur: Jean-Michel
Race

**Spikevax - elasomeran -
EMA/H/C/005791/II/0078/G**

Moderna Biotech Spain, S.L., Rapporteur: Jan
Mueller-Berghaus

**Spikevax - elasomeran -
EMA/H/C/005791/II/0079/G**

Moderna Biotech Spain, S.L., Co-Rapporteur:
Andrea Laslop

**TRODELVY - sacituzumab govitecan -
EMA/H/C/005182/II/0016/G**

Gilead Sciences Ireland UC, Rapporteur: Jan
Mueller-Berghaus

**Vimizim - elosulfase alfa -
EMA/H/C/002779/II/0039, Orphan**

BioMarin International Limited, Rapporteur:
Johann Lodewijk Hillege

**Vydura - rimegepant -
EMA/H/C/005725/II/0002/G**

Biohaven Pharmaceutical Ireland DAC,
Rapporteur: Janet Koenig

**Xofigo - radium-223 -
EMA/H/C/002653/II/0047**

Bayer AG, Rapporteur: Janet Koenig

WS2340/G

**Fluenz Tetra-
EMA/H/C/002617/WS2340/0119/G
Pandemic influenza vaccine H5N1**

**AstraZeneca-
EMA/H/C/003963/WS2340/0053/G**

AstraZeneca AB, Lead Rapporteur: Christophe
Focke

WS2344

**Ryzodeg-
EMA/H/C/002499/WS2344/0048
Tresiba-EMA/H/C/002498/WS2344/0056**

**Xultophy-
EMA/H/C/002647/WS2344/0044**

Novo Nordisk A/S, Lead Rapporteur: Kristina
Dunder

WS2346/G**Blitzima-****EMA/H/C/004723/WS2346/0059/G****Truxima-****EMA/H/C/004112/WS2346/0062/G**

Celltrion Healthcare Hungary Kft., Lead

Rapporteur: Sol Ruiz

WS2347/G**Infanrix hexa-****EMA/H/C/000296/WS2347/0318/G**

GlaxoSmithkline Biologicals SA, Lead

Rapporteur: Christophe Focke

B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Alecensa - alectinib -**EMA/H/C/004164/II/0042**

Roche Registration GmbH, Rapporteur: Filip Josephson, "Submission of the final report from study JO28928 (J-ALEX) a Randomized Phase III Open-Label Study Comparing the Efficacy and Safety of Crizotinib and CH5424802 in ALK-Positive Advanced or Recurrent Non-Small Cell Lung Cancer."

Kesimpta - ofatumumab -**EMA/H/C/005410/II/0007**

Novartis Ireland Limited, Rapporteur: Thalia Marie Estrup Blicher, "Update of sections 5.1 and 5.2 of the SmPC in order to add information on the pharmacologic profile of ofatumumab subcutaneous administration to properly evaluate and group Kesimpta into the therapeutic landscape of Multiple Sclerosis based on feedback from the German and other HTA bodies, requiring additional information on the pharmacologic profile of ofatumumab (s.c.) to adequately inform payors and prescribers."

Nerlynx - neratinib -**EMA/H/C/004030/II/0029**

Pierre Fabre Medicament, Rapporteur: Bruno Sepodes, "Update of section 5.2 of the SmPC in order to add information on distribution and on the effect of neratinib on CYP substrates based on non-clinical studies XT218036 and 20325317; study XT218036 was designed to evaluate neratinib as a substrate of the human transporters OATP1B1 and OATP1B3 and study 20325317 objective was to determine the inactivation kinetic constants (kinact and KI) of

Neratinib and M6 for the human cytochrome P450 (CYP) isoenzymes 2B6 and 3A4 using pooled human liver microsomes (HLM). In addition, the MAH is also taking this opportunity to introduce editorial changes.”

**Regkirona - regdanvimab -
EMA/H/C/005854/II/0008**

Celltrion Healthcare Hungary Kft., Rapporteur: Filip Josephson, “Update of section 5.1 of the SmPC in order to update the information on the clinical resistance data based on final genotype and phenotype results from study CT-P59 3.2 Part 2; this is a Phase 2/3, randomized, parallel-group, placebo-controlled, double-blind study to evaluate the efficacy and safety of CT-P59 in combination with standard of care in outpatients with Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection.”

**Veklury - remdesivir -
EMA/H/C/005622/II/0042**

Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, “Update of section 5.1 to provide in vitro data on the antiviral activity of remdesivir against the Omicron subvariants BA.2.12.1, BA.4 and BA.5 following procedure II/0034/G based on in vitro study “Remdesivir Antiviral Activity against Omicron Subvariants BA.2.12.1, BA.4 and BA.5 in A549-hACE2-TMPRSS2 Cells”.”

**VEYVONDI - vonicog alfa -
EMA/H/C/004454/II/0026**

Baxalta Innovations GmbH, Rapporteur: Jan Mueller-Berghaus, “Update of sections 4.8 and 5.1 of the SmPC in order to add ‘headache’ to the list of adverse drug reactions (ADRs) with frequency very common and to update information based on final results from study 071301 and other available data; study 071301 is a prospective, phase 3, open-label, international multicenter study on efficacy and safety of prophylaxis with rVWF in severe von Willebrand disease. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to introduce minor editorial changes to the PI and bring it in line with the latest QRD template.”

**Xarelto - rivaroxaban -
EMA/H/C/000944/II/0097**

Bayer AG, Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in order to add 'eosinophilic pneumonia' to the list of adverse drug reactions (ADRs) with frequency 'very rare', based on post-marketing data; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet."

WS2343

Ozempic-

EMA/H/C/004174/WS2343/0033

Rybelsus-

EMA/H/C/004953/WS2343/0028

Novo Nordisk A/S, Lead Rapporteur: Johann Lodewijk Hillege, "Submission of an updated final report from study NN9535-4386 (SUSTAIN-11) in order to amend an error. This study was listed as a category 3 study in the RMP and was previously assessed in procedure EMA/H/C/004174/II/WS/2141. This is a Phase IIIb A 52-week, multi-centre, multinational, open-label, active-controlled, two armed, parallel-group, randomised trial in subjects with type 2 diabetes to evaluate the effect of semaglutide once-weekly versus insulin aspart three times daily, both as add on to metformin and optimised insulin glargine (U100) in subjects with type 2 diabetes."

WS2358

Elebrato Ellipta-

EMA/H/C/004781/WS2358/0028

Trelegy Ellipta-

EMA/H/C/004363/WS2358/0025

GlaxoSmithKline Trading Services Limited, Lead Rapporteur: Jayne Crowe, "Update of section 4.8 of the SmPC in order to add 'urinary retention' and 'dysuria' to the list of adverse drug reactions (ADRs) with frequency rare; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and bring it in line with the latest QRD template."

B.6.10. CHMP-PRAC assessed procedures

Beovu - brolocizumab -

EMA/H/C/004913/II/0018

Novartis Europharm Limited, Rapporteur:

Alexandre Moreau, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of sections 4.2 and 5.1 of the SmPC in order to introduce an alternative posology regimen for wet AMD and update information based on modelling and simulation studies; the Package Leaflet is updated accordingly. The RMP version 9.0 has also been submitted."

**COMIRNATY - tozinameran -
EMA/H/C/005735/II/0143**

See 9.1 and B.5.3

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst "Addition of a new strain (Omicron BA.4-5) resulting in a new Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose dispersion for injection presentation. The SmPC, the Package Leaflet and Labelling are updated accordingly. A revised RMP version 7.1 has been approved."

**Ilumetri - tildrakizumab -
EMA/H/C/004514/II/0036**

Almirall S.A, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Adam Przybylkowski

**Imnovid - pomalidomide -
EMA/H/C/002682/II/0047, Orphan**

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Eva A. Segovia, "Update of section 4.4 of the SmPC, Annex IID and Article 127a and the tools/documents included in the Educational Healthcare Professional Kit, in order to harmonise the terminology utilised in the RMP and PI documents relating to the safety concern of teratogenicity and its risk minimisation measure of the Pregnancy Prevention Plan across the 3 IMiDs. These proposed changes will only have a limited impact on the National Competent Authority (NCA)-approved content/text of the educational materials, and the key messages to the HCP and patients. Furthermore, the regulatory obligations regarding the PPP will not be impacted. The updated RMP version 16 was provided."

**Revlimid - lenalidomide -
EMA/H/C/000717/II/0123**

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, "Update of section 4.4 of the SmPC,

Annex IID and Article 127a and the tools/documents included in the Educational Healthcare Professional Kit, in order to harmonise the terminology utilised in the RMP and PI documents relating to the safety concern of teratogenicity and its risk minimisation measure of the Pregnancy Prevention Plan across the 3 IMiDs. These proposed changes will only have a limited impact on the National Competent Authority (NCA)-approved content/text of the educational materials, and the key messages to the HCP and patients. Furthermore, the regulatory obligations regarding the PPP will not be impacted. The MAH is also taking the opportunity to update the RMP with PASS Protocol milestones. The updated RMP version 38 was provided.”

**Thalidomide BMS - thalidomide -
EMA/H/C/000823/II/0076**

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, “Update of section 4.4 of the SmPC, Annex IID and Article 127a and the tools/documents included in the Educational Healthcare Professional Kit, in order to harmonise the terminology utilised in the RMP and PI documents relating to the safety concern of teratogenicity and its risk minimisation measure of the Pregnancy Prevention Plan across the 3 IMiDs. These proposed changes will only have a limited impact on the National Competent Authority (NCA)-approved content/text of the educational materials, and the key messages to the HCP and patients. Furthermore, the regulatory obligations regarding the PPP will not be impacted. The MAH is also taking the opportunity to update the RMP with PASS Protocol milestones, and to make some editorial changes in the labelling. The updated RMP version 20 was provided.”

B.6.11. PRAC assessed procedures

PRAC Led

**Kaletra - lopinavir / ritonavir -
EMA/H/C/000368/II/0193**

AbbVie Deutschland GmbH & Co. KG, PRAC Rapporteur: Nathalie Gault, PRAC-CHMP liaison: Jean-Michel Race, “Submission of the final report from study P19-106 listed as a category

3 study in the RMP. This is a European Pregnancy and Paediatric Infections Cohort Collaboration (EPPICC) observational study assessing the safety and effectiveness of Kaletra oral solution in children aged 14 days to 2 years with human immunodeficiency virus 1 (HIV-1) infection in Europe. The RMP version 10.0 has also been submitted.”

PRAC Led

Menveo - meningococcal group A, C, W135 and Y conjugate vaccine - EMEA/H/C/001095/II/0112

GSK Vaccines S.r.l, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, “Submission of an updated RMP version 10 in order to remove several safety concerns.”

PRAC Led

NUVAXOVID - SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda - EMEA/H/C/005808/II/0022

Novavax CZ, a.s., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, “Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on pericarditis and myocarditis and to add pericarditis and myocarditis to the list of adverse drug reactions (ADRs) with frequency not known following the outcome of MEA/014.4 based on PRAC assessment on pericarditis and myocarditis. The Package Leaflet is updated accordingly.”

PRAC Led

Spikevax - elasomeran - EMEA/H/C/005791/II/0077

Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen, PRAC-CHMP liaison: Thalia Marie Estrup Blicher, “Update of section 4.8 of the SmPC to include ‘Acute and Delayed urticaria’ as an adverse reaction, with the frequency ‘Rare’, as requested by the PRAC in the 13th Safety Summary Report (EMEA/H/C/005791/MEA/011.12). The Package Leaflet is updated accordingly.”

PRAC Led

**SYLVANT - siltuximab -
EMA/H/C/003708/II/0038, Orphan**

EUSA Pharma (Netherlands) B.V., PRAC
Rapporteur: Brigitte Keller-Stanislawski,
"Submission of the report from study
ACCELERATE (Advancing Castleman Care with
an Electronic Longitudinal Registry, E-
Repository, And Treatment/Effectiveness
Research): An International Registry for
Patients with Castleman Disease -
NCT02817997 listed as an obligation in the
Annex II of the Product Information.
This is a study Report to cover the data
collected for 100 patients over a 5 year period
in the ACCELERATE Registry study to collect
information on patients with Castleman's
Disease who are candidates to receive Sylvant
or are currently receiving treatment with
Sylvant. The Annex II is updated accordingly."

B.6.12. CHMP-CAT assessed procedures

**CARVYKTI - ciltacabtagene autoleucel -
EMA/H/C/005095/II/0002, Orphan,
ATMP**

Janssen-Cilag International NV, Rapporteur: Jan
Mueller-Berghaus, CHMP Coordinator: Jan
Mueller-Berghaus

**Zolgensma - onasemnogene abeparvovec -
EMA/H/C/004750/II/0034/G, Orphan,
ATMP**

Novartis Europharm Limited, Rapporteur: Carla
Herberts, CHMP Coordinator: Johann Lodewijk
Hillege

B.6.13. CHMP-PRAC-CAT assessed procedures

**Zolgensma - onasemnogene abeparvovec -
EMA/H/C/004750/II/0033/G, Orphan,
ATMP**

Novartis Europharm Limited, Rapporteur: Carla
Herberts, CHMP Coordinator: Johann Lodewijk
Hillege, PRAC Rapporteur: Ulla Wändel Liminga,
"Update of sections 4.2, 4.4 and 4.8 of the
SmPC in order to introduce additional guidance
on liver function laboratory tests and monitoring
before and after infusion and update information
based on new safety information on the topic of
acute liver failure (ALF) following two reports of
fatal ALF."

Update of sections 4.2 and 4.4 of the SmPC in order to provide additional guidance relevant to patient's overall health status prior to dosing and to strengthen the existing description and guidance on systemic immune response.

Update of section 4.4 of the SmPC in order to indicate prompt attention to thrombotic microangiopathy (TMA) and to reflect the risk of life-threatening or fatal outcomes.

The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted. In addition, the MAH took the opportunity to update the Annex II."

B.6.14. PRAC assessed ATMP procedures

B.6.15. Unclassified procedures and worksharing procedures of type I variations

WS2243/G

Herceptin-

EMA/H/C/000278/WS2243/0184/G

MabThera-

EMA/H/C/000165/WS2243/0193/G

Roche Registration GmbH, Lead Rapporteur: Jan Mueller-Berghaus

WS2348

Ongentys-

EMA/H/C/002790/WS2348/0052

Ontilyv-EMA/H/C/005782/WS2348/0007

Bial - Portela & C^a, S.A., Lead Rapporteur: Martina Weise

WS2354/G

Abseamed-

EMA/H/C/000727/WS2354/0100/G

Binocrit-

EMA/H/C/000725/WS2354/0099/G

Epoetin alfa Hexal-

EMA/H/C/000726/WS2354/0099/G

Sandoz GmbH, Lead Rapporteur: Alexandre Moreau

B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Yearly Line listing for Type I and II variations

B.7.2. Monthly Line listing for Type I variations

B.7.3. Opinion on Marketing Authorisation transfer (MMD only)

B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)

B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)

B.7.6. Notifications of Type I Variations (MMD only)

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1. PMF Certification Dossiers:

E.1.1. Annual Update

E.1.2. Variations:

E.1.3. Initial PMF Certification:

E.2. Time Tables – starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures Tabled in MMD and sent by post mail (folder E).

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

G.2. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

G.2.1. List of procedures concluding at 12-15 September 2022 CHMP plenary:

Neurology	
Slowing down the loss of ambulation and speech in symptomatic paediatric patients 2 years of age and older with late infantile or juvenile types of GM1 or GM2 gangliosidosis. (SME)	The CHMP denied eligibility to PRIME and adopted the critical summary report.
Halting or slowing down the progression of ataxic dysphagia in patients 2 years of age and older with Niemann Pick disease type C (SME)	The CHMP denied eligibility to PRIME and adopted the critical summary report.
Infectious Diseases	
GBS-NN/NN2 vaccine Prevention of Group B streptococcal invasive disease in infants by active immunisation of pregnant women. (SME)	The CHMP granted eligibility to PRIME and adopted the critical summary report.
Cardiovascular Diseases	
Treatment of Acute Ischemic Stroke (AIS) (SME)	The CHMP denied eligibility to PRIME and adopted the critical summary report.
Oncology	
Treatment of metastatic melanoma ATMP	The CAT and the CHMP denied eligibility to PRIME and adopted the critical summary report.
Endocrinology-Gynaecology-Fertility-Metabolism	
DTX401 Treatment of glycogen storage disease type Ia (GSDIa, von Gierke disease) ATMP	The CAT and CHMP granted eligibility to PRIME and adopted the critical summary report.

G.2.2. List of procedures starting in September 2022 for October 2022 CHMP adoption of outcomes

H. ANNEX H - Product Shared Mailboxes – e-mail address